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Since 1971 enzyme immunoassay techniques have been used to estimate 
hormones and drugs in biological f lu id s .  This thesis describes the 
development of enzyme immunoassays (EIAs) fo r  measuring serum concentrations 
of n o rtr ip ty l in e , methotrexate, and triiodothyronine. The resultant 
assays appear to compare favourably with presently used methods for  
estimating these compounds. The basis of enzyme immunoassay fo r  b ile  
acids has also been established. The princip le  of using simultaneous 
EIA fo r  multicomponent mixtures has also been demonstrated using solutions 
containing triiodothyronine and thyroxine. In this simultaneous assay 
g-D-galactosidase was conjugated to T  ^ and a lka line  phosphatase was 
conjugated to T^. The bifunctional imidoester dimethyl adipimidate 
appeared to be the most satisfactory linking agent for each enzyme. In 
the other assays $-galactosidase alone was used as the enzyme labe l. In 
order to separate free and bound labelled material prior to measurement 
of enzyme a c t iv i ty  a second antibody (post or pre prec ip ita tion)  
techniques were found to be very satisfactory. The techniques which 
are described should be applicable with minor modifications to the assay 
of a wide range of endogenous and exogenous compounds in biological f lu id s .
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CHAPTER 1
GENERAL INTRODUCTION
Drug Therapy
1. Serum Drug Concentrations as Therapeutic Guides
Dosages of any individual drug needed fo r  optimal therapeutic effects  
may d i f fe r  widely among patients. The "usual dose" of many potent 
drugs accomplishes l i t t l e  in some persons, causes serious to x ic ity  in 
others, and is fu l ly  satisfactory in few. The in a b i l i ty  of standard 
dosage schedules to exert a s u ff ic ie n t ly  intense pharmacologic e ffec t  
in many patients is often misinterpreted.and drug to x ic ity  often arises  
through a fa i lu re  to reduce the usual dosage appropriately in other 
patients. The importance of the la t te r  problem is reflected in the 
frequency and severity of adverse reactions to drug therapy. More than 
ha lf  these reactions are dose-related -  that is ,  they resu lt from dosages 
that are too high for the patient affected (Koch-Weser et al 1969). The 
habitual administration of the conventional dose can be sa tis fied  only 
when a drug's therapeutic margin is very Targe and when i ts  fu l l  therapeutic  
potential is not required. Therapy with potent drugs becomes safer and 
more e ffec tive  when the dosage is adjusted to the need and tolerance of 
each patient.
How can one determine the optimal dose of a drug for each patient? Dosage 
adjustments are easy when the in tensity  of a drug's pharmacologic effects  
can be quickly and accurately gauged during i ts  c l in ic a l use. For example 
dosage requirements for guanithidine or warfarin can vary by a factor of 
50 from one patient to another. Nevertheless, these drugs are useful
tnerapeutic agents, Decause th e ir  optimal individual dosage is read ily  
determined by measuring the upright a r te r ia l  pressure or the prothrombin 
time. Unfortunately, such simple and exact indexes of the in tensity  of 
therapeutic a c t iv i ty  are the exception;and the dosage of most drugs 
cannot be " t itra ted "  in this fashion.
With many drugs, ascertainment of the best dosage for individual patients  
is d i f f i c u l t  because the pharmacologic response is not quantifiable  in the 
usual c l in ic a l s ituation . The physician may not even know whether the 
prescribed dosage is producing the expected therapeutic benefit , p a rt ic u la r ly  
when the drug is given for prophylactic purposes. The practice of increasing 
drug dosage until mild toxic manifestations appear,and then decreasing i t  
s l ig h t ly , is  feasible only for some drugs;and can be uncomfortable,if not 
hazardous,to the patient. In this quandary determinations of drug 
concentrations in the blood are becoming increasingly helpful.
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2. Relation o f Dosage, Serum Concentration, and E ffe c t
The enormous individual differences in the re la tion  between the dosage 
of a drug and the in tensity  of i ts  pharmacologic action are not surprising 
when one considers the many factors that may influence the biological 
effects of an o ra lly  administered drug (Figure 1 .1 ) .  I t  is not generally  
appreciated that the v a r ia b i l i ty  of the dose-effect re la tion  among patients 
is very commonly due to individual differences in the serum concentration 
achieved with a given dosage schedule rather than to a d if fe re n t  in tensity  
of action associated with the same serum concentration. For many drugs 
the re la tion  between the amount administered and the resulting concentration 
in the body is quite unpredictable. In contrast, the in tensity  of the 
pharmacologic action generally correlates rather well with the concentration 
of the free drug in the serum (Brodie 1967, Brodie e t al 1971, Prescott 1972, 
Kock-Weser 1972, Vesell 1971, Vesell e t  al 1971). Changes in the serum 
concentration of most drugs are probably accompanied by s im ilar changes in 
th e ir  concentration a t the s ite  of action and in the number of drug-receptor 
complexes. This is true only fo r  drugs that act reversibly -  i . e . ,  whose 
action does not outlast th e ir  presence at the receptor site-.*but the great
r>
majority of drugs probably f a l l  into this category.
Why is the re la tion  between the dosage of a drug and i ts  concentration in 
the serum so variable? I t  is influenced by the b io a v a i la b i l i ty  of the dosage 
form used, the co-administration of other substances (food, drugs e t c . ) ,  by 
host factors that a ffec t  the completeness of gastro-in testina l absorption, 
by body size and composition, by d istr ibution  through f lu id  compartments, 
by binding a t inactive s ites , and by rates of metabolism and excretion 
(Carpenter 1972). All these determinants are subject to much individual 
variation . There are large genetically  controlled differences in the rate  
of biotransformation of many, drugs. Superimposed on these are differences
due to induction or inh ib ition  of drug metabolizing enzyme systems by 
environmental factors and by administration of other drugs.
Individual and temporal differences may also ex is t however in the processes 
that determine the re la tion  between serum drug le v e l,  concentration at  
the s ite  of drug action, and in tensity  of action (Figure 1 .1 ) .  Thus, 
serum concentrations of drugs are not perfect indexes of the degree of  
pharmacologic response. Knowing the serum concentration of a drug, one 
cannot necessarily predict exactly how intense the therapeutic or toxic  
action w i l l  be in individual patients . However a more accurate prediction  
can usually be made from the serum level than from the dosage. For th is  
reason dosage adjustments can often be guided by knowledge of serum leve ls .
There has been particu lar concern about the value of serum level 
determinations of reversibly acting drugs whose ratios of serum to tissue  
concentration are very low because they are extensively bound in tissues. 
This concern appears to be un justified  as long as the serum concentration 
of unbound drug can be re lia b ly  measured. The serum concentration of such 
drugs remains in dynamic equilibrium with th e ir  concentration at pharmaco­
lo g ic a lly  inactive tissue sites and at th e ir  receptors. Some individual 
and temporal variations in the ra tio  of serum to tissue concentration do 
occur;but these are usually not large enough to invalidate  the meaning of 
serum concentrations. This has been well demonstrated with digoxin, where 
ra tio  of myocardial to serum concentration is 40 to 50 in most persons and 
does not vary greatly  with time, over a wide range of serum leve ls .  
Regardless of the degree of tissue binding, serum concentrations of most 
drugs generally serve as a useful index of the degree of receptor occupancy. 
In fa c t ,  drug concentration at the receptors may correlate better with the 
serum level than with the concentration in the tissue on which the drug 
exerts i ts  action because a large proportion of tissue binding is often to 
"non-receptor" s ites .
Even when the ra t io  of the serum concentration of a drug to i ts  
concentration at the s ite  of action varies appreciably among individual 
patients and with time, serum level usually remains a better index of 
drug concentration a t the receptor s ite  than dosage.
Serum levels of drugs whose action is not rapidly reversible reveal 
l i t t l e  about th e ir  therapeutic a c t iv i ty .  They have been described as 
"h it  and run" drugs;and include reserpine, some inhib itors  of monoamine 
oxidase and cholinesterase, and many cytotoxic drugs (Brodie 1967). The 
in tensity  of th e ir  effects is presumably dependent on th e ir  in i t i a l  serum 
concentration but is not related to the level at any given time. The 
serum concentration of other drugs may be proportional to the in tensity  
of a pharmacologic e ffec t but not to the c l in ic a l ly  important index of 
th e ir  action. For example, at any given time the serum warfarin concentration 
correlates with the hepatic synthesis of the vitamin K-sensitive c lo tt ing  
factors but not with the prothrombin complex concentration in plasma 
(prothrombin time). The la t te r  is determined not only by the synthesis 
rate but also by the catabolism of the c lo tting  proteins, a slow process.
Measurements of serum levels of a drug become useful guides for dosage1 
adjustments only when the therapeutically  e ffec tive  range of serum 
concentrations has been defined by careful c lin ic a l studies (Bigger et al 
1968, Kutt and McDowell 1968, Koch-Weser and Klein 1971, Asberg et al 1971).
At present this has been accomplished for few important drugs (Table 1 .1 ) .  
Compared to the large individual variations in the optimal dosages of 
these drugs, the width of th e ir  therapeutic serum concentration ranges is 
re la t iv e ly  narrow. Concentrations of these drugs below the accepted 
therapeutic range may exert beneficial effects in a few subjects but are 
l ik e ly  to be inadequate in most patients. Within the therapeutic range the 
in tensity  of the desired e ffec t of the drug increases with i ts  serum 
concentration. *
in occasional patients concentrations in the upper therapeutic range 
may have toxic actions. As serum concentrations rise  above the 
therapeutic range, the frequency and severity of toxic effects increase 
progressively. Some patients can to lera te  serum concentrations considerably 
above the usual therapeutic leve ls , and a few may even require them 
for a fu l ly  satisfactory response. Thus some overlap between therapeutic 
and toxic serum concentrations is the ru le; and i t  is considerable fo r  
certain drugs, such as the d ig i ta l is  glycosides. Whenever concentrations 
above the usual therapeutic range are produced for therapeutic purposes, 
patients must be closely monitored against the. appearance of serious 
to x ic ity .
TABLE 1.1 Ranges of Serum Concentrations of Various Drugs
Usual Range of 
Drug Therapeutic
Serum Concentrations
14-30 y g / l i t r e  
0.9-2 y g / l i t r e  
1 0 - 2 0  m g /l itre  
1.5-4 m g /l itre
0 .5 -1 .3  mEq/1itre 
50-140 y g / l i t r e
4-8 m g /l itre  
20-50 y g / l i t r e  
2-5 m g /l itre  
150-300 m g /l itre
Digitoxin  
Digoxin
Diphenylhydantoin
Lidocaine
Lithium
N ortrip ty line
Procainamide
Propanolol
Quinidine
Salicylates
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During the la s t  decade the value to c lin ic a l practice of determination 
of serum concentrations has been convincingly demonstrated for several 
important drugs. Such assays are generally unnecessary during treatment 
with drugs of lim ited effectiveness and potency,and in patients who respond 
well to the usual dosage regimen of any drug. They are also superfluous 
for drugs whose in tensity  of action can be judged accurately from th e ir  
effects on the patient and whose dosage can be adjusted on that basis. 
Nevertheless, a broad area of c lin ic a l usefulness remains. Measurement 
of serum concentrations generally c la r i f ie s  the picture when usual doses 
of a drug f a i l  to produce therapeutic benefits or resu lt in unexpected 
to x ic ity .  I t  is p a rt ic u la r ly  helpful in patients with gastro in tes tina l,  
cardiovascular, hepatic, or renal disease,in whom the re la tion  between 
dosage and plasma concentration may be grossly abnormal. I t  is also 
useful when many drugs are being administered concomitantly and may be 
a lte r ing  each other's metabolic fa te . Serum concentrations are often 
valuable fo r regulating the dosage of drugs used chronically fo r prophy­
la c t ic  purposes. Determinations of drug concentrations in serum w il l  
become more widely applicable as we expand our knowledge of the pharmacologic 
correlates of serum levels to more drugs and improve our techniques fo r  
the accurate measurements of unbound drug concentrations. By monitoring 
serum concentrations of potent drugs with narrow margins of safety, we 
shall be able to indiv idualize  dosages and to increase the efficacy and 
safety of pharmacotherapy. The basic pharmacological concepts of drugs have 
been extensively discussed in the textbooks by La Du and co-workers (1971), 
Melmon and M orrelli (1972), Levine (1973), and Goldstein and co-workers (1974'
1.2. Methods of Measurement
During the las t  decade serum concentrations of many drugs have been 
measured during th e ir  therapeutic use. This has become possible through 
the development o f methods of analysis that permit determination of very 
low drug concentrations. Methods for drug measurements have been 
extensively reviewed (Brodie 1971, Brodie et al 1971, La Du et al 1971, 
Marks et al 1973, Reid 1976, Williams, Nunn and Marks 1978).
Immunoassay Techniques
Many methods have been developed to follow reactions between antigen 
and antibody. "Classical" methods include haemagglutination, complement 
f ix a t io n  and immunodiffusion.
A more recent development is the use of labelled antigens and antibodies, 
a suggested c lass if ica tion  is outlined in Figure 1.2.
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Figure 1.2 A Classification of Drug Binding Assays
The term "binding assay" is used to cover several techniques that are 
based on the same principles as radioimmunoassay. Such assays are 
subdivided prim arily  by reference to the binding protein employed, as th is  
is the reactant which imposes both sp e c if ic ity  and s e n s it iv ity .  Thus 
immunoassays employ specific antibodies, while c ircu la ting  binding 
protein assays ( CBPA) use a natura lly  occurring plasma protein. For 
example, i t  has not yet proved possible to obtain satisfactory antibodies 
against the major c ircu lating  form of Vitamin D (25-hydroxycholecalciferol) 
so plasma (Belsey et al 1971; Preece et al 1973) from ra ch it ic  rats is  
therefore usually employed as the binding protein fo r  i ts  assay. A th ird  
group, receptor binding protein assays, employ proteins that are usually  
extracted from the target organ of the drug (Haddad and Chyu 1971).
These assays can be further subdivided into three groups, namely(1 )those in 
which no labelled reactant is employed and(2) those' in 'which the assay dependd 
upon observing the d istr ibution  of e ither (a)the labelled drug or of (b) the
labelled binding protein a f te r  separation of the bound and free fractions .
The la s t  two groups are f in a l ly  subdivided according to the nature of the 
labe l.  The use of enzymes as labels of antigens, haptens or antibodies in  
immunotests and quantitative immunoassays was i n i t i a l l y  explored independently 
by two groups of investigators (Engvall and Perlmann 1971a, 1971b, 1972, 
Engvall e t al 1971, Van Weemen and Schuurs 1971, 1972, 1974).
The nomenclature of assays with enzymes as labels requires some atten tion .
The most widely used names are:
(A) ELISA enzyme-linked immunosorbent assay (Engvall and Perlmann, 1971)
(B) EMIT system enzyme-multiplied immunoassay technique (Bastian i, 1978).
(A) is usually applied to antibody assays, while (B)
is almost en t ire ly  used for measuring low molecular weight compounds by a
method which does not require a separation step prior to f in a l assay ( i t  is a 
homogeneous enzyme immunoassay: see below).
The term "EIA" or "Enzyme immunoassay" (Van Weemen and Schuurs 1971) 
is a more general one,covering every method in which the extent of 
binding of enzyme-labelled antigen, hapten or antibody to i ts  immune 
reactant is measured.
EIA1s can be c lass ified  as homogeneous or heterogeneous (Rubenstein 
et al 1972):
( i )  Assays in which the label in the labelled reagent behaves d if fe re n t ly  
according to whether i t  is bound or not bound to -its specific  
counterpart in the immune reaction, and which therefore do not require a 
physical separation of the reactants into two fractions , are called  
homogeneous immunoassays (Rubenstein et al 1972).
( i i )  Assays in which the label behaves more or less id e n t ic a l ly  
irrespective of whether or not i t  is bound to i ts  specific  counterpart 
in the immune reaction, and which therefore require a separation of the 
reactants into two fractions , are called "heterogeneous-immunoassays"
(N.B. a l l  radioimmunoassays are heterogeneous assays).
1.2. A. Radioimmunoassay and Protein-Binding Methods
The f i r s t  radioimmunoassay was developed for insulin by Yalow and 
Berson in 1960. I n i t i a l l y ,  th is technique was applied predominantly by 
endocrinologists, to the assay of c irculating levels of peptide and 
protein hormones ; and was la te r  extended to compounds, such as steroids 
and the thyroid hormones, which require linkage to a c a rr ie r  molecule in 
order to induce the formation of a suitable antibody.
In 1968, Oliver e t al published the f i r s t  radioimmunoassay for a drug, 
d ig itox in ; and since that time such assays have been established fo r  a 
large number of drugs. These assays are proving of considerable value 
in pharmacokinetic studies and also in c l in ic a l practice, especially fo r  
drugs such as digoxin, gentamicin, whose therapeutic levels approach those 
at which serious side-effects  may occur,.
Basis of Radioimmunoassay
The technique is based on determining the percentage of the tota l amount 
of Ag (F+B) that is present in the antibody-bound fraction (%B)•
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Ag*Ab
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i i i  iii
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K2
K1 Ag Ab 
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i i  Ag Unlabelled Antigen (e .g . Hormone (X) Standard (S) or Unknown (U))
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iv Ag*Ab Labelled Antigen Bound to Antibody (B*)
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vi Ag Ab Unlabelled Antigen Bound to Antibody 
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This percentage depends on only three factors:
(a) I t  is d ire c t ly  related to the tota l amount of Ab present.
(b) I t  is d ire c t ly  related to the av id ity  (K) with which Ab binds
Ag, where K = K-j/I^ = (Ag:Ab) / (Ab)(Ag) and (Ag Ab), (Ab) and (Ag) re fe r  
to the molar concentrations of Ag Ab complex, free antibody and free  
antigen respectively, at equilibrium.
(c) I t  is inversely related to the tota l amount of Ag present.
In an immunoassay, the same concentration of the same Ab is present in
each tube, i . e .  factors (a) and (b) are kept constant so that the only factor
that influences the percentage of the to ta l Ag in the bound fraction  is the 
tota l amount of Ag present. In order to determine the percentage of the 
to ta l Ag that has been bound, a constant amount of Ag* is added to each 
tube (to act as a tracer) and the bound and free fractions are separated by 
one of a number of techniques. The percentage of the to ta l counts present 
in the bound fraction can then be determined and w il l  accurately re f le c t ,  
and be inversely related to,the tota l amount of Ag present. An unknown 
amount of the compound to be assayed can thus be quantified by comparing the 
distribution  of the tracerw ith  the d istr ibution produced by a series of 
standards. This d istr ibution  can be expressed in a number of ways such as 
the percentage of to ta l counts that are bound ( %B )  or free { % F )  or the ra t io  
of the counts in the two fractions ( i . e .  F/B or B/F) plotted against the 
concentration, or the logarithm of the concentration, of unlabelled antigen 
present in the system.
Requirements fo r  a Drug Radioimmunoassay
i . A Suitable Antiserum - Basic Principle
The production o f a suitable antiserum is .th e  most important step in 
developing an immunoassay for a drug, as i t  is the antibody which determines 
se n s it iv ity  and s p e c if ic ity . .  The drug must f i r s t  be linked covalently to 
a larger molecule to form a complex that is immunogenic,and the homogeneity 
of the immunogen assessed and, i f  necessary, a purif ica tion  step introduced. 
The purif ied  complex is then used to immunise. Appropriate animals are 
bled at various times and th e ir  sera assessed for the presence, t i t r e ,  
s p e c if ic ity  and av id ity  of the resultant antibodies.
i i . Preparation of the Immunogen
Considerable attention must be given in the preparation of an immunogen to 
leave exposed that part of the hapten molecule which d if fe rs  from i ts  main 
metabolites and natural or synthetic analogues. This aspect is important 
because the resultant antibodies are usually directed against the most 
exposed part of the molecule ( i . e .  the portion of the molecule well removed 
from the point of the attachment of the drug to the macromolecule), and i t  
is essential to develop a re la t iv e ly  specific assay i f  the need for a complex 
and time-consuming in i t i a l  sample pu rif ica tion  step is to be avoided.
Production of the immunogen requires the a v a i la b i l i ty  of a c a rr ie r  molecule 
which incorporates an available reactive group(s) and i ts  conjugation 
with a reactive group on an appropriate part of the drug.
A varie ty  of c a rr ie r  molecules have been employed, of which the most 
common have been human and bovine serum albumin (Table 1 .2 ) .  Of the 
various active groups on proteins (Table 1 .3 ) ,  the most valuable, from 
the standpoint of conjugation, is the E-amino group of lysine. Albumin 
has 59 such groups, together with a terminal ami no-group, although many 
are hindered s te r ic a l ly  and are therefore unavailable for conjugation.
Direct conjugation of the drug to the ca rr ie r  molecule can be accomplished, 
provided that the drug has a suitably reactive group, such as a carbonyl 
group (e .g . ,  barbiturates, prostaglandins and lysergic acid derivatives)  
or an amino group (e .g . amphetamine). Methods for d irec t conjugation, 
together with other functional groups that can be modified or r
permit the introduction of a carbonyl or amino group into the molecule? 
are l is ted  in Table 1.4.
Particular problems are encountered with some drugs, including phenytoiri 
(5,5-diphenyl-hydantoin), because they are chemically unreactive in th e ir  
natural form. I t  may be possible, however,to use one of th e ir  major 
metabolites (e .g . $-hydroxyphenytoin in the case of phenytoin) as the 
hapten and, in this way, to obtain antibodies that w il l  bind the parent 
molecule. The degree of substitution can vary from about 2 to 100 hapten 
molecules per ca rr ie r  molecule: but available evidence suggests that  
conjugates with a re la t iv e ly  low hapten to c arr ie r  ra tio  (less than 15:1) 
are the most immunogenic. There is also evidence that a bridge of four 
carbon atoms in length increases the immunogenicity of the hapten, probably 
by preventing the ca rr ie r  molecule from causing steric  hindrance between 
the drug and antibody-producing s ites . I t  is essential to appreciate, 
however, that animals immunised with such conjugates w i l l  produce populations 
of antibodies directed against the c arr ie r  molecule and the bridge as well 
as against the hapten. Indeed, the a f f in i t ie s  of the f i r s t  two populations
TABLE 1.2 C arrie r molecules used in  drug radioimmunoassay
Serum albumin, especially of bovine and human origin  
Egg albumin, (Ovalbumin)
Gamma-globulins
Haemocyanin, thyroglobulin, fibrinogen
Synthetic polypeptides, expecially poly-L-lysine and polyglutamic acid 
Synthetic polymers, such as polyvinylpyrrolidone
TABLE 1.3 Active groups of protein carriers (fo r  conjugation to haptens)
£-Amino group of lysine
Phenolic group of tyrosine
Sulphydryl group of cysteine
Carboxyl group of aspartic or glutamic acid
Terminal amino and carboxyl groups
Active positions on rings of tyrosine, tryptophan and h istid ine  which 
can be attached to haptens by diazonium salts
Imidazole ring of h istid ine
^ > ~ l e s s  reactive than the above
Hydroxyl group of serine
TABLE 1.4 Methods o f cova len tly  lin k in g  a drug to  a c a r r ie r  p ro te in
See Erl anger 1973 and references therein fo r  principles and methods of 
making drug-.protein conjugates
Functional group on drug Method of conjugation
Carboxyl ( i )  Use of isobutyl chloroformate to form a mixed 
anhydride, which w i l l  react d ire c t ly  with protein  
amino groups to form peptide bonds.
( i i )  Use of carbodiimides (R-N=C=N-r ' , where R and
1-E thy l- 3 - (3-dimethyl ami nopropyl) carbodiimide or 
l -cyc lohexy l-3 -[2 -m orpho liny l-(4 )-e thy l] 
carbodiimide can be used in aqueous solutions and 
dicyclohexylcarbodiimide in organic solvents to 
form peptide bonds.
( i i i )  Use of N-hydroxysuccinimide, in presence of 
dicyclohexylcarbodiimide, to form the N-hydroxy- 
succinimide ester, which may be more active than 
the free carboxyl group.
Aromatic amino Direct diazotisation to the active positions of 
tyrosine, tryptophan or h istid ine  residues.
Aliphatic amino ( i )  Use of carbodiimides (see above)
( i i )  Use of glutaraldehyde to link  amino groups
( i i i )  Use of 2-xylyene diisocyanate or toluene-2,4- 
diisocyanate to link  amino groups.
TABLE 1.4 continued
Aliphatic  amino cont.
Nitro
Hydroxyl
\
Carbonyl
( iv )  Use of 4-nitrobenzoyl chloride to form
4-nitrobenzoyl amide, which can then be reduced 
to the 4-ami nobenzoyl derivative and linked by 
diazotisation as for an aromatic amino group.
Reduce to a primary amino group and then as above
( i )  Addition of equimolar proportions of anhydrides 
of dicarboxylic acids (e .g. succinate) to the 
drug gives ha lf  esters (e .g . hemisuccinate) and 
the free carboxyl group can then be linked as above
( i i )  Introduction of a carboxyl group using u>-halo- 
substituted carboxylic acids.
( i i i )  Formation of a chlorocarbonate with phosgene and 
use of the Schotten-Baummann reaction to l ink  i t  
d ire c t ly  to amino groups on the c a rr ie r  molecule.
( iv )  Use of oxidising agents to convert the alcohol 
into a carboxylic acid.
( i )  Formation of the 0-(Carboxymethyl)oxime using 
0-(Carboxymethyl)hydroxyl amine and reaction of 
the free carboxyl group as above.
( i i )  Introduction of a carboxyl group using 
4-hydrazinobenzoic acid.
TABLE 1.4 continued
Carbonyl cont. ( i i i )  Sch iff  base formation d ire c t ly  with primary
amino groups on the ca rr ie r  molecule.
Active hydrogen • ( i )  D irect conjugation using the Mannich reaction
( i i )  Reaction with diazotised 4-aminobenzoic acid 
to give a derivative with a free carboxyl 
group.
are often greater than that of the hapten-directed antibodies. These 
factors may influence the choice of labe lling  technique.
i i i .  Immunisation
The production of a suitable antiserum remains an a r t  rather than a 
science (Hurn et al 1971) and depends on such variables as the species of 
animal used, the dose and frequency of immunisation and apparently, on 
chance. Rabbits and guinea-pigs have been commonly employed;although there 
is an increasing tendency to immunise larger mammals, such as goats or 
sheep. The response to the particu lar immunogen appears t ( \  be genetically  
determined, probably by a single gene transmitted as a Mendel!ian dominant. 
Hence i t  is best to immunise at least four, and preferably more, random 
bred animals. Relatively  small amounts (about 100 yg) of the immunogen 
are dissolved in saline and used to prepare a stable w a te r- in -o il  emulsion 
with an adjuvant. The adjuvant is essential,as i t  ensures that the immunogen 
is released slowly, fa c i l i ta te s  i ts  phagocytosis by macrophages and 
stimulates the reticulo-endothelia l system,with a resultant m ultip lication  
of macrophages and of immunologically competent lymphoid c e l ls .
The immunogen is injected into any of a variety  of s ite s , with recent 
evidence favouring intradermal administration (Va ituka itis  e t al 1971).
A fter a delay of 7-8 days, c ircu lating antibodies, predominantly of the 
IgM class, are detectable and increase in concentration over several weeks.
I t  is usual to give a booster in jection a f te r  4 weeks or more,and to take 
blood 10-14 days la te r .  The response to the second in jection  d if fe rs  from 
the primary response in being more rapid (about 4 days), increasing to a 
maximum in about 10 days and involving a greater production of antibodies, 
almost e n t ire ly  of the IgG class. There is evidence that the most avid 
antibodies are produced by resting the animal for 3-6 months before giving 
a f in a l boost (Hurn et al 1971).
iv .  Assessment o f an ti sera
The presence of several d if fe re n t  antigenic determinants in most immunogens 
results in the production of several antibody populations, each orig inating  
from a single clone of cells  and directed against a single determinant.
Every serum, including each bleed from an individual animal, must be 
assessed care fu lly . The t i t r e  is determined by means of an anti serum 
d ilu tion  curve. From a practical standpoint, the av id ity  of the anti serum 
can be regarded as synonymous with the se n s it iv ity  that can be achieved 
in an assay and is determined by setting up a standard curve. The data 
from such an experiment can also be used to establish the equilibrium  
constant by means of a Scatchard p lo t, (Scatchard 1949), in which the 
ra tio  of bound to free antigen is plotted against the concentration of 
bound antigen, expressed in moles per l i t r e .  F in a lly ,  the s p e c if ic ity  
can be determined (a) by constructing a series of standard curves using 
the drug, i ts  major metabolites, s tru c tu ra lly  analogous and other exogenous 
compounds and s tru c tu ra lly  related endogenous compounds, and (b) by 
assaying actual samples obtained from people(i)not receiving- and(ii)receivinnc  
the drug, to ensure that results obtained are indeed due to the presence 
of the drug i t s e l f .  A cross check against an a lte rnative  method for assaying 
the drug (e .g . GLC Mass Spectometry) is frequently helpful.
v. Selection of label in immunoassay
During the las t  two decades there has been a large increase in the number 
and variety  of immunodiagnostic tests performed. One of the reasons *for  
this has been the development and perfection of methods which use labelled
antigens or antibodies resulting in tests with very high levels of 
s e n s it iv ity  and s p e c if ic ity .  These labels can be of many types Fig 1*2 
e.g. radioisotopes (Yalow and Berson 1959, 1960, Ekins 1960), enzymes 
(Engvall and Perlmann 1971a, 1971b, 1972, Van Weemen and Schuurs 1971,
1972, 1974), fluorescent dyes (Aalberse 1973, Cukor e t al 1976), electron-  
dense compounds (F e r r i t in ,  Singer and Schick 1961), protein-bacteriophage 
(Haimovich and Sela 1969, Haimovich et al 1970), and stable free radicals  
(Leute e t al 1972a, 1972b, Bastiani e t al 1973).
There are many factors influencing the choice of label in immunoassay 
techniques, these are:
1. The label should be cheap and available in highly purified  form: 
measuring equipment should be already available in most laboratories  
and preferably inexpensive.
2. I t  should be detectable at very low concentrations.
3. The labe lling  procedure should be simple and i t  should be easy to
purify the conjugate.
4. The labelled antigen or antibody should have long shelf l i f e .
5. Its  measurement should be simple and precise,and id ea lly  no separation 
stage should be involved.
6 . I t  should not be susceptible to interference in i ts  measurement from 
non specific factors in biological f lu id s .
7. I t  should not be susceptible to interference from the anti gen-anti body 
reaction.
8 . I t  should be applicable to a wide range of haptens, antigens and
antibodies.
9. I t  should be automatable, or a t least po ten tia lly  semi-automatable.
All radioimmunoassays are heterogeneous assays which make necessary a 
separation of bound from free ia b e i . . The radioisotopes used as labels in 
RIA are 131I 125I 3H l h C and 75Se. Most drug immunoassays currently
employ an isotopica lly  labelled drug both to permit determination of the 
f in a l d istr ibu tion  between the bound and free fractions and, when an 
in i t i a l  purif ica tion  step is included, to enable allowances fo r  any 
losses to be made.
The isotopes used f a l l  into two groups, each with i ts  advantages and 
disadvantages. One comprises the beta-emitters 3H and 11+C, while the 
other includes the gamma-emitting isotopes 125I ,  131I and 75Se. When 
the number of samples that w i l l  require assay is small, there are many 
advantages in employing the drug labelled with 3H. Thus, replacement 
of XH by 3H does not cause s teric  or other changes in the molecule and 
seldom, therefore, influences i ts  antigen ic ity ; the resultant labelled  
drug is chemically stable, which together,with the long h a l f - l i f e  of 3H 
(12.3 years), helps to ensure a prolonged s h e l f - l i f e ;  and there is minimal 
health hazard. Nonetheless, 3H-labelled drugs have a number of disadvantages 
for use in radioimmunoassays. 'These include th e ir  low specific  a c t iv ity ,  the 
cost of l iqu id  s c in t i l la n t  and counting via ls  and, because antibody 
binding of the labelled antigen may s ig n if ica n tly  reduce the counts obtained, 
perhaps a need to dissociate the antigen antibody complex i f  the 
bound fraction is to be counted.
t
There is considerable merit in employing a drug labelled with a gamma- 
emitting isotope when the number of samples to be assayed is  large. The 
samples can be counted d ire c t ly  in a gamma-counter, without the need for  
l iqu id  s c in t i l la n t  or denaturing the antibody; no correction fo r  quenching 
or chemiluminescence is required; and the counting time can be markedly 
reduced, thereby increasing sample throughput, because of the much higher 
specific  a c t iv i t ie s  that can be attained.
Thus i t  requires approximately 10,000 atoms of 1-tfG and 100 atoms of 3H to 
produce the same number of disintegrations per minute as one atom of 
i2 5 i .  i25 j has marked advantages compared with 131I fo r  la b e l l in g ,  
including i ts  greater isotope abundance, better counting e ff ic ien c y ,  
longer h a l f - l i f e  and lesser health hazard (as i t  is less penetrating).
Labelled drugs can be prepared by using a normal synthetic ro u te . But 
this may be very expensive:and a cheaper a lte rn a tiv e , fo r 3H, is to 
hydrogenate the molecule or to exchange i t  with t r i t ia te d  water. A 
varie ty  of methods have also been introduced fo r  radioiodinating drugs 
without causing marked structural a lterations in th e ir  antigenic determinant. 
These include the substitution of 125I for 127I in the small number of 
drugs (such as thyroxine) that contain iodine in th e ir  molecules, and 
the iodination of a suitable derivative of the drug made s p e c if ic a lly  for  
the purpose. Among the compounds used to prepare such derivatives are 
tyrosine, tyramine and histid ine residues,and the active acylating agent 
3-(4-hydroxyphenyl) propionic acid N-hydroxysuccinimide ester. Thus 
iodine-labelled dig itoxin  has been prepared by f i r s t  linking i t  to tyrosine  
methyl ester,and lysergic acid diethylamide has been radioiodinated a f te r  
i n i t i a l  covalent linkage to a suitable synthetic polymer. The iodination  
can be performed a f te r  the derivative has been made or, as is essential with 
oestrogens whose A ring would be iodinated with consequent loss of a n t i ­
gen icity , a compound can be iodinated f i r s t  and then linked to a drug.
Another approach has been to radioiodinate the tyrosine and h istid ine  
residues of a protein covalently linked, by one of the reactions discussed 
e a r l ie r ,  to the drug. Under no circumstances should the conjugate employed 
as the immunogen be used for this purpose,as the antiserum w i l l  usually 
contain antibody populations directed against the c a rr ie r  molecule and/or 
bridge, which are often of higher av id ity  than those directed against the dru
Thus the addition of even large amounts of unlabelled drug w il l  not 
compete with the labelled conjugate. Success can be achieved,provided 
that both the c a rr ie r  protein and the reaction employed to produce the 
conjugate fo r la b e l l in g ,d i f fe r  from those used for preparing the immunogen.
The actual radioiodination is usually performed by using chloramine T to 
oxidise iodide-125 to active iodine-125,and a small reaction volume is 
employed so as to ensure a high y ie ld  of labelled compound (Hunter e t al 
1962) . Sodium metabisulphate is then added in order to reduce any unreacted 
iodine-125 back into i ts  inactive form. Exposure of the drug to strong 
oxidants and reducing agents may, on occasion, damage the antigen,and 
enzymic oxidation with lactoperoxidase or gaseous diffusion can be employed 
in order to minimize this damage. The reaction mixture usually contains 
free unreacted Na125I ,  unlabelled drug, undamaged labelled drug, and 
labelled drug that has been damaged during the procedure. A varie ty  of 
physicochemical techniques have been employed for p u rif ic a t io n , including 
gel and adsorption chromatography and electrophoresis. Assessment of the 
s u ita b i l i ty  of a labelled drug involves studies of i ts  binding in an excess 
of antibody (which should usually exceed 90%) and a check of the s e n s it iv ity  
of the standard curve obtained when i t  is used as the tracer. Regular 
checks of i ts  radiochemical purity  are also essential.
v i . Method for Separating the Antibody-bound and Free Fractions
All radioimmunoassays require a separation procedure because the bound 
fraction does not precipitate  spontaneously at the low concentrations 
employed. Procedures that explo it physicochemical or immunological 
differences between the two fractions, .-(some of which are l is te d  in ; ,
Table 1.5) are available in a wide variety .
TABLE 1.5 Techniques employed for the separation of bound and free antigen
Basis of Method
D iffe re n tia l migration 
of bound and free  
fractions, caused 
mainly by:
(a) differences in 
charge
(b) differences in 
re la t iv e  molecular mass
Adsorption methods
(a) Free fraction
Material or technique used
paper chromatography or 
chromatoelectrophoresis. 
Electrophoresis on starch gel, 
cellulose acetate, or polyacrylamide 
wick chromatography
Gel f i l t r a t io n
*Gel equ ilib ra tio n , using e.g. 
thyopac 4
*coated charcoal 
*s i l ic a te s ,  e .g. talcum powder, 
Quso G-32, Fu lle r 's  earth and 
FIori si 1
Anion-exchange resin e.g.
Amber!ite CG-400
References
Berson et a l (1956)
Hunter & Greenwood(196'
Orskow (1967)
Haber, Page & Richards 
(1965)
Herbert e t al (1965) 
Rosselin et al (1966)
Meade & Klitgaard (196
(b) Bound fraction Anion-exchange resin , e.g. DEAE- Frenkel, Keller &
cellulose McCall (1966)
TABLE 1.5 continued
Basis of Method Material or techniqe used References
Fractional p re c ip it ­
ation of bound fraction  
using:
*An organic solvent
Salt
Acid
Ethanol -  NaCl
Ethanol
Dioxan
Polyethylene glycol
Sodium sulphate 
Ammonium sulphate
Trichloroacetic acid a f te r  enzyme 
proteolysis of free fraction
Odell e t al (1965) 
Heding (1966)
Thomas & Ferin (1968) 
Desbuquois & Aurbach 
(1971)
Grodsky & Forsham(1960' 
Chard et al (1971)
Mitchell & Byron (1967'
Immunological 
precipitation of bound 
fraction (double­
antibody method)
*Precip ita tion  a f te r  f i r s t  antibody Utiger et al 1962
i ncubation ( post-preci pi ta t i  on)
Preincubation of f i r s t  and second 
antibodies prior to assay (pre­
precip ita tion)
Second antibody linked to solid  
matrix (double-antibody - solid phase) (1971)
Morgan & Lazarow (1963] 
Hales & Randle (1963)
den Hollander & Schuurs
Solid-phase methods
*F irs t  antibody Antibody-coated discs and tubes
Antibody linked to f in e ly  divided 
solid phase, e .g. activated  
Sephadex
Polymerized antibody 
Second antibody (see above)
Antigen (immunoradio- 
metric assay)
* Denotes most commonly employed methods
Catt & Tregear (1967) 
Wide & Porath (1966)
Donini & Donini (1969) 
Miles & Hales (1968)
In selecting and assessing a separation technique, i t  is useful to 
consider the c r i te r ia  that should be f u l f i l l e d .  The major requirements 
of an ideal separation (R a tc li f fe  1974) are that i t  should:
i .  Completely separate bound and free fractions , with a wide margin 
fo r  e rro r , in  the conditions used for separation. This implies that the 
method should not in terfe re  with the primary binding reaction. Failure  
to meet this requirement w i l l  impair precision and s e n s it iv ity  of the 
assay;
i i .  be simple, quick and cheap,and use reagents and equipment that are 
read ily  availab le . Any method that lacks p ra c t ic a b il i ty  n u l l i f ie s  a major 
potential advantage of saturation analysis, that of large sample capacity;
i i i .  not be affected by plasma or serum. Failure to meet th is  requirement 
causes d i f f ic u l t ie s  in standardization which may not be completely solved 
by equalizing the concentration of serum or plasma in a l l  tubes.
No single separation method is ideal;and, in establishing a new assay, 
i t  is wise to compare at least two, and preferably three, procedures that 
d i f fe r  in the principles on which they operate. Those which depend on the 
d if fe re n t ia l  migration of the two fractions, such as paper or column 
chromatography, are too complex;and the number of samples that can be 
processed is too small for routine use. Gel equilibration is ,  however, a 
valuable adaptation of the la t t e r ,  especially for use with low-avidity  
binding proteins, because i t  is v ir tu a l ly  independent of time and temperature, 
An appropriate porous gel, which excludes the bound but not the free fraction, 
is added to the assay via ls  in accurately measured amounts and is present 
throughout the reaction. Once equilibrium has been reached, an a liquot of 
the supernatant solution, which contains the antibody-bound antigen, is 
counted.
Adsorption techniques, based on the use of coated charcoal, are simple, 
rapid, applicable to large numbers of samples and are among the most 
popular separation methods fo r  drug assay. Their use depends on the 
av id ity  with which the charcoal binds a particu lar drug and i t  is essential 
that the charcoal is pre-treated (e .g . by the addition of serum) in order 
to prevent i t  also adsorbing gamma-globulins, and, therefore, some of 
the bound frac tion .
Precipitation of the bound drug, by addition of neutral salts or organic 
solvents, also has much to recommend i t ,  provided that the concentration 
of the precip itant used is care fu lly  chosen so as to bring down a l l  the 
bound and none of the free frac tion .
Two other separation methods must be mentioned because of th e ir  universal 
a p p l ic a b il i ty .  One, the second antibody technique,involves converting the 
bound fraction into an insoluble m icelle , by addition of an excess of 
anti serum raised against the IgG of the species used to produce the 
antibody employed in the actual assay. I t  is based on the finding that  
the antigenic determinants of IgG are separate from i ts  binding s ite s ,  
and f in a l separation of the bound fraction involves centrifugation or 
f i l t r a t io n .  The second antibody can be added before, during or a f te r  the 
f i r s t  reaction. The other universal technique depends on the use of 
antibody attached covalently, or by adsorption, to an insoluble support 
with separation achieved merely by pouring o f f  the supernatant 
containing the free frac tion . A variety  of insoluble supports have been 
used, including paper discs, the walls of polystyrene or polypropylene 
tubes and cellu lose, sepharose or sephadex p artic les .
1.2. B. Use o f A lte rn a tive  Immunoassay Techniques Employing Radioisotopes
Immunoradiometric Assay
This technique d iffe rs  from radioimmunoassay in that the drug is  
measured d ire c t ly  by combination with an excess of specific  isotop ica lly  
labelled antibodies (Woodhead et al 1974). The assay involves the 
preparation of a specific immunoadsorbent by covalently linking the 
drug to a solid support such as powdered cellu lose. This immunoadsorbent 
is used to extract specific antibodies from the immune serum, which are 
radioiodinated while s t i l l  bound to the solid phase and then eluted by 
decreasing the pH. Samples and standards are incubated fo r  an appropriate 
time with a constant amount of labelled antibody, which is present in 
excess. Unreacted antibody is then removed by adsorption on to an excess 
of immunoadsorbent;and the higher the concentration of drug the greater 
is the number of counts in the supernatant..
The advantages of immunoradiometric assays are the re la t iv e  ease of 
labe lling  antibody molecules, the high specific a c t iv i ty  that can be 
achieved owing to the many tyrosine residues present, the s ta b i l i ty  of 
the labelled product and the improved s p e c if ic ity  that is possible i f  the 
method is modified to a "sandwich"technique (Addison et al 1971). In this  
technique, the drug is incubated with immobilised antibodies directed  
against one part of the molecule and labelled antibodies directed against 
a second antigenic determinant are then added. This approach also offers  
the p o ss ib il i ty  of employing a universal labe l, the drug and unlabelled 
antibody f i r s t  being reacted and a second labelled antibody then being 
added that is directed against IgG molecule of the species providing the 
in i t i a l  anti serum.
1.2. Co Enzyme Immunoassay (EIA)
The application of EIA methods to the measurement of antigens, haptens 
and antibodies grew out of the use of enzyme-labelled antigens and 
antibodies in histochemistry and cytochemistry (Avrameas 1972) and 
the use of RIA fo r  the quantitation of humoral substances (Skelley e t  al 
1973). EIA methods overcome some of the lim itations of RIA and the 
advantages of these methods are l is ted  in Table 1.6.
TABLE 1.6 Advantages of EIA Methods
1. Specific and sensitive assays of wide a p p lic a b il i ty .
2. Equipment required is re la t iv e ly  cheap and is widely availab le .
3. Reagents are re la t iv e ly  cheap and have a long s h e l f - l i f e .
4. Manipulations are simple.
5. Assays may be very rapid and a separation step may not be required.
6 . The Variety of labels available may allow m ultip le , simultaneous assays 
to be performed.
7. Potential for automation.
8. No radiation hazards.
Choice of the Enzyme
Enzymes make suitable labels because th e ir  ca ta ly t ic  properties allow 
them to act as am plif ie rs . Thus a single molecule of certain enzymes 
can catalyze the formation of more than 105 molecules of product per 
minute (Alpert et al 1974).
No single enzyme is ideal fo r  use as a label in every conceivable 
type and use of EIA. Instead, one must determine which enzyme is most 
suitable fo r  a particu lar assay system. C r ite r ia  important for the 
choice of enzyme are:
(1) turnover number of the pure enzyme
(2) purity  of the enzyme preparation
(3) s e n s it iv ity  of i ts  detection
(4) s im plic ity  and speed of detection of the enzyme reaction
(5) absence of in terfe r ing  factors or of enzyme-like a c t iv i ty  in the 
te s t  f lu id
(6) s ta b i l i t y  of the enzyme and i ts  conjugate
(7) a v a i la b i l i ty  and cost of the enzyme and its  conjugate
(8) presence of po ten tia lly  reactive groups in the enzyme which allow 
linkage to other molecules while retaining a substantial part of 
the enzyme a c t iv i ty
(9) s u i ta b i l i ty  of the enzyme fo r homogeneous EIA ( i f  applicable).
The f i r s t  three c r i te r ia  determine the s e n s it iv ity  of the eventual assay. 
Generally speaking, the smaller the amount of enzyme label which can be 
detected, the more sensitive the resulting assay w il l  be. A sensitive  
assay cannot only be attained by selecting as label a highly purif ied  
enzyme with a high turnover number, but also by selecting a fluorogenic 
or radioactive substrate rather than a chromogenic substrate. C learly ,
the selection of substrate also effects the p ra c t ic a b il i ty  of the system, 
because measuring fluorescence or rad ioactiv ity  requires more care and 
more sophisticated equipment than measuring colour in tens ity . The choice 
between homogeneous and heterogeneous EIA w i l l  also influence not Dnly 
the p ra c t ic a b il i ty  of the assay but also the s e n s it iv ity .
The absence in the test f lu id  of factors in terfering with the enzyme 
a c t iv i ty  measurement is not an absolute requirement, since problems can 
usually be avoided by adopting an appropriate protocol.
Dilution of sample is the simplest approach, but has a d irec t a ffect  
on the attainable s e n s it iv ity .  Where this is not a problem, i t  is most 
often the only measure taken, as was the case in heterogeneous EIA1 s for  
IgG (Engvall e t  al 1971a, 1971b, Avrameas e t  al 1972, Masseyeff e t  al 
1973) and specific  antibodies (Engvall et al 1972, Saunders et al 1976, 
Bout e t al 1975, Pesce et al 1974, Carlsson e t  al 1972, 1975).
Enzymes Used
The following enzymes have been used as labels in EIA.
For heterogeneous EIA: 
horse-radish peroxidase (EC 1.11.1 .7)  
alkaline phosphatase (EC 3 .1 .3 .1 )
B-D-galactosidase (EC 3 .2 .1 .23)  
glucose oxidase (EC 1 .1 .3 .4 )  
glucoamylase (EC 3 .2 .1 .3 )  
carbonic anhydrase (EC 4 .2 .1 .1 )  
catalase (EC 1.11.1 .6)  
acetylcholinesterase (EC 3 .1 .1 .7 )
For homogeneous EIA:
glucose-6-phosphate dehydrogenase (EC 1.1 .1 .49)  
lysozyme (EC 3 .2 .1 .17 )
B-D-galactosidase (EC 3 .2 .1 .23)  
malate dehyrogenase (EC 1.1 .1 .37)
Detection of Enzyme Labels
Various substrates have been used, the product of the enzyme reaction  
in most cases being detected by photometry (or with the naked eye).
However, for 3-D-galactosidase fluorimetry has also been used, whereas 
glucoamylase, acetylcholinesterase and lysozyme have also been 
determined only by fluorim etry , s c in t i l la t io n  counting and tu rb id ity  
measurements, respectively. Very recently, new techniques for enzyme measuremeni 
based on chemiluminescence have been introduced(Velan e t  al 1978). The 
chemiluminescence results from the oxidation of pyragallol by H2 O2 which 
is catalyzed by peroxidase-labelled antigen. Thermometric methods of 
enzyme measurements have also been devised (Thermometric Enzyme-Linked 
Irmiunosorbent Assay TEL ISA Mattiasson e t al 1977, Mattiasson and Nilson 
1977, Mattiasson and Borrebaeck 1978, Mattiasson e t  al 1978). In 
TELISA, a microcolumn f i l l e d  with a polymer support containing covalently  
bound antibodies is used. This microcolumn-is well insulated from the 
surroundings. A continuous flow is pumped throughthe antibody bed.
Before the antigen-containing sample to be analyzed is introduced, a 
fixed amount of enzyme-label led antigen is added. On passage of the sample 
through the immunosorbent in the enzyme thennistor column, competitive 
binding of native and enzyme-labelled antigen to the antibodies w i l l  take 
place. The amount of enzyme bound to the column is measured by introducing 
a pulse of substrate. As the substrate is converted into product, heat is 
evolved and measured. The change in temperature of the solute passing the 
heat sensitive semiconductor induces a change in resistance. This change 
is amplified and is registered on a s tr ip  chart recorder.
Preparation of Enzyme-Labels
Many methods for coupling enzymes (or protein in general) to  other 
substances are known. Although the success of any coupling method w i l l  
depend on a correct choice of conditions ( ra t io  enzyme/protein or hapten; 
concentrations, pH, reaction time and temperature). Which conditions are 
optimal should be established separately for any two substances to be 
coupled to each other.
A. Methods for coupling enzyme to proteins
1. Glutaraldehyde method
Glutaraldehyde has been used for enzyme-protein coupling in two ways:
( i )  A one-step procedure, in which enzyme, the other protein and 
gluteraldehyde are reacted in a single step (Avrameas et al 1969),
Habeeb et al 1968). This method has been used fo r  the preparation of 
conjugates of a lkaline phosphatase (Engvall e t  al 1971a, 1971b, 1971c, 1972, 
Ruitenberg e t  al 1975 , Belanger e t  al 1973,1976 , Carlsson et al 1972, 1975 , 
1976, Hoffman 1973, Holmgren e t al 1973),glucose oxidase (Maiolini e t  al 
1975a, 1975b, Masseyeff e t al 1973), acetylcholinesterase (Van der Waart 
and Schuurs 1976) and horse radish peroxide (Van Weemen and Schuurs 1971, 
1974, Van Weemen 1974, Stimson 1975, Pesce et al 1974).
( i i )  A two-step procedure, in which enzyme and glutaraldehyde are f i r s t  
reacted, and the other protein is then coupled in a second step, a fte r  
removal of excess glutaraldehyde (Avrameas and Ternyck 1971). The reaction  
scheme is i l lu s tra te d  in Figure 1.4.
1 .
Protein  NH2 + CH0.CH2.CH2.CH2„CH0 + NH2 -Enzyme
T
Prote in------- <■ N = C H .C H 2 .CH2 .CH2 . C H =  N-Enzyme
Further^omplex reactions
2 .
Horse radish peroxidase-------  NH2 + CHO0CH2.CH2.CH2.CHO
I
Horse radish peroxidase  N =  CH0CH2.CH2CH2.CHO
Remove excess glutaraldehyde 
+ Protein — NH2
Horse radish p e ro x id as e ^ -N =  CHoCH2.CH2CH2.CH= N Protein
Figure 1.4 Formation of Enzyme-protein Conjugates using the
1) one-step and 2) two-step glutaraldehyde method.
2. Periodate method
This method (Nakane and Kawaoi 1974) has been used to couple horse radish 
peroxidase via i ts  carbohydrate moiety to other proteins (Ruitenberg e t  al 
1974, 1975a, 1975b, Sparcio e t  al 1975, Habermann 1976,
Kleinhammer e t  al 1976).
The reaction involves:-
( i )  blockage of the amino residues of the enzyme by reaction with 
fluorodinitrobenzene;
( i i )  oxidation by periodate of the carbohydrate residues of the enzyme 
to produce aldehyde groups;
( i i i )  reaction between these adldehydes and free amino residues on the 
second protein;
( iv )  s tab il isa tio n  of the crosslink by reduction with sodium borohydride 
(Figure 1 .5 ).
The enzyme y ie ld  of horse radish peroxidase can be as high as 70% (Nakane 
and Kawaoi 1974).
3. N,N*-O-Phenylenedimaleimide method
Recently, 6-D-galactosidase has been linked to other proteins via i ts  
sulphydryl groups by means of N,N'-O-phenylenedimaleimide (Figure 1 .6 ) .
The sulphydryl groups present in the other protein are obtained e ither by 
reduction of disulphide bridges (Kato e t al 1975a, 1975c, 1976) or by 
mercaptosuccinylation (Kato e t  al 1975b). The method is a two step procedure.
Enzyme'
NH;
carbohydrate
O2N
(1) Fluorodinitrobenzene
(2) Periodate
(3) Protein
(4) NaBH^
H-N NO2
Enzyme
CH 2 - NH Protein
Figure 1.5 Formation of enzyme-protein conjugates using the 
periodate oxidation method
P R O T E I N - S H
I
HS-ENZYME
Figure 1.6 Formation of enzyme-protein conjugates using the 
maleimide method
O
ANTIBODY—NH2 C= 0
N
HS-ENZYME
0
Figure 1.7 Formation of enzyme-protein conjugates using MBS.
In the f i r s t  step, the other protein is activated with N,N*-0-phenyl-  
enedimaleimide. A fter  removal of excess reagent the f-galactosidase  
is coupled. V ir tu a l ly  no enzyme a c t iv i ty  is lo st during the coupling 
procedure (Kato et al 1975b).
4. MBS method
Insulin has been coupled via its  amino groups to the sulphydryl groups 
of £-D-galactosidase (Figure 1.7) by means of m-maleimidobenzoyl-N-hydroxy 
succinimide ester (MBS) in a two-step procedure (Kitagawa and Aikawa 1976) 
Losses of enzyme a c t iv i ty  are very small. At least 1 0 %  of the enzyme 
a c t iv i ty  is linked to immunoreactive insu lin . For a more extensive review 
a r t ic le  see (Kennedy et al 1976).
B. Methods for coupling enzyme to hapten
The methods fo r  coupling haptens to  enzymes are usually d if fe re n t  from 
those for coupling proteins to enzymes because the small hapten molecules 
may d i f fe r  greatly  in the number and nature of th e ir  functional groups, 
in s o lu b il i ty  etc. These features,and the precisely known structure of 
the hapten, influence the choice of s ite  of the hapten to which the 
enzyme is attached. This may have an important influence on both the 
se n s it iv ity  and sp e c if ic ity  of the resulting enzyme-immunoassay.
1. Mixed anhydride method
This method (Figure 1.8) has been used to couple haptens to horse radish 
peroxidase (Van Weemen and Schuurs 1972, 1975, 1976, Stimson and S in c la ir  
1974, Bosch et al 1975, Van Hell e t  al 1976, Van Weemen e t  al 1975) and 
to 3-D-galactosidase (Comoglio e t  al 1976), and also, for use in 
homogeneous EIA, to lysozyme (Schneider e t  al 1973, Rubenstein et al 1972) 
and to malate dehydrogenase (Rowley e t al 1975).
2. Carbodiimide method
This method (Figure 1.8) has been used to couple progesterone-11 a- 
hemisuccinate to B-D-galactosidase (Dray e t  al 1975). I t  has also been 
used to couple c o r t is o l-2 1-hemisuccinate to alkaline phosphate (Ogihara 
et al 1977).
3. Periodate method
This method was used to obtain a conjugate of adenosine with B-D-galactosidase 
(Lauer and Erlanger 1974).
4. Miscellaneous methods
An acetamide derivative and a mercaptoethyl derivative of morphine have 
been formed from the amino and sulphydryl groups, respectively , of malate 
dehydrogenase (Rowley et al 1975). Very recently , a new cross-linking reagent 
N-(3-maleimidopropionylglycyloxy) succinimide (MPGS) has been used to couple 
antib io tics  (e .g . viomycin, gentamicin and p e n ic i l l in )  with 3-D-galactosidase
(Kitagawa and Kanamaru 1978).
2 .
Figure 1
Hapten  COOH + CH3(CH3) .CH.CH2-  0
\
C = 0
Cl
0 p
, li II
H3(CH3 ),CH.CH2  0 — — C—  0—  C— HAPTENt
Protein —
Protein
0
C— HAPTEN
Hapten —  COOH + N R - j = C = N R 2
NR-
Hapten—  C—  0—  C
NR,
0
II T
Hapten—  C— NH—  Protein
+ NHo - Protein
.8 Formation of hapten-protein conjugates using
1) the mixed anhydride method
2) carbodiimide condensation.
Hapten-NH2+ MBS M B S-acy la ted  Hapten
Dithiothreitol 
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m
Figure 1.9 Preparative method for hapten-MBS-protein conjugate
Hapten ( -N H 2 )
<° > 
n - ch2ch2conhch 2 c o o -n
MPGS
1^—CH2CH2CO NH CH2CO NH -Hapten
p -G a l  ( -S H )
' r
p - D - G a l - S <N - C H 2CH2 CONH CH2 CON H -  Hapten<
Figure 1.10 Preparation of hapten-MPGS-fr-D-Galactosidase conjugate
The labelling  of an tib io tics  with 3-D-galactosidase was performed in 
aqueous mild conditions by a two-step reaction using the sim ilar MBS 
method (Figure 1 .9 , Figure 1.10)
Types of Enzyme-Immunoassay
1. Competitive EIA for antigen
Labelled antigen competes with unlabelled antigen for binding to a 
limited quantity of antibody (Figure 1.11). The antibody-bound antigen 
is separated from the free antigen by the use of solid-phase antibody or 
a second antibody with sp e c if ic ity  fo r  the f i r s t .  The enzyme a c t iv i ty  
in e ither the bound or free fraction is determined and related to the 
concentration of the unlabelled antigen (Engvall e t al 1971). This 
procedure is analogous to the classical RIA method (Yalow and Berson 1960).
2 . "Immunoenzymometric" assay for antigen
Antigens react with excess labelled antibody and, a fte r  incubation, excess 
solid-phase antigen is added (Figure 1 .12). The solid-phase antigen reacts  
with the free labelled antibody remaining and, a fter  separation of the 
solid-phase, the enzyme a c t iv ity  associated with soluble antigen is measured 
and related to the concentration of antigen (Maiolini e t al 1975). This 
assay is analogous to the inmunoradiometric assay (Miles and Hales 1968).
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3. Sandwich EIA fo r  antigen
This procedure requires the antigen to have at least two binding sites  
(Figure 1 .13 ). The antigen reacts with excess solid-phase antibody; 
and,after incubation followed by washing, the bound antigen is treated  
with excess labelled antibody. After further washing the bound label is  
assayed, and this provides a d irec t measure of the amount of antigen
present (Maiolini and Masseyeff 1975). This assay is analogous to the
"two-site" immunoradiometric procedure (Addison and Hales 1971). A 
variation of this method ("double sandwich" EIA) involves a th ird  antibody 
(Belanger e t al 1973). This antibody carries the label and reacts with 
unlabelled second antibody already bound to the antigen. As before, the
amount of antigen is found by measuring the amount of bound label.
4. EIA for antibody
Antibody binds to excess solid-phase anti gen;and, a fte r  incubation 
followed by washing, labelled second antibody with s p e c if ic ity  for the 
f i r s t  antibody is added (Figure 1.14). The bound label is assayed a f te r  
further washing and i t  provides a d irec t measurement of the amount of 
specific antibody present (Engvall and Perlmann 1972). This assay is  
analogous to the radioallergosorbent technique (Wide et al 1967).
5. Homogeneous EIA for haptens
This type of EIA does not require separation of free and bound la b e l,  because 
the assay depends on inhib ition  or activation of the enzyme label by 
antibody binding (Rubenstein et al 1972) (Figure 1.15).
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o. uuier Lift s
Other types of EIA are possible;and two additional EIA1 s fo r  antibodies 
have been b r ie f ly  described (Schuurs and Van Weemen 1972). In the f i r s t  
(Type 6a), labelled and unlabelled antibody compete fo r solid-phase 
antigen. In the second assay (Type 6b) labelled antigen reacts with 
antibody; solid-phase antibody is then added and the remaining labelled  
antigen reacts with i t .  The amount of antibody is determined in both 
cases by measuring the enzyme a c t iv i ty  in the free or bound fractions a fte r  
centrifugation.
Bound/free separation in heterogeneous assays
A number of EIA1s have been described in which the immune complex formed 
is precipitated with a second antibody (double antibody technique): e .g.  
a-foetoprotein (Belanger et al 1976, Kirkpatrick et al 1977), TSH (Miyai 
et al 1976), a2H-globulin (Fuccaro-Decaens e t al 1974), and cortiso l  
(Comoglio e t al 1976, Ogihara et al 1977).
However, the great majority of heterogeneous enzyme-immunoassays described 
in the l i te ra tu re  have been performed with a solid phase which was prepared 
prior to the assay proper. Two types of solid phase can be distinguished, 
namely: loose material suspended in the test medium, or the inner wall of 
the test tube. Many investigators use cellulose (Engvall and Perfmann 1971b 
Van Weemen and Schuurs 1971, 1972, 1974) or agarose (Van Weemen and Schuurs 
1971, Stimson 1975, Kato et al 1975a, 1975c, 1976) to which antigen or 
second antibody are bound by various methods (Gurvich e t al 1961, Campbell 
1967, Axen et al 1967, Wide 1969).
immune reactants nave a iso Deen crusb-1 mK.eu <anu mbuiuui i u eu  uy  means 
of ethylchloroformate (Avrameas and Ternyck 1967) glutaraldehyde 
(Avrameas 1969, Avrameas and Guilbert 1972, Dray et al 1975,
Maiolini et al 1975), polyacrylamide (Biogel P-300) (Avrameas and Guilbert 
1971) and paper or plastic  discs (Saunders and Wilder 1974, Halbert and 
Anken 1.977) have also been,used as solid phases.
For many tes ts , polystyrene tubes are coated with e ither antigen ( Engva11 
and Perlmann 1972, Ruitenberg et al 1976a, 1976b,)'or antibody 
(Engvall and Perlmann 1971a, 1971b, Stimson and S in c la ir  1974, Stimson 1975) 
and serve both as container for the reaction and inmunosorbent. Even more 
convenient, p art icu la r ly  for qu a lita t ive  tests,are m icrotitra tion  plates 
coated with antigen (Voller et al . 1975b, 1975c, 1975d, 1976, Voller et al 
(1975) or antibody (Wolters e t al 1975a, 1976b, B ar t le t t  e t al 1976a).
Applications of Enzyme-Immunoassays 
EIA1s for Antigens and Haptens
The antigens and haptens that have been measured by EIA’s are l is te d  in 
Table 1.7 together with de ta ils  of the enzyme used and the se n s it iv ity  
obtained. Molecules that have been measured include macromolecular 
hormones, other serum proteins, bacterial toxins, drugs and steroids. 
Most of the assays have been applied to serum, but there are also assays 
for components of cerebrospinal f lu id  (Mukojima e t  al 1974) and urine 
(Van Weemen and Schuurs 1971).
T A B L E  1 . 7  E n z y m e - I m m u n o a s s a y s  f o r  A n t i g e n s  a n d  H a p t e n s
Antigen or hapten 
IgG
igE '
Haptoglobulin 
Factor V I I I
aj-Foetoprotein
human
c^H-Globul in
Enzyme Assay S e n s itiv ity  
type
AP 1 25 y g /l i t r e
AP 1 1 y g /l i t r e
P 1 10 m g /litre
P 1 0.2 m g /litre
P 1 50 y g /l i t r e
GO 2 50 y g /l i t r e
BG 3 0,4 ng
BG 3 50 pg
AP 1 10 y g / l i t r e
AP 1 2 y m o l/litre
AP 2
GO 2 0.7  y g /l i t r e
GO 3 10 y g /l i t r e
AP 1 1 y g /l i t r e
AP 3 1 y g /l i t r e
AP 1 1 y g /l i t r e
P 1 50 y g /l i t r e
R e f e r e n c e
Engvall and Perlmann 1971b 
Engvall e t al 1971 
Avrameas and G uilbert 1971 
Avrameas and G uilbert 1972 
Mukojima e t al 1975 
Masseyeff e t al 1973 
Kato et al 1975, 1976 
Kato et al 1975b
Hoffman 1973
Miedema e t al 1972
B a rtle tt  e t al 1976a, 1976b
M aiolin i e t al 1975 
M aiolin i e t al 1975b 
Belanger e t al 1973 
Belanger e t al 1974 
Belanger e t al 1976
Fuccaro-Decaens et al 1974
Albumin, Serum GA 1 Schuurs and Van Weemen 1972
T A B L E  1 . 7  c o n t i n u e d
Antigen or hapten Enzyme
Carcinoembryonic AP
antigen
Choriogonadotropin P
P
AC
P
Pregnancy-associated P
a-macroglobulin
H epatitis  P
surface antigen
Placental lactogen P
F e rr it in  AP
Insulin  AP
GA
BG
BG
P
A s s a y  S e n s i t i v i t y
t y p e
1 20 y g / l i t r e
1 0.1 K ilo in t .
u n i ts / l i t r e
2 10 in t .  u n i ts / l i t r e
1 <10 in f .  u n i ts / l i t r e
50 mlU/ml
3 0.2 m g /litre
3 3 y g /l i t r e
1 5 m U /litre
2 8 p .m o l/l itre
1 75 U / l i t r e
1 0.3 m U /litre
1 0.2 m U /litre
1 0.5 uU
1 5 m U /litre
R e f e r e n c e
Hammarstrom e t al 1975
Van Weemen and Schuurs 1971
Van Weemen and Schuurs 1974
Van Weemen and Schuurs 1976
Yorde et al 1978 
Stimson and S in c la ir  1974
Wolters e t al 1976
Kleinhammer e t al 1976
Boenisch 1976
Miedema e t al 1972 
Ishikawa 1973 
Kato et al 1975 
Kitagawa and Aikawa 1976 
Kleinhammer e t al 1976
T h y r o t r o p i n A P  1 1 0  m U / 1 i  t r e M i y a i  e t  a l  1 9 7 6
T A B L E  1 . 7  c o n t i n u e d
Antigen or hapten Enzyme
Cortisol BG
AP
GO
Oestriol P
0estradiol-17g BG
P
Progesterone P
BG
BG
Testesterone P
P
Vibrio  Cholerae:
exotoxin AP
1ipopolysaccharide AP
Herpes simplex virus P
Arabis mosaic virus AP
P l u m  p o x  v i r u s  A P
A s s a y  S e n s i t i v i t y
t y p e
1 1 y g /l i t r e
1 10 y g /l i t r e
1 70 n m o l/litre
1 200 p m o l/litre
2 pg
200 pg 
1 500 p m o l/litre
1 160 p m o l/litre
2 y g /l i t r e  
100 pg
4 90 y g /l i t r e
4 1.3 m g /litre
2 -
2 0.9 p m o l/litre
2  0 . 0 6  p m o l / l i t r e
R e f e r e n c e
Comoglio and Celada 1976 
Ogihara e t al 1977 
Holder 1978
Bosch e t al 1978
Abuknesha and Exley 1978 
Joyce e t al 1978
Joyce e t al 1978 
Dray e t al 1975 
Gros et al 1976
Rajkowski e t al 1978 
Yorde e t al 1978
( Holmgren and Svennerholm 
( 1973
Miranda e t al 1977
V oller e t al 1976
V o l l e r  e t  a l  1 9 7 6
TABLE 1.7 continued 
Antigen or hapten
Ornithine 5-amino 
transferase
Adenosine
DNP-lysine
Gentamicin
P e n ic illin
B ile  Acid 
Viomycin
E n z y m e  A s s a y  S e n s i t i v i t y
t y p e
BG 2 0.03 fmol
BG 1 0.5  ymol/ml
AP 3 10 n m o l/litre
AP 1 50 y g /l i t r e
BG 1 10 y g / l i t r e
BG 1
BG 1 10 y g /l i t r e
P 1 0.05 y m o l/litre
BG 0.3 y g /l i t r e
R e f e r e n c e
Hamaguchi e t al 1976
Lauer and Erlanger 1974
Engvall and Perlmann 
1971a, 1971b
Borrebaeck e t al 1978 
Kitagawa and Kanamaru 1978
Ise tta  e t al 1976 
Kitagawa and Kanamaru 1978
Matern e t al 1978 a>
1978 b.
Kitagawa and Kanamaru 1978
AP, A lkaline phosphate; BG, 8-D-Galactosidase; P, Peroxidase; GO, Glucose oxidase; 
AC, Acetylcholinesterase; GA, Glucoamylase.
Antibodies against macromolecules, viruses, bacterial products and 
eucaryotic parasites have been id en tif ied  and measured using EIA. These 
are l is te d  in Table 1.8 together with the enzyme used.
The antibody EIA may be used in a simplified form for screening large 
numbers of samples and fo r  obtaining qu alita t ive  results without the use 
of spectrophotometry.
Homogeneous El A1s fo r  haptens
The homogeneous EIA's for haptens are lis ted  in Table 1 .9 , together with 
the enzymes used as labels and the s e n s it iv ity  of each assay. Kits are 
conmercially avaiTable (the "EMIT" system) for assay of drugs of abuse 
in urine, a n t i-e p i le p t ic  drugs, cardiovascular drugs , anti depressants , 
chemotherapeutics and hormones in serum.
In p r in c ip le , EIA can be applied to a l l  antigen, hapten and antibody systems. 
EIA1s have so fa r  been developed fo r  serum proteins, tumour antigens, hormones 
drugs, antigens derived from various micro-organisms and antibodies directed  
to  them. These applications are l is ted  in the Tables 1 .7 , 1.8 and 1.9.
They constitute a most important contribution to the solution of diagnostic 
problems in many situations.
T A B L E  1 . 8  E I A ' s  f o r  A n t i b o d i e s
Antibody against E n z y m e  A s s a y  R e f e r e n c e
t y p e
Amoeba, s tra in  HK-9 Bos et al 1975
Albumin, Serum AP 4 Engvall and Perlmann 1972
Allergens, various
Carcinoembryonic antigen AP 4 Simmons and Perlmann 1973
Chori ogonadotropi n 6a Schuurs and Van Weemen 1972
DNA P 4 Pesce e t al 1974
P 4 . Matre e t al 1974
Dextran AP Larsson e t al 1975
Echinococcus granulosus 4 Bout e t al 1975, Farag e t 
al 1975
Escherichia Coli enterotoxin AP 4 Holmgren 1973
0 and Kj antigens AP Ahlstedt e t al ‘ 1974, Jodal 
et al 1974, Smith e t al 1974, 
Hanson e t al 1975
a i - F o e t o p r o t e i n A P 4  B e l a n g e r  e t  a l  1 9 7 3 ,  1 9 7 4
T a b l e  1 . 8  c o n t i n u e d
Antibody against E n z y m e  A s s a y  R e f e r e n c e
t y p e
y-Globulin 4 Streefkerk and Deelder 1975
IgG myeloma proteins AP 4 M ellstedt e t al 1974
Immunoglobulin lig h t  chains AP 4 Perlmann e t al 1972
Hog cholera virus 4 Saunders and Wilder .1974
Onchocera Volvulus AP 4 B a rt le tt  e t al 1975
Plasmodium species AP 4 V o lle r e t al 1974
AP 4 V o lle r e t al 1975
Rubella virus AP 4 V o lle r and Bidwell 1975
Salmonella species, 0 antigens AP Carlsson et al 1972, 
Carlsson e t al 1975
Schistosoma mansoni P 4 Bout et al 1975
AP 4 Huldt et al 1975
P 4 Streefkerk and Deelder 1975,
Deelder, and Streefkerk 1975
Streptolysin 0 
Toxoplasma gondii
GO 6b Schuurs and Van Weemen 1972
P 4 Bout et al 1975
T a b l e  1 . 8  c o n t i n u e d
Antibody against
Treponema pallidum  
T ric h in e lla  s p ira lis
E n z y m e  A s s a y  R e f e r e n c e
t y p e
AP 4 Veldkamp and Visser 1975
AP 4 Ruitenberg e t al 1975
P 4 Ruitenberg e t al 1975, 1976
AP 4 Engvall and Ljungstrom 1975
Trypanosoma cruzi AP 4 V o lle r e t al 1975
Trypanosoma rhodescense 
a Trypanosoma brucei AP 4 V o ller e t al 1975
Vibrio  cholerae, exotoxin and 
lipopolysaccharide
AP 4 Svennerholm 1975, Ahlstedt
et al 1974, Holmgren and 
Svennerholm 1973
AP, a lka lin e  phosphatase, 
60, glucose oxidase 
P, peroxidase
T A B L E  1 . 9  H o m o g e n e o u s  E I A  f o r  H a p t e n s
Hapten
Drugs of abuse:
Morphine and other opiates
Barbiturates  
(Phenobarbital sodium)
Benzodiazepines
Amphetamine
Methadene Hcl
Benzoyl ecoganine (Cocaine 
m etabolite)
E n z y m e  S e n s i t i v i t y  R e f e r e n c e
MD
L
L
0.5  m g /litre  Schneider e t al 1973, 1974,
Syva Corp, Rubenstein e t al 1972, 
Bastiani e t al 1973
10 n m o l/litre  Rowley et al 1975
0.5 m g /litre  Broughton and Ross 1975
0.5 m g /litre  Mule et al 1974
G6PD
G6PD
4 -2 0  y m o l/litre
Mule et al 1974
Brunk et al 1976,
Booker and Darcey 1975
Broughton and Ross 1975, 
Walberg 1974, O elle rich  e t al 
l97o
Spiehler e t al 1976
1.7 n m o l/litre  Haden et al 1976,
Broughton and Ross 1975 
McIntyre et al 1975
Broughton and Ross 1975 
McIntyre e t al 1975
Scheider et al 1974
Cannabinoids in Urine MD 25 y g /l i t r e  Rodgers et al 1978
T a b l e  1 . 9  c o n t i n u e d
Hapten E n z y m e  S e n s i t i v i t y R e f e r e n c e
A n ti-e p ile p tic  drugs 
in serum:
Diphenylhydantoin G6PD 2.5-30 m g /litre Syva corp, Booker and Darcey 
1975, Brunk e t al 1976, 
Fin ley e t al 1976
Primidene G6PD 2.5-20 m g /litre  Syva corp
Others:
Digoxin G6PD 640 p m o l/litre Chang e t al 1975, Sun & Soiehler 
1976, Rosenthal e t al 1976
Tobramycin BG Burd e t al 1978
Thyroxine MD -  Delvigne et al 1978
MD 260 n m o l/litre  Ullman et al 1975, Jaklitsch
et al 1976, Gallen and Forman 
1977
E strio l MD 2 n m o l/litre  Kohen et al 1978
AD 2 nm ol/-litre
Carbamazepine G6PD 4 p m o l/litre  James e t al 1976
Gentamicin P 3.7 y m o l/litre  Lee and Kenny 1975
L, Lysozyme; P, Peroxidase; MD, Malate Dehydrogenase; AD, Alcohol Dehydrogenase; 
G6PD, Glucose-6-Phosphate Dehydrogenase; BG, B-D-Galactosidase
P ra c t ic a b i l i t y  of EIA
The degree to which EIA w i l l  be used in the future c le a r ly  depends on 
the p ra c t ic a b il i ty  of the assays. Practical considerations include reagent 
s ta b i l i t y ,  attainable s e n s it iv i ty ,  accuracy and precision, s p e c if ic ity ,  
complexity of performance, sample s ize , assay time, f a c i l i t i e s  required, 
cost of equipment, health hazard etc. The sum of these factors determines 
the p r a c t ic a b i l i ty , as compared with other assay methods. The weight 
attributed to each factor w i l l  vary with application and with user (and 
available f a c i l i t i e s ) .
Several authors have compared, in some d e ta i l ,  the p ra c t ic a b il i ty  of EIA 
with tha t of RIA (Fuccaro-Decaens e t al 1974, Pesce e t al 1974, Saunders 
and Wilder 1974, Maiolini and Masseyeff 1975, Chang e t  al 1975, 1976, Mule 
et al 1974, and Brattin. and sunshine 1973), haemagglutination in h ib it ion  
(Mule et al 1974, and Brattin  and Sunshine 1973), gas-liquid chromatography 
(Booker and Darcey 1975, Mule et al 1974, Van der Slooten and Van der Helm 
1976, Spiehler et al 1976), free radical assay technique (B ra tt in  and 
Sunshine 1973) and immunohistology (Pesce et al 1974). In Table 1.10,Ts a 
b rie f  comparison of a number of characteristics of homogeneous and hetero­
geneous EIA with RIA (as the major representatives of highly sensitive an tig  
hapten assays) and with immunofluorescence (as a major representative of 
antibody assays in the microbiological f i e ld ) .  As is evident from th is  
table EIA compares favourably with both RIA and immunofluorescence.
However, EIA is s t i l l  in i ts  infancy, and improvements in a l l  the components 
of the technique are certa in . These include sensitive methods of enzyme 
immunoassay; better cross-linking reagents; separation procedures that are 
rapid and reproducible, and simultaneous assay of several components in a 
sample. Developments in these areas should lead to improved assays. The 
present study describes experiments which demonstrate the f e a s ib i l i t y  of
some of these approaches to improving enzyme immunoassay..
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CHAPTER 2
DEVELOPMENT OF ENZYME IMMUNOASSAYS FOR BILE ACIDS
Immunogens fo r  b i le  acids have been prepared by coupling e ither  
glycocholic acid and glycochenodeoxycholic acid to bovine serum 
albumin using the mixed, anhydride procedure. Two d if fe re n t  schedules 
for  immunisation were used.
Bleeding and boosting the animals was continued for twelve months.
<
A 6-D-galactosidase enzyme conjugate was prepared by the mixed anhydride 
method (y ie ld  17%). Using this label and second antibody to achieve 
separation of free and bound fractions the,basis for an immunoassay 
for glycocholic acid has been established.
Terminology
Trad it io n a lly  the term b ile  acid has been applied to a free b i le  acid 
and the term b i le  s a lt  to a conjugated b i le  acid. In man, b i le  salts  
are mostly both conjugated and ionised. In this chapter the terms 
b ile  acid and b ile  s a lt  w i l l  be used interchangeably.
1 Chemistry and Physical Properties of Bile Acids 
A. Stucture
Bile acids, in common with other steroids share the four-ring structure  
perhydrocyclopentanophenanthrene.
Human b ile  contains three main b i le  acids, cholic, chenodeoxycholic, 
and deoxycholic, with very small amounts of lithocho lic  acid.
3
Chenodeoxycholic acid 
3a, 7a-Di hydroxy-5B-Cholanoic acid
Cholic acid 
3a,7a,12a-Trihydroxy-53-Cholanoic acid
B. S o lu b i l i t y
Bile acids are colourless c rys ta ll in e  solids. The free acids are 
poorly soluble in aqueous media whereas the sodium salts are free ly  
soluble. S o lu b ility  increasing with the number of hydroxyl groups 
and is greater fo r  taurine than glycine conjugates.
C. Conjugation
When b i le  acids leave the l iv e r  cell and enter the b i l ia r y  t ra c t  they 
are almost completely conjugated .
The amino acids taurine and glycine are conjugated by peptide linkage
(
to the carboxyl groups on the side chain of the b ile  acids. Secondary 
b ile  acids returning to the l iv e r  are re-conjugated. Conjugation occurs 
via the formation of an activated acyl-CoA, which is condensed with 
glycine or taurine, to give the amino acid conjugate and free CoA-SH.
In man there are six major b ile  acids namely the glycine and taurine  
conjugates' of cholic , chenodeoxycholic and deoxycholic acid,
TABLE 2.1
Relative Proportions of the Six Main Bile Acids in 
Human B ile  (Sjbvall 1960)„
Glycocholic Acid 
Glycochenodeoxycholic Acid 
Glycodeoxycholic Acid 
Taurocholic Acid 
Taurochenodeoxycholic Acid 
Taurodeoxycholic Acid
Therefore, by choosing cholic acid and chenodeoxycholic acid to 
establish an enzyme immunoassay technique, 78% of to ta l b i le  acids 
can be accounted fo r  (th is  includes both taurine and glycine conjugates).
C lin ical Aspects
The synthesis of primary b i le  acids and the conjugation of a l l  b i le  
acids takes place in the l iv e r .  The amphipathic nature of the b i le  
acids solubilises non-polar l ip id s  and fa c i l i ta te s  the absorption of 
fa t  in in the upper small in tes tin e . In the d ista l ileum, these 
b ile  acids are ac tive ly  reabsorbed. Aerobic bacteria of the human 
colon are able to 7-hydroxylate and deconjugate these primary b i le  
acids to th e ir  secondary forms. The deconjugated taurine or glycine  
moieties are mainly excreted into faeces and some are passively 
absorbed. About 0.5 g of b ile  acids are lost via the faeces per day, 
representing 2% of the to ta l c ircu lating  b ile  acids. This loss is  
counter-balanced by the synthesis of about 0.5 g of b i le  acids per day 
by the l iv e r  (E vera ll ,  1974; and Williams, 1974).
Sherlock and Walshe in 1948 f i r s t  showed that b i le  acids are increased 
in the serum of patients with hepatobiliary disease, this has since been 
confirmed by numerous other investigators. The level of serum b ile  
acids may be affected by changes at any point in i ts  enterohepatic c irc u la t io n ,  
such as gall bladder contraction, in testina l absorption or hepatic 
clearance. In l iv e r  disease, the rate of b ile  acids clearance is  
reduced. The concentration of serum b ile  acids re flects  the frac tion  of 
enterohepatically circulated b i le  acids which have escaped extraction
by the l iv e r  (Hofmann, 1976). Makino e t a_l_ (1969) found that the 
amount of unconjugated serum b ile  acid levels rose in patients with 
active hepatic portal c irrhosis. In contrast to obstructive jaundice, 
the increase in the serum b ile  acids was exclusively in conjugated 
b ile  acids. Thus the determination of the concentration of b i le  acids 
in serum may be used to assess hepatocyte function of the b i l ia r y  
system (Rudman e t al_ 1957; Carey 1958; Osborn et al_ 1959; Neale e t al_ 1971; 
and Korman e t al_ 1974). Recently, Pennington e t  al_ 1977 have provided 
evidence that the cholic acid : chenodeoxycholic acid ra t io  may also be 
useful in the c l in ic a l  diagnosis of hepatobiliary diseases. A number 
of workers have suggested (Kaplowitz e t al_ 1973; Barnes e t_  al_ 1975;
La Russo e t al_ 1974; 1975) that exogenous and endogenous tolerance tests  
of b i le  acid metabolism are helpful in detecting 's i le n t '  l iv e r  dysfunction. 
Some reports have suggested that two hour post-prandial serum b ile  acid 
level is an especially sensitive indicator of hepatic disease (Barnes 
et a_I 1975; Kaplowitz and J a v it t  1973). Because most of the b i le  acid 
pool is sequestered in the gall bladder, reduced clearance of b i le  acids 
from the portal blood may not be apparent in the fasting s tate . For more
detailed information about the value of b ile  acid measurement the reader
\
is referred to the review by Bianchi, Gerok and Sickinger (1976).
Analytical Methods for Bile Acids
Many techniques have been described for the estimation of b i le  acids in 
serum. Various th in - la y e r ,  glass-paper chromatography (Ganshirt e t al 1960, 
Hofmann 1962; Eneroth, 1963; and Hamilton et a]_ 1959). Gas-liquid  
chromatography (GLC) and gas chromatography - mass spectrometry (GC-MS) 
(SjBvall e t al 1961; Sandberg et al 1965; Axelson et al 1974; Back e t al 1974)
methods have been described. Using GLC ind irect structural id en t if ic a t io n  
may be achieved (Eneroth et al_ 1966) by determining the retention times 
of a series of derivatives. The importance of GC-MS procedures for  
analysis of b i le  acids is ascribable to the fac t that 1) other methods 
are unable to provide both q u a lita t ive  and quantitative information on 
such small quantities of m ateria l, and 2) complex mixtures can be analysed 
d ire c t ly  with a high degree o f s p e c if ic ity .  Among its  many c lin ic a l  
applications has been the id e n tif ic a t io n  of 3 $-hydroxy-5-cholenoic acid 
in urine of cholestatic infants (Makino et_ aj_ 1971) and the discovery of 
a congenital defect in b ile  acid formation characterized by excretion of 
trihydroxy caprostanic acid (Eyssen et a1_ 1972).
Enzymic methods for the determination of b ile  acids, being simpler than 
previous methods and requiring re la t iv e  inexpensive equipment,are now 
widely used (Marcus et al_ 1956; Hurlock et al_ 1957; Iwata e t al_ 1964;
Frosch et'al_ 1967; Murphy et al_ 1970; 1972). These methods combine 
enzymic conversion of b ile  acids with f luorim etric  determination of NADH, 
thereby increasing the s e n s it iv ity  by up to one thousand fo ld . In most 
enzymic assays the sp e c if ic ity  of the method is partly  sacrificed in order 
to increase sample processing speed. Results obtained with such methods 
can lead to confusion and must be interpreted with caution un til i t  can be 
shown that relationships between individual b i le  acids and possible 
in terfe r ing  compounds in the sample do not change with changing experimental 
conditions.
The most recently introduced major method for b i le  acid analysis is 
radioimmunoassay, f i r s t  described by Hofmann and co workers for the 
analysis of cholic acid conjugates in plasma (Simmonds et al_ 1973). Other 
radioimmunoassay methods have since been reported (Van den Berg et al_ 1976; 
Murphy et al 1974; Mi has et al 1977; Spenney et al 1977; Roda et al 1977;
Demers et al_ 1976; flatern et al_ 1977; 1978; and Schalm et al_ 1977)
The present chapter describes the establishment of a basis for an 
enzyme immunoassay of glycocholic acid. Since this work commenced 
enzyme immunoassay fo r b ile  acids in plasma has been reported 
(Matern et al 1978).
3-D-Galctosidase (EC 3 .2 .1 .23 ) from Escherichia Coli was purchased 
from Boehringer Mannheim, Mannheim, West Germany, as a suspension in 
2.2 mmol/litre ammonium sulphate. Glycocholic acid [ 3H(G)] of 
specific a c t iv i ty  1.86 Ci/mmole and Chenodeoxycholic acid [ 3H(G)] 
of specific  a c t iv i ty  5.0 Ci/mmolewere purchased from New England Nuclear, 
Boston, Mass. Glycocholic acid, glycochenodeoxycholic acid 
0-nitrophenyl-3-D-galactopyronoside and Tris(hydroxymethyl) aminoethane 
(T r is ) ,  were purchased from Sigma, London, England. Sephadex G-25 gel 
(Pharmacia Fine Chemicals, Uppsala, Sweden). All other reagents were 
purchased from British  Drug House Chemicals L td .,  Parkstone, England.
Preparation of Immunogens
The method used for the preparation of the b i le  ac id -prote in  conjugate 
was the "mixed anhydride" technique described by Erl anger et al_ (1959). 
Glycocholic acid (50 mg; 100 pmoles was dissolved in 2 ml of dioxane:DMF(l:4 v/v 
and 100 ul of tri-n-butylam ine (lOOymoles dioxane:DMF(l:4 v/v))was added and 
kept s tirred  at 4° Cc Ethyl chloroformate/dioxane:DMF (100 yl ;100pmoles 1 :9v/v)  
at 4° C was then added to the b i le  acid solution. The reaction was allowed 
to proceed for 1 hour at 4° C and the mixture was then added to serum 
albumin (.45 mg; 1 pmol) in 5 ml of water-dioxane (3:2 v /v) containing 
100 y1 sodium hydroxide (0.2 m o l / l i t r e ) .  The pH of the reaction mixture was 
checked to be 8-8 .5  and was monitored every 15 min for the next hour.
The reaction mixture was l e f t  overnight at 4° C and checked for pH 
to ensure the pH was s t i l l  8 -8 .5 ,  diluted with water and freeze dried 
to remove solvents* The freeze dried residue was dissolved in 20 ml 
phosphate buffer (pH 7.5 100 m m ol/litre) loaded on to c e n tr if lo  membrane 
cones (Amicon) and l e f t  to spin at 2000 r.p.m. (Mistral 4L) for 1 hour.
The residue was washed with buffer three times and freeze dried. By 
using 3H-glycocholic acid as a tracer throughout the above protocol, the 
m olar-ratio of glycocholic acid to serum albumin was found to be 45:1.
The same technique was used fo r preparing the glycochenodeoxycholic acid -  
serum albumin conjugate immunogen. In this case the m olar-ratio  was 
found to be 27:1.
Immunisation Schedule
Either the glyco- or glycochenodeoxy cholate conjugate (1 mg) was 
dissolved in s te r i le  water (1 ml) containing 0.1 ml Bacille  Calmette Guerin 
(BCG vaccine) and emulsified with two parts of Marcol adjuvant which 
consists of Marcol 52 (Esso Petroleum Co.) containing 10% Arlacel 
(H i l l  Top Research Co., Ohio, U .S .A .). Two white female rabbits (3 months 
old) were used in this schedule, the i n i t i a l  dose was given by the low 
dose, m u lt i -s i te ,  intradermal technique (Va ituka it is  e t  a^ 1971 ) over 
60 sites (0c05 m l/s i te )  on the back were in jected. Booster in jections  
were given intramuscularly according to the response ( i . e .  a f te r  the peak 
response followed by the lowest t i t r e ) .  The booster in jections,containing  
0 .5  mg of the conjugate per 0 .4  ml of the tota l volume of emulsified dose, 
were injected in the legs (4 s ites , 0.1 m l/s i te ) .
Another two white female rabbits (3 months old) were injected each 
with one conjugate using an a lte rna tive  schedule in which the in i t i a l  
dose (800 yg) was dissolved 133 y l  s te r i le  water containing 0.1 ml 
BCG vaccine emulsified with two parts of Marcol adjuvant (266 y l )  
and injected intramuscularly (0.1 m l/s i te ,  4 s ites) into each leg. 
Booster in jections were given every two weeks intramuscularly in the 
legs (4 s ites) fo r  the f i r s t  month and then one month a f te r  that. The 
fourth boost was given a fte r  a further few months. (NB one of the two 
rabbits died during the experiment. The animal death was found not to be 
related to the course of in jections i t  had received).
Preparation of glycocholic acid - 3-P-galactosidase Conjugate
The method used fo r  preparing the enzyme conjugate was the mixed anhydride 
technique, a representative procedure is as follows: 15 y moles of
glycocholic acid was dissolved in 0.1 ml of dimethylformamide followed 
by addition of 15 ymoles of tr i-n -butylam ine, the temperature of the 
mixture was maintained at 4° C. 15 ymoles of isobutyl chioroformate at  
4° C was added and the reaction was allowed to proceed for 30 min a t 4° C. 
The mixture was then added dropwise to a s t ir re d , ice cooled solution of 
3 n moles of 3-D-galactosidase dissolved in 4 ml of d is t i l le d  water 
previously adjusted to pH 9.5 (using d ilu te  sodium hydroxide). During 
the coupling reaction, the pH of the solution was monitored and any decrease 
in pH was corrected immediately by dropwise addition of 0.1 ;N sodium 
hydroxide, to keep the pH at -  9 .0 . S tirr in g  and cooling was continued 
for four hours;the mixture was l e f t  overnight in the cold room, the pH 
being maintained at - 9 .0.
The re la t iv e ly  low molecular weight compounds were separated from the 
enzyme by gel f i l t r a t io n  on a Sephadex G-25 column using Tris buffer  
(50 m m ol/l itre , pH 7.5 containing, per l i t r e ,  magnesium chloride, 10 mmol, 
sodium chloride, lOOmmol and 2-mercaptoethanol, 10 mmol) as eluant.
Fractions containing enzyme a c t iv i ty  were pooled, the f in a l solution  
contained 0 . 0 2 % w/v sodium azide and 0 . 1% w/v bovine serum.albumin.
Determination of the Immunoreactivity of 3 -D-Galactosidase-Glycocholic 
acid Conjugate. .
The percentage of 3 -D-galactosidase bound to immunoreactive glycocholic 
acid was determined by incubating an a liquot of the enzyme-conjugate with 
excess glycocholic acid antiserum. Enzyme conjugate bound by glycocholic 
acid antibody was precipitated using the second antibody (Donkey a n t i- ra b b it  
IgG  antibody). 3 -D-Galactosidase a c t iv i ty  was determined in the 
precip ita te  a f te r  washing once with diluent buffer containing phosphate 
buffer (100 mmol per l i t r e  pH 7 .4 , sodium chloride, 100 m m ol/l itre ,
0.1% w/v BSA).
Enzyme Immunoassay Procedure
All d ilutions of anti serum and label were made with d iluent buffer.
400 yl of buffer was aliquoted into a series of tubes. 0.1 ml of d iluted  
enzyme-labelled glycocholic acid was added. A series of d i f fe re n t  
dilutions of antiserum (0.1 ml) were added to tubes. The tubes were l e f t  
to incubate at room temperature fo r  seven hours and 0 . 1  ml of second 
anti body(optimized dilution)was added and incubation continued overnight 
at 4° C. The tubes were then spun down at 2000 r.p.m. for 30 min and the 
precip ita te  washed twice with diluent buffer (1 .5 ml x 2 ).
A serum d ilu tio n  curve was plotted as the ra tio  of the fraction  bound 
to the to ta l a c t iv i ty .
Serum d ilu tion  curve of Glycocholic acid anti serum determined by 
radi oimmunoassay usi ng second anti body fo r  the separati on of bound 
and free phases.
A stock solution of glycocholic acid [ 3H(G)H in methanol (5.55 x 106 dpm/ml) 
was diluted 1 :1 01  with d iluent buffer (which contained phosphate buffer  
100 m m ol/litre , pH 7 .4 , 0.1% w/v BSA) to y ie ld  a working radiolabelled  
glycocholic acid standard (5.55 x 10  ^ dpm/ml). The assay tubes were set 
up as in the enzyme immunoassay procedure with the exception that the 
enzyme labelled glycocholic acid (0 . 1  ml) was replaced by radiolabelled  
glycocholic acid (0.1 ml). The incubation was carried out in a 37° C 
water bath for two hours and then various dilutions (optimized) were 
added to the assay tubes. The tubes were incubated overnight at room 
temperature and then spun for 30 minutes at 2000 rpm on a M istral 4L (MSE).
The supernatants (0 .4  ml) were added to s c in t i l la t io n  v ia ls  containing 
4 ml of sc in til lan t(to luene/m etapo l, 2:1, with 0.4% w/v ppo, 2 ,5-diphenyloxazol 
and 0.01% w/v dimethyl-popop, 1 ,4-bis 2-2 (5-phenyloxazolyl)benzene) and 
counted in a s c in t i l la t io n  counter (LKB 1210 ULTROBETA, LKB Instruments L td . ,  
South Croydon, Surrey).
Serum d ilu tion  curve of Glycocholic acid antiserum determined by 
radioimmunoassay using saturated ammonium sulphate for separation of 
the bound and free phases.
The working radiolabelled glycocholic acid was the same as described in 
the previous section. The assay was carried out in 3 ml capacity
flat-bottomed glass specimen tubes. Non-specific binding was 
ascertained by setting up s im ilar tubes containing diluent buffer  
(0.1 ml) in place of double diluted antisera (0.1 ml). To each tube 
was also added 0.25 ml of the diluent buffer , and 0.4 ml of 0.5% 
f i l te r e d  bovine gamma (y)-g lobulin  solution, this was followed by 50 v»l 
of working label of glycocholic acid. After vortex mixing b r ie f ly ,  the 
tubes were l e f t  to incubate in a 37° C water bath fo r  2 hours. Following 
incubation, 0 . 8  ml of saturated ammonium sulphate solution was added 
to each tube, except the to ta l tube, and l e f t  to cool a t 4° C for  
30 min. The tubes were then centrifuged at 4° C fo r  another 30 min.
The supernatant was aspirated, the precip ita te  washed again with d iluent  
buffer: saturated ammonium sulphate 1:1  (1 ml) centrifuged as before and 
aspirated. D is t i l le d  water (0.1 ml) was added to each assay tube to 
dissolve the residue, followed by s c in t i l la n t  (2 m l). The samples were 
then counted.
R E S U L T S
1. Immunisation Response
The radioimmunassay technique using the saturated ammonium sulphate 
procedure fo r  separation of free and bound was used for determining 
the t i t r e s  of anti serum. In the various rabbits under study maximum 
binding occurs at f in a l d ilutions of 1 / 2 0 0  ( i . e .  in i t i a l  d ilu tion  of 1/ 2 0 ) .
The results are shown in Figures 2.1, 2.2 and 2.3, for three rabbits ,
(the fourth rabbit died at an early  stage in the experiment). Antisera 
t i t r e s  showed s ign if icant increases in response to boosting doses of 
immunogen.
2. Cross-Reacti vi ty of the Anti sera
Preliminary results fo r the cross-reactiv ity  of the glycocholic acid 
anti serum showed that i t  cross-reacted with the glycocholic acid to 
100%, with taurocholic acid to 1 00%, and with glycochenodeoxycholic acid 
to 19%. Preliminary results for the cross-reactiv ity  of glycochenodeoxycholic 
acid antiserum showed that i t  cross-reacted with, glycochenodeoxycholic acid
to 100% and with taurochenodeoxychtolic acid to 50.%.
3. Preparation of Enzyme-Glycocholic acid Conjugate
The percentage of enzyme retention a fte r  conjugation was 75%.: by using 
glycocholic acid [ 3H(G)] as tracer to monitor this coupling, i t  was found 
that 33 molecules of glycocholic acid were couple to one molecule of
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3 -D-galactosidase in this experiment.
The antiserum d ilu tion  curve Figure 2*4 indicated a maximum binding 
of 17% at a 1/21 i n i t i a l  d i lu tion  of glycocholic acid antiserum. The 
non-specific binding of the 3 -D-galactosidase-glycocholic'acid  
conjugate to the anti serum was checked and was found to be in s ign if ican t  
for practical purposes.
Anti serum d ilu tio n  curves by radioimmunoassay
Two methods of separating the bound from the free fractions were 
employed, one using saturated ammonium sulphate and the other a second 
antibody.
The results are shown in Figure 2 .5 . At the anti serum d ilu tion  of 
1 / 2 0  ( i n i t i a l ) ,  the maximum binding for the saturated ammonium sulphate 
separation was about 71%, whilst for the second antibody separation i t  
was approximately 51%. (NB. The antiserum used was from the bleed that  
followed the prime in jection by four months to test the 3 -D-galactosidase- 
glycocholic acid conjugate and to do this experiment).
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Figure 2.4 Enzyme immunoassay antiserum d ilu t ion  curve against glycocholic acid using
second antibody for the separation of free and bound ohase.
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Figure 2 -5 Radioimmunoassay serum d ilu t ion  curve of Glycocholic acid using 
saturated ammonium sulphate (■) and second antibody ( • )  for the separation 
of bound and free phase.
The mixed anhydride procedure was used to prepare the immunogens 
( i . e .  BSA-cholyglycine and BSA-chenyl g lycine). The three antisera  
produced gave high t i t r e s  a f te r  boosting. The results of assessment of 
the anti sera suggest that they are adequate fo r measuring both 
conjugated cholic acid and chenodeoxycholic acid.
The mixed anhydride coupling procedure was used for preparing the 
8-D-galactosidase-glycocholic acid conjugate, to ensure that the side 
chain carboxyl group alone in the glycocholic acid structure was 
coupled to the enzyme. Coupling procedure involving the three hydroxyl 
groups (3a, 7a, 12a hydroxyl groups) in the glycocholic acid structure  
are probably important as antigenic determinants for the antibody binding 
sites (s p e c if ic ity  resu lts ).  The molar ra tio  used between glycocholic 
acid and 8 -D-galactosidase was 5000:1. From the radio label tracer  
study, there seems to be l i t t l e  doubt that glycocholic acid was 
successfully conjugated to the enzyme, probably about 30 molecules of 
hapten per molecule of 8 -D-galactosidase. This indicated that 1:4 free  
amino groups on the enzyme were involved in the conjugation. Gomoglio 
and Celada (1976) described the enzyme immunoassay method fo r c o r t is o l ,  
using the same coupling method. They obtained a substitution of 10 moles 
of cortisol per one molecule of 8 -D-galactosidase with 12,000:1 molar 
ra tio  of hapten to the enzyme. This figure is considerably less than the 
present finding.
I he reason why giycochonc acid showed a higher degree of incorporation 
than cortisol remains to be established. ' ' .
The immunoreactivity of the enzyme labelled glycocholic acid conjugate 
was very poor as determined from the antiserum d ilu tion  curve with a 
maximum binding of 17% at 1 /2 1  i n i t i a l  d i lu tion  of the anti serum using 
second antibody to separate bound and free fractions. There were 
several attempts to improve on these results by varying the second 
antibody concentration, the incubation time and incubation temperature, 
but none of these steps s ig n if ic a n tly  altered the degree of binding 
obtained. I t  is l ik e ly  that the second antibody separation 
■procedure was responsible for. th is 'd i f f ic u l ty ;  radioimmunoassay 
was carried out using second antibody separation technique and saturated 
ammonium sulphate, and the results indicated that a higher maximum 
binding and t i t r e  could be obtained using saturated ammonium sulphate 
(71% and t i t r e  of 320 i n i t i a l )  of 51% and t i t r e  <80 in i t i a l  (when second 
antibody was used). These results may be interpreted to indicate that some 
of the antibodies may belong to the IgM rather than to the IgG class; and 
that th is is the reason that the second antibody (anti IgG) fa i le d  .to precipita  
the f i r s t  antibody completely. Saturated ammonium sulphate lacks such 
sp e c if ic ity  in precip ita tion and therefore is a more e ffec tive  prec ip ita ting  
agent in this case.
Because of the lack of time, no further work has been carried out to 
establish an enzyme immunoassay for b ile  acids. The following experiments 
were planned:-
Improvement in the enzyme label by a) the use of higher molar ra tios  of 
hapten to enzyme, and b) the incorporation of bridge of four carbon atoms 
between the hapten and the enzyme (Wold et al_ 1967).
The use of a more avid second antibody to determine whether improved 
precip ita tion of f i r s t  antibody is possible using anti IgG.
Using higher t i t r e  bleeds of f i r s t  antiserum ( lack of time prevented
using the highest t i t r e  bleeds which were obtained to tes t the. . . .  
enzyme la b e l) .
Trying d if fe re n t  conditions for the assay to make i t  suitable for  
determination of b i le  acids (e .g . varying the incubation time and 
incubation temperature, varying the incubation volume).
The use of solid phase separation through attaching the f i r s t  antibody 
to e.g. cellu lose, sepharose, (tube w a ll ,  e ither covalently or uncovalently).
CHAPTER 3
NORTRIPTYLINE ENZYME IMMUNOASSAY
A double antibody enzyme-immunoassay method has been developed 
which enables accurate and specific quantitative determination in 
plasma of the t r ic y c l ic  antidepressant drug n o rtr ip ty l in e .  
N ortrip ty line  anti serum was raised in a sheep against a n o rtr ip ty l in e -  
bovine serum albumin conjugate prepared by use of N-4-(bromobutyl) 
phthalimide and 1-e th y l- 3 (3-dimethyl ami nopropyl)carbodiimide. The 
enzyme label was prepared by coupling 6-D-galactosidase, EC3e20lo23, 
from Escherichia Coli to desmethylnortriptyline by means of the 
bifunctional cross-linking reagent dimethyl adipimidate. Eighty 
per cent of the enzyme a c t iv i ty  was retained a f te r  coupling; 75% 
of the enzyme a c t iv i ty  was conjugated to desmethylnortriptyline.
A no rtr ip ty l in e  standard curve was set up by assaying the enzyme 
a c t iv i ty  associated with bound frac tion , following the addition of a 
donkey anti sheep second antibody. The s e n s it iv ity  of the assay was 
1 ng/ml, the in t ra -  and inter-assay precision (cv) were less than 
5 and 8 % respectively. Results for no rtr ip ty l in e  in plasma samples 
correlated well with those determined by e ither radioimmunoassay or 
gas-chromatography.
I N T R O D U C T I O N
Chemistry
3 - (3-methyl ami nopropylidene)-!,2:4,5-dibenzocyclohepta-l,4-diene,
10,11-Dihydro-5-(3-methyl ami nopropylidene) -5H-di benzo[a ,d] cycloheptene
N ortrip ty line  Hydrochloride C-J9H22C1N Mol eWt 299.8 
proprietary names: Acetaxa; Allegron; Aventyl; N ortr i len .
A white powder. M.P. 213-215°C
S o lu b il i ty .  Soluble at 20°C 1 part in 50 parts of water, 1 part in 
10 parts of alcohol(95 per cent); and 1 part in 5 parts of chloroform; 
almost insoluble in solvent ether and in benzene.
CH - C H 2- C H 2- N H - C H 3
Therapeutic Use and General Considerations
The t r ic y c l ic  anti depressant drugs such as am itr ip ty lin e ,  
n o rtr ip ty lin e  ( a dibenzocycloheptadiene d e r iv a tive ) , imipramine, 
desipramine (a dibenzazepine d e r iv a tiv e ) , and other closely related  
compounds have a range of therapeutic and toxic properties. They 
are widely prescribed for treatment of depression. Their efficacy in 
a lle v ia t in g  depression has been well established (Glassman and Pere l, 1973; 
American Psychiatric Association, 1974; and Schildkraut, 1974). But 
published data are in c o n fl ic t  regarding the relationship between 
drug concentrations in plasma and optimal response:
(Asberg e t al 1971; Burrows et al 1972, 1974; Braithwaite e t al 1972,
1978; Z iegler e t al 1976, 1977, 1978; Potter et al 1978; Coppen et al 
1978; Montgomery et al 1977; Cooper et al 1976; and Nakra e t al 1977).
They demonstrate marked pharmacokinetic heterogeneity -  largely  due to 
genetic factors (Alexanderson et al 1969; Hammer e t al 1966; and Sjoqvist 
et al 1967). Large differences in plasma levels are observed in subjects 
receiving identical da ily  dosage regimes. This puts the t r ic y c l ic  
antidepressants in the group of drugs for which blood drug measurements 
would be po ten tia lly  useful c l in ic a l ly ,  by permitting t i t ra t io n s  of 
drug dose fo r  individual patients thus probably optimising the drug's 
efficacy and.reducing its side-effectSo
A na ly tica l Techniques fo r  Measuring T r ic y c lic  Anti depressants
Numerous techniques fo r  measuring t r ic y c l ic  drugs in biological 
f lu ids  have been described. Colorimetric (Harrmann et al 1960) or 
f luorim etr ic  (Dingell e t al 1964); Moody, 1973) methods lack s p e c if ic ity  
and s e n s it iv ity .  These deficiencies can be partly  overcome by gas 
chromatography (Braithwaite e t al 1970, 1971; Dorrity e t  al 1977;
Gifford e ta l  1975; Borga et al 1972 and Schwertner e t al 1978).
Current GLC methods place heavy demands on both human and instrumental 
time and, despite the a v a i la b i l i ty  of solid micro sample in jec to rs ,
GLC techniques are not read ily  amenable to handling large numbers of 
biological samples.
The introduction of GLC-mass spectrometry (Hammer et al 1971) and 
GLC-mass fragmentography (Wilson et al 1977; Frigerio e t al 1972; 
and Biggs et al 1976) as quantitative techniques have reduced the 
l im i t  of detection. However, such approaches are costly to be employed 
widely and there is thus a demand fo r more chemically oriented methods 
with high s e n s it iv ity  and precision.
Thin-layer chromatographic methods (Farber et al 1974) do not o rd in a r i ly  
have s u ff ic ie n t  s e n s it iv ity  or precision to qualify  them for routine 
assay of biological samples.
Radioactive isotopic tracer techniques (Carnis e t al 1976; Hammer et  
al 1967; Harris e t al 1970) often provide much of the i n i t i a l  information 
about the pharmacokinetics upon which subsequent dose regimens are 
devised, but potential health hazards and economic considerations 
c learly  prevent i ts  routine application.
Radioimmunoassays have been reported for t r ic y c l ic  drug measurements 
(Aherne et al 1976; Read e t al 1978; Maguire et al 1978; Mould et al 1978 
Robinson et al 1977; and Spector e t al 1975). This technique combines 
the p o ss ib il i t ie s  of high sample turnover with the required s p e c if ic ity  
and s e n s it iv ity .
The present study describes an enzyme immunoassay for n o rtr ip ty l in e .
The assay incorporates use of a 8 -D-galactosidase-desmethylnortriptyline  
conjugate as tracer , with the separation of "free and bound" tracer  
being effected by means of a second antibody and i ts  comparison with 
radioimmunoassay and GLC.
Desmethylnortriptyline hydrochloride was a generous g i f t  from 
Dr. Ro A. Braithwaite, Poisons U nit, Guy‘ s Hospital, London.
N ortrip ty lin e  was a g i f t  from L i l l y  Research Centre L td .,  Windlesham,
Surrey, England. P ro tr ip ty line  was a g i f t  from Merck Sharpe and 
Dohme Research Laboratories, Dorval, Quebec, Canada. Imipramine, 
desipramine and carbamazepine were g if ts  from Geigy Pharmaceuticals L td . ,  
Basle, Switzerland. Am itripty line was donated by Dr. A. C. Moffat,
Home Office Central Research Establishment, Aldermaston, Berkshire,
England. Dibenzepine was purchased from Wander Pharmaceuticals L td .,  
Middlesex, England. B-D-galactosidase (EC 3 .2 .1 .23 ) from Escherichia Coli 
was purchased from Boehringer Mannheim, Mannheim, West Germany, as a 
suspension in 2.2 mmol/litre ammonium sulphate. Tris(hydroxymethyl) 
ami noethane(tris) was purchased from Sigma, London, England.
Dimethyladipimidate dihydrochloride (Pierce Chemical Co., Rockford, 111 .) ,  
was stored in 10-mg aliquots under reduced pressure -20°C.
2-Mercaptoethanol was from Koch-Light Laboratories L td .,  Colnbrook,
Bucks, England. Sephadex G-25 gel (Pharmacia Fine Chemicals) and bovine 
serum albumin, a 300 g /  l i t r e  solution from Armour Pharmaceutical Co.,
London, England, were also used.
The n o rtr ip ty l in e  antiserum (bleed S26, 10 /6 /76 ), supplied by Dr. G. W. Aherne 
et aj[ 1976 of this Department, was raised in a sheep against a 
nortrip ty line-bovine serum albumin conjugate prepared by use of 
N-4-(bromobutyl)phthalimide and 1-e th y l- 3 - (3-dimethyl ami nopropyl) 
carbodiimide. The donkey anti-sheep second antibody was purchased from 
Guildhay Anti sera, Guildford, Surrey, England. All other reagents were 
purchased from BDH Chemicals L td . ,  Parkstone, England.
Diluent buffer contained sodium phosphate (5 m m ol/litre , pH 7 .4 ) ,  
magnesium chloride ( 1 0  m m o l/l itre ),  2 -mercaptoethanol ( 1 0  m m o l/l itre ),  
sodium chloride ( 1 0 0  m m o l/l itre ), and bovine serum albumin (1 g / l i t r e )  
in d is t i l le d  water. This buffer was prepared from Tris(50 m m ol/litre ,  
adjusted with acetic acid to pH 7.5) and containing, per l i t r e ,  magnesium 
chloride ( 1 0  mmol), sodium chloride ( 1 0 0  mmol), and 2 -mercaptoethanol,
(10 mmol). Sodium bicarbonate buffer (100 m m ol/litre , pH 9.9) also 
contained per l i t r e ,  magnesium chloride ( 1 0  mmol) and 2 -mercaptoethanol 
( 1 0  mmol).
The &-D-galactosidase substrate solution contained Q-nitrophenyl-B-D- 
galactopyronoside (2 .3  m m o l/l itre ), sodium phosphate buffer (100 m m ol/litre ,  
pH 7c0), magnesium chloride (1 mmol/litre and 2-mercaptoenthanol 
( 1 0  m m o l/ l i t re )c
Plasma samples collected from patients receiving treatment with 
no rtr ip ty l ine  were assayed by gas liqu id  chromatography by Dr. Braithwaite  
(using the method of Braithwaite et al_ 1971) and by radioimmunoassay, 
with use of t r i t ia te d  imipramine as labe l, by Dr. G. Mould (using the 
method of Mould et al 1978)
Procedures
Preparation of the Desmethylnortriptyline-B-D-galactosidase Conjugate
A representative procedure is as follows: Desmethylnortriptyline (570 yg; 
2000 nmoles)and dimethy adipimidate DMA (488 yg; 2000nmoles) Were dissolved 
in dry methanol (0 .4 ml) containing 5% v/v N-ethylmorpholine a t 20° C.
An aliquot (100 pi; 500nmoles)removed a f te r  30 min and added to
(TOO yg; 200 pmoles)of B-D-galactosidase in 1 ml of the bicarbonate 
buffer. This solution was maintained fo r 90 min at 20° C, when the 
reaction was terminated by adding 1 ml of the Tris  buffer.
Purif ica tion  of the Enzyme Conjugate
To separate compounds of low re la t iv e  molecular weight from the enzyme, 
the solution was applied to a sephadex G-25 column and eluted with 
Tris buffer. The fractions containing enzyme a c t iv i ty  were collected,  
pooled and sodium azide and bovine serum albumin were added to give
0.02% and 0.1% w /v . The solution was stored at 4° C un til required. 
Fig 3*1 shows the proposed structure for the conjugate.
Determination of the Immunoreactivity of 3 -P-Galactosidase- 
Desmethylnortriptyline Conjugate.
The percentage of B-D-galactosidase bound to immunoreactive 
desmethylnortriptyline was determined by incubating a portion of the 
treated enzyme (equivalent to 6*5 enzyme units) with excess 
n o rtr ip ty l in e  anti serum ( 0 . 1  ml, 2 0 - fo ld  d ilu tion  of anti serum).
Enzyme conjugate bound by no rtr ip ty l in e  antibody was precipitated by 
a second antiserum against the f i r s t  antibody. B-D-galactosidase 
a c t iv i ty  was determined in the precip ita te  a f te r  washing i t  once with 
diluent du ffe r, ( 2 ml).
CH-CH2-CH2-N ' 0*
VCH2 -CH2-CH2 -CH2-NH-C-fBSA
Proposed structure of the nortrip ty line/bovine serum
albumin (BSA) conjugate.
+
NHo n ^ NH2IJ
CH2 -CH2-CH2“ NH-C-CH2 -CH2 -CH2 -CH2-C- ;NH Enzyme
Proposed structure of the desmethylnortriptyline- 
8-D-galactosidase Conjugate.
Figure 3«1
Determination o f N o r tr ip ty lin e  Concentration
The assay protocol is i l lu s tra te d  in Table 3*1. All d ilutions of 
anti serum, la b e l ,  standards, and samples were made with d iluent  
buffer. The f i r s t  anti serum was used at an in i t i a l  d i lu tio n  of 
300-fold. The second antiserum [bleed HP/D3/1ID, 5/4/19763 was 
used at an i n i t i a l  d i lu tio n  of 3 -fo ld .
The enzyme-labelled desmethylnortriptyline was diluted to give 6.5  
enzyme units per tube.
The primary standard was prepared by dissolving 1 mg of no rtr ip ty lin e  
in 10 ml of d iluent buffer. This was further diluted to give a 
standard of 100  ng /  ml, which was further diluted to give the range 
of concentrations, 1 to 20 ng /  ml, used in the assay.
The reagents were added to the tubes in the order indicated in the 
protocol. Calibration curves were plotted as the ra tio  of the fraction  
of the enzyme-labelled n o rtr ip ty l in e  bound at a given no rtr ip ty lin e  
concentration to the fraction bound when no n o rtr ip ty l in e  was present,
i . e .  (B/T:Bo/T) = B/Bo, where B = enzyme a c t iv i ty  bound a t a given 
concentration, Bo = enzyme a c t iv i ty  bound at zero concentration, and 
T = tota l enzyme a c t iv i ty .
TABLE 3*1 Protocol for N ortr ip ty line  Enzyme Immunoassay, 
(the volumes are expressed in y l ) .
Reagent Total Non-specific tube binding tube
Anti serum 
Dilution  
tube'
Zero Standard Sample
tube tube tube
iluent Buffer
tandard
ample
nzyme Label 
i r s t  Anti serum
500 400 400
100 100 100
100
Incubate for 90 min at 20° C
100
100
300
100
100
100
300
100
100
100
acond Anti serum 100 100 100 100 100
Leave to incubate overnight at 4° C, add 1.5 ml diluent buffer to a l l  tubes 
xcept tota l tube and spin for 20 min at 4° C on MSE (MISTRAL 4L) at 2000 r .p .m . , 
spirate the supernatant and wash with 2 ml of diluent buffer, spin, aspirate, 
id substrate solution (1 ml) to the p rec ip ita te , mix and leave fo r  2 hrs at 20° C, 
a stop the reaction add carbonate buffer (1.5 ml, 0.2 m o l( l i t r e ) ,  centrifuge and 
sasure the absorbance of the supernatant at 420 nm.
Factors A ffe c tin g  the N o rtr ip ty lin e  -Enzyme Immunoassay
Preparation of Enzyme-Nortriptyline Conjugate
The e f fe c t  of varying the incubation times (10, 30, 60 min) between 
no rtr ip ty l in e  and dimethyl adipimidate on the e ffic iency  of conjugating 
B-D-galactosidase to no rtr ip ty l in e  was studied a t a molar ra tio  of 
5000 fo r  n o rtr ip ty l in e  and dimethyl adipimidate to 1 fo r  enzyme.
H3-n o r tr ip ty l in e  was used to determine the reaction y ie ld . A fter the 
reaction has been terminated, the reaction mixture was applied to 
Sephadex G-25 column to separate the re la t iv e ly  low molecular weight 
compounds from the enzyme conjugate and free enzyme. Fig 3*2 shows 
two major peaks, one fo r  the enzyme a c t iv i ty  and the other for  
H3-n o r t r ip ty l in e .  This experiment indicated that very low incorporation 
of the enzyme to no rtr ip ty lin e  has occurred. This resu lt was ascertained 
by the following experiment to test the immunoreactivity of the prepared 
enzyme label. Serum d ilu tion  curves were set up using the three enzyme 
labels ( i . e .  from 10, 30, 60 min incubations with dimethyl adipimidate) 
in each case 6.5 enzyme units were added to each assay tube. Fig 3*3 
shows the maximum binding of the label to the no rtr ip ty l in e  anti serum is  
ju s t below 15% ( i . e .  the degree of incorporation of the enzyme to the 
immunoreactive n o rtr ip ty lin e ) . The cause of this low immunoreactivity 
of the enzyme-nortriptyline label may be that no rtr ip ty lin e  is a 
secondary amine and so less predisposed to such reactions than 
a primary amine compound. Thus, using a primary amino 
group on the side chain of n o rtr ip ty lin e  may solve this problem.
Desmethylnortriptyline is a minor metabolite for n o rtr ip ty l in e  (Borga 
al 1971),and has a primary amino group on the side chain;and this is the 
only difference in stucture between i t  and nortriptyline.Desmethylnortriptylin<  
was conjugated to B-D-galactosidase and used as a label for  n o rtr ip ty l in e  
enzyme immunoassay. ■
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Optimization of Second Antibody Dilutions in the Assay
In determining the immunoreacti v i ty  of 3-D-galactosidase-desmethyl- 
n o rtr ip ty lin e  conjugate, a serum d ilu tion  curve was carried out.
The second antibody donkey anti sheep gamma globulin was used to 
achieve complete separation of bound from free labe l. ( I t  is simplest 
and most usual to add the second antiserum when the requisite  : 
incubation period fo r  the primary reaction is completed). The 
incubate was then returned to the cold room (4° C) for a further  
period (often 16-24 hour) a f te r  which the tubes were centrifuged fo r  
20 min at 2000 rpm (Mistral 4L MSE) and the supernatant containing the free  
label fraction was aspirated while the bound label remained in the 
tubes as a small p rec ip ita te . Substrate solution was added and the 
enzymatic reaction was terminated a f te r  ( 2  hours) by adding sodium 
carbonate solution, centrifuge and measure optical densities a t 420 nm. 
Table 3.2 shows the results . This procedure allows some non-specific 
trapping of free enzyme in the p rec ip ita te . However, this can be reduced 
by a subsequent wash in diluent buffer followed by a second centrifugation  
step. Generally such trapping as does occur is so s ligh t ( and in my 
case rather constant) that the extra labour involved in the washing 
step is not rewarded. A lte rn a tive ly , almost the same e ffe c t  can be 
gained by adding additional diluent buffer to the incubate (say 2 ml) 
immediately prio r to centrifugation. Then the proportion of free label 
appearing in the bound compartment generally is only 1-2%. Carrier non- 
immune sheep serum (NISS) in d if fe re n t d ilutions was used a t high 
dilutions of f i r s t  antibody (th is  was carried out with methotrexate 
enzyme immunoassay Chapter 4 ) .
TABLE 3«2 Optimization of second antibody d ilu tion  in anti serum 
d ilu tio n  curve fo r  n o rtr ip ty lin e  anti serum.
1st Antibody D ilu tion 2nd Antibody Dilution
(N ortr ip ty lin e  Antiserum) Donkey Antisheep B/T %
S269 10/6/76 HP/D3/11D, 5/4/1976
25 1 73
2 50
3 19
50 1 71
2 50
3 17
100  1 60
2 70
3 60
4 40
200 2 65
4 58
6 45
8 30
500 4 42
6 40
8 28
10 15
1 00 0  6 28
10 20
14 12
Preparation o f Enzyme-Desmethylnortriptyline Conjugate
a. E ffect of d if fe re n t  Incubation Times between the Desmethylnotriptyline 
and Dimethyladipimidate.
Three d if fe re n t  labels of enzyme-desmethylnortriptyline conjugate . 
were prepared, using the . procedure indicated above but allowing 
d if fe re n t  times of incubation between the desmethylnortriptyline and the 
dimethyladipimidate prior to th e ir  addition to the enzyme solution. The 
labels were prepared as follows: Dissolve desmethylnortriptyline (570 yg)
and dimethyladipimidate (488 yg) in dry methanol (0*4 ml) containing 
5% V/V n-ethylmorpholine.
A 10 min
Maintain a t 20° C
B 30 mi n 
C 60 min
Transfer 100 yl to B-D-galactosidase (100 yg) in 1 ml of bicarbonate 
buffer.
Maintain at 20° C 90 min
Apply to a Sephadex G-25 column equilibrated with Tris buffer. Elute 
and pool enzyme peak.
Serum d ilu tion  curves were set up using the same amounts of enzyme 
(6.5 enzyme un it)  in each assay tube.
Fig 3*4 shows that as the time of incubation of desmethylnortriptyline  
and dimethyladipimidate increases the incorporation of desmethylnortriptyli 
into the enzyme increases but the enzyme a c t iv i ty  decreases. The label 
formed during a 30 min incubation period has 75% of the enzyme bound to 
desmethylnortriptyline, with minimum loss of enzyme a c t iv i ty .  This label 
was used to set up the standard curves.
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Figure 3,.4. Binding of s-D-galactosidase-desmethylnortriptyline 
conjugate by notriotyl ine antiserum. {□) . Untreated enzyme. The 
time in minutes for the reaction between DMA and desmethylnortriptyline 
before transferring to enzyme solution. (#)10 min, (■) 30 min, (a ) 50 min.
b. E ffe c t o f d if fe re n t Molar-Ratios o f g-D-galactosidase and
Desmethylnortri p ty li  ne
Drug-enzyme labels were prepared using the same procedure as before with 
a 30 min incubation time between dimethyladipimidate and n o rtr ip ty l in e ;  
but the f in a l molar ra tio  between $-D-galactosidase and desmethylnortriptyline  
was varied between 1 to 2500 and 1 in 5000 (the period of incubation of 
enzyme with desmethylnortriptyline/dimethyladipimidate was kept a t 30 min).
Fig 3.-5 shows that as the molar ra tio  was increased the degree of 
incorporation of desmethylnortriptyline into the enzyme increased but the 
enzyme a c t iv i ty  decreased. Thus longer time periods fo r  the f in a l colour 
development and lower anti serum dilutions would be needed i f  the enzyme 
label prepared using a molar ra tio  of 5000 to 1 rather than a molar 
ra tio  of 2500 to V'was selected.
Effect of normal human plasma and serum on the n o rtr ip ty l in e  standard curve
Three sets of standard curves were set up using the same reagents. In the 
f i r s t  series of tubes 50 v>l of normal serum was added. In the second,
50 yl of normal serum was added;and in the th ird  series d iluent buffer  
was added. The results indicate that there is l i t t l e  interference of 
plasma or serum constituents on displacements of the standards by the 
enzyme label Figure 3 .6 .
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Figure 3.5 Effect of d if fe ren t  molar ra t io  between DNTL and enzyme 
on preparation of the enzyme conjugate.
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Figure 2.6 Effect of normal human plasma and serum 
on nortr ip ty line  standard curve.
Checking the e ff ic ie n c y  o f the phase separation
A radioimmunoassay procedure (Mould e t al_ 1978) was used to compare 
three d if fe re n t  separation techniques fo r  free and bound labels.
Three sets of serum d ilu tion  curves were set up using the H3-imipramine 
as labe l. In the f i r s t  set 200 ^g of DASP was added to each assay tubes, 
while in the second set an optimized amount of second antibody for each 
d ilu tion  of f i r s t  antibody was added. In the th ird  set the required 
amounts of dextran coated charcoal indicated in the procedure of Mould 
et al 1978 was added. After carrying out these separations . the results  
were plotted as a ra tio  of per cent bound to the tota l counts. Fig 3.7 
shows that the three d if fe re n t  phase separations gave identical serum 
dilu tion  curves.
S ta b i l i ty  of reagents
The enzymic a c t iv i ty  and the immunoreactivity of the enzyme label were 
studied during storage condition for six months in liqu id  form a t 4° Cc 
The concentration of the enzyme label was 100 ug of enzyme in 10 ml of 
Tris buffer containing 0.02% W/V sodium azide and OJ% w/v bovine serum 
albumin. The results indicated that the enzyme a c t iv i ty  of the label 
decreased by less than 10% and the immunoreactivity decreased by less 
than 1% a fte r  six months of storage at the above conditions.
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Figure 3.7 N ortrip ty line  Anti serum Dilution Curve Using D iffe ren t  
Methods of Separation Free and Bound Fraction
C harac te ris tics  o f N o r tr ip ty lin e  Enzyme Immunoassay
1 ’ S ens it iv ity
The s e n s it iv ity  of no rtr ip ty l in e  enzyme immonoassay was determined from 
a standard'curve constructed using no rtr ip ty line  anti serum (S26, 10/3/76 - 
) .  The se n s it iv ity  of the assay was calculated as the concentration 
of no rtr ip ty l in e  measured at twice the standard deviation of zero 
binding (zero ng of unlabelled n o r t r ip ty l in e ) , and the value was found 
to be 1 ng n o rtr ip ty lin e  per mle Fig 3*8 shows the n o rtr ip ty l in e  standard 
curve. Fig 3-9 shows the comparison of standard curves obtained in the 
immunoassay with these produced using the radioimmunoassay of Mould et al 
1978 in which a H3-imipramine was employed. The results indicate that  
the se n s it iv ity  in the enzyme immunoassay and in the radioimmunoassay is 
more or less the same.
i i . Assay Variation
An estimate of the intra-assay variation of n o rtr ip ty l in e  assay was 
determined by measuring the same sample twenty times. Samples from 
n o rtr ip ty l in e -trea ted  patients having low, medium and high (30, 125, 
and 250 ng/ml) n o rtr ip ty l in e  concentrations were used. The co e ff ic ie n t  
of variation was less than 5% in a l l  cases0 The between-assay variation  
was estimated by assaying a number of samples on a t least four d if fe re n t  
occasions during 10 days. The coeff ic ien t of variation was less than 
8% (Table 3 -3 ).
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TABLE 3*3 In tra -  and Inter-Assay Estimates of Precision of 
N ortrip ty line  Enzyme Immunoassaya
Intra-Assay Variation Mean + S.D. Number of Coeffic ient of
ng/ml estimations variation c .v .
Sample No.
1 29.8 + 1 .1 20 3.6
2 123.9 + 5.1 20 4.1
3 343 + 00 cn 20 2.5
Inter-Assay Variation  
Sample No.
1 31.8 + 1.67 4 5.2
2 60.3 + 1 . 8 4 3.0
3 126 + 5.4 4 4.3
4 332 + 10 4 3.1
5 610 + 33 4 5.4
aResults fo r  inter-assay variations are based on duplicate estimations 
for 10 days.
. A na ly tica l recovery o f n o r tr ip ty l in e
Known amounts of n o rtr ip ty l in e  were added to plasma samples.
Table 3.4 shows the e ffe c t  of plasma volume on the recovery of no rtr ip ty l in e  
added to plasma samples. All the added no rtr ip ty lin e  was accounted 
for when as much as 25 ul of plasma was present. Increasing the volume 
of plasma to 50 yl,however, diminished the recovery of n o rtr ip ty l in e  
by as much as 20%. High plasma volumes are not l ik e ly  to be used for  
routine measurements because the therapeutic plasma levels of n o rtr ip ty l in e  
reportedly l i e  between 50 to 250 ng/ml plasma (Ziegler e t  al_ 1976,
Asberg e t 1971, Braithwaite e t  al_ 1972, Ziegler et al_ 1977).
Cross-Reactivity
The cross-reactiv ity  of the no rtr ip ty lin e  anti serum (S26, 10/6/76) with 
n o rtr ip ty l in e  metabolites and other s tru c tu ra lly  related t r ic y c l ic  
anti depressants was assessed by means of cross-reactiv ity  curves.
Curves were set up :the percentage of cross-reactiv it ies  was calculated  
from the curves by applying the formula:-
Amount of n o rtr ip ty lin e  inh ib iting  binding a t zero by 50% . . .
---------------- --------------------------------------------------------------- --------------------- X 100=%Cross-Reactivit
Amount of cross-reactant inh ib iting  binding at zero by 50%
From Table 3 .5  the results indicate that the antiserum does not cross 
react with the major metabolite of no rtr ip ty l in e  i . e 0j 1 0 -hydroxynortriptyline  
(Knapp et al 1972; Alvan et al 1977; and Ziegler et al 1976) or with other 
t r ic y c l ic  anti depressants in which the nucleus i t s e l f  is a lte red : but does 
cross-react up to 40% with the minor metabolite desmethylnortriptyline.
Table 3.5 gives a comparison of cross-reactiv it ies  encountered using the 
enzyme label with those using a H3-n o rtr ip ty l in e  label and a H3-imipramine
TABLE 3*4 The e ffec t  of various amounts of plasma on the 
recovery of N ortr ip ty lin e .
Amount 
of n o rtr ip ty l in e  
in ng/ml plasma
Added Recovered
Volume of 
plasma present 
in assay '(y l)
Percentage recovery 
of n o rtr ip ty l in e  
s .d .+
40
32
40
40
50
25
12.5
80 + 2 
100 + 4 
100 ? 1
100
96
98
100
20
10
5
96 + 4 
9 8 + 3  
100  + 2
250
247.5
250
250
9 9 + 4  
100 + 2 
100 + 3
+Mean of three measurements
TABLE 3 ‘5 Cross-reaction+ of various TAD drugs in both EIA and RIA 
(Aherne et al 1976) .
Hapten Percentage cross-reaction
EIA RIAa RIA1
N ortrip ty lin e 100 100 100
A m itriptyline 153 no 153
Imipramine 89 90 89
Desmethylnortri p ty l i  ne 45 11 -
P ro tr ip ty line 42 90 42
Desipramine 24 54 24
Carbamazepine < 3 1.1 < 3
Dibenzepine < 3 - <3
10-Hydroxyami t r ip t y l i  ne - 1.3 -
+The cross-reaction is expressed as
amount of no rtr ip ty lin e  inh ib iting  binding at zero by 50%
------------------------------------------------------------------------------   x
amount of cross-reactiv ity  inh ib iting  binding at zero by 50%
a using H3-imipramine label (Mould et al 1978) 
b using H3-n o rtr ip ty l in e  label (Aherne et al 1976)
label. A s l ig h t ly  d if fe re n t  order of cross-reactiv it ies  was obtained 
for each 3H -tracer0 The same results were found by Maguire e t al (1978) 
using the same antiserumc A possible explanation might be that the 
d iffe re n t a f f in i t ie s  of the anti serum for the two tracers produce 
d iffe re n t e q u il ib r ia  between antigen, labe l!ed -tracer, and antibody 
(Maguire et al 1978).
An explanation of the fac t that the anti serum bound more strongly to 
am itr ip ty line  than to the drug i t  was raised against, n o rtr ip ty l in e ,  
can be found by examination of the proposed structure of the n o rtr ip ­
tyline/bovine serum albumin conjugate (Fig. 3 .1 ) .  The conjugate 
actually  is more closely related s tructura lly  to the te r t ia ry  amine, 
am itr ip ty lin e , than to n o rtr ip ty l in e .
Comparison with the Gas-Liquid Chromatography and the Radioimmunoassay methods
The enzyme immunoassay method was compared with (1) the radioimmunoassay in 
which 3H-labelled imipramine was used and with (2) a gas-liquid chroma­
tographic method in which a flam e-ionization detector was used (Braithwaite  
e t al 1971)0 A set of 21 plasma samples from patients being treated with 
n o rtr ip ty lin e  was assayed by each of the three procedures. For the two 
immunoassay techniques the same batch of the n o rtr ip ty l in e  anti serum was 
used. There was good agreement among the results of a l l  three methods.
The correlation coeffic ients ( r )  fo r  enzyme immunoassay vs. radioimmunoassay, 
and enzyme immunoassay vs. gas-liquid chromatography, were 0.98 and 0.97, 
respectively, with a confidence l im i t  of 99% (p < 0 .001). The regression 
lines were (y = 0.9x + 15.5) and (y = 0.9x + 11.6) respectively where 
y = results obtained with enzyme immunoassay. Scattergrams are shown 
in Figures 3.10, 3.11.
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Imidoesters react in alkaline solution with amines to form imidoamides 
(amidines Equation 1 ). For protein modification this reaction possesses 
many advantages. The reaction occurs a t moderately a lkaline pH's 
( i . e .  between 7 and 10, depending upon the pK of the amine), in aqueous 
solvent, and at room temperature. Of the many reactive groups in proteins, 
only amino groups w il l  react; and the products, l ik e  the amino groups they 
replace, are protonated a t physiological pH. Both e- and a- amino groups 
may be modified (Hunter and Ludwig 1962)
H2 \  p H > 8 . 5  5 H2
P —  NH, + , C -R  —  » - P  — NH— C— R + R1 OH 1.
R 0
+I
H OR NH? .  H OR „
1 -«-N // 2 Ki '4. k2
P — N : ^ ^ C  »» P —  N+ —  —  NH,— -— ►
H
I
P — N+ NH, + R OHVI
R
The reaction rate is strongly pH dependent (Hand and Jencks 1962;
Hunter and Ludwig 1962). Kinetic data suggest that the cationic form of the 
imidoesterand the unprotonated amine are the reactive species. The 
rate-determining step, depending upon the pH, is e ither addition of amine 
(free base) to the cationic imidoester (K-j) or breakdown of the tetrahedral 
orthoamide to amidine and alcohol (K2 ) (Equation 2). Iri moderately a lka line  
solution, the la s t  step (K2 ) is subject to general base cata lys is .
At higher pH, the overall second-order rate constants (corrected to 
include only unprotonated amine) increase with increasing nucleophilic ity  
of the amine (Hunter and Ludwig 1962)0 Imidoesters are unstable and 
slowly hydrolyze in aqueous solution to the corresponding amide and 
alcohol. Between pH 7 and 11, the rate of hydrolysis is slow compared 
to the rate of th e ir  reaction with amines. Hydrolysis is not subject 
to general base catalysis in the moderately a lkaline pH region and is  
not enhanced by the presence of protein. Ami dines are stable in neutral 
or acidic solution, but slowly hydrolyze a t high pH (Ludwig and Byrne 1962). 
Dimethyl adipimidate, a bifunctional imidoester, has been used to form 
cross-linkages in several proteins. I ts  reaction with bovine pancreatic 
ribonuclease has been shown to give both in te r -  and intramolecular cross- 
linked products (Hartman and Wold 1967). Bifunctional imidoesters appear 
to be extremely useful as protein cross-linking agents and have been 
discussed in this regard by Hartman and Wold (1967) and Wold (1967).
In the present studies, dimethyl adipimidate was used as a cross-linking  
agent between the enzyme B-D-galactosidase and desmethylnortriptyline. 
In te res ting ly , when no rtr ip ty lin e  i t s e l f  reacted with the enzyme under 
the same conditions used to conjugate desmethylnortriptyline, only 15% 
of the enzyme was bound by the specific antiserum. This difference in 
re a c t iv i ty  of no rtr ip ty l in e  as compared with desmethylnortriptyline may 
be explained by the fac t that the former contains a secondary amine while 
the la t t e r  contains a reactive primary amine.
The enzyme immunoassay developed here for n o rtr ip ty l ine has a detection 
l im i t  of 1 ng n o rtr ip ty lin e  per ml which is comparable to the detection 
l im i t  of the corresponding radioimmunoassay. This s e n s it iv ity  is not 
normally required for routine measurements but may be useful in 
pharmacokinetic studies. The analytical recovery of n o rtr ip ty l in e  in the 
'presence of various amounts of plasma l ik e ly  to be used in practice indicates
that n o rtr ip ty l in e  measurements are unarrectea Dy natural co n s titu en t  
of plasma when as much as 25 yl of plasma was used. Increasing the 
plasma volume to 50 v l , however, diminished the recovery to 80%.
The assay has a precision which is within acceptable immunoassay standards, 
with an intra-assay estimate of coeff ic ien t of variance of less than 5% 
and an inter-assay coeffic ien t of variance of less than 8 %.
The enzyme label was s t i l l  usable a fte r  storage in solution a t 4° C for  
six months.
Previous experiments (Mould et al 1978; Maguire et al 1978) have shown 
that the anti serum does not cross-react with the major metabolites of 
no rtr ip ty lin e  e.g. 10-hydroxynortriptyline (Knapp et al 1972, Alvan et. al 
1977, and Ziegler e t  al 1976). Desmethylnortriptyline showed some 
cross-reactiv ity , but evidence strongly suggests that i t  is present 
is only minor amounts (Borga et al 1971). A d if fe re n t  order of cross­
re ac t iv ity  was obtained by ^-imipramine and 3H -nortrip ty line  tracers .
Similar results were found by Maguire e t al (1978 ) . using 
3H-imipramine and 3H-am itrip tyline with the same antiserum. An explanation 
possibly might be that the d if fe re n t a f f in i t ie s  of the anti serum for  
the two tracers produce d if fe re n t eq u ilib r ia  between antigen, labe lled -  
tracer, and antibody (Maguire et al 1978). Because other secondary amine 
t r ic y c l ic s  can cross-react with the anti serum, Maguire's procedure can be used 
to measure each one, since they are rare ly  prescribed concurrently. I f  
a more specific  assay is required, i t  could be obtained by incorporation 
prior to separation procedure by column chromatography or th in - la y er  
chromatography. However, in order to prepare a highly specific  anti serum 
for n o rtr ip ty l in e , the selection of immunogen should be reconsidered.
Conjugation of no rtr ip ty lin e  to an immunogenic protein through a ring 
hydroxyl group (Read and Fahmay 1978) . The 2-hydroxy no rtr ip ty lin e
might be appropriate as i t  is only a minor metabolite of n o rtr ip ty l in e .
The performance of the enzyme immunoassay was compared with that of the 
radioimmunoassay andwith a gas-chromatography methodv Irr each case .the results  
correlated w e ll .  Thus the double antibody enzyme immunoassay described 
has the a ttr ibu tes  of s im p lic ity , s e n s it iv ity ,  and re la t iv e  s p e c if ic ity .
I t  would appear to be suitable fo r  routine measurements of n o rtr ip ty l in e  
plasma samples from patients undergoing no rtr ip ty l in e  treatment,providing  
. they are not ^iimultaneously receiving another t r ic y c l ic  anti depressant 
drug capable of reacting with the anti serum (Albassam et al 1978a, 1978b).
The technique of enzyme immunoassay has proved useful for measuring drugs 
and hormones in biological f lu ids (Voller et al 1976; Wisdom 1976;
Scharpe e t al 1976; and Schuurs et al 1977): and i t  holds great promise for  
application in a wide variety  of conditions.
CHAPTER 4
METHOTREXATE ENZYME IMMUNOASSAY
S U M M A R Y
An enzyme-immunoassay technique was developed for measuring methotrexate 
in plasma. 3 -D-galactosidase, EC.3 .2 .1 .23  from Escherichia Coli was 
conjugated to methotrexate by means of the mixed-anhydride method and 
used as label in a double antibody immunoassay for methotrexate. 
Approximately 90% of the enzyme was conjugated to "immunologically 
reactive" methotrexate with 90% retention of enzyme a c t iv i ty .  Separation 
of bound and free labelled drug was achieved using second antibody. Both 
post-precipitation and pre-precip itation of f i r s t  and second antibodies 
were t r ie d .  The enzyme a c t iv i ty  of the bound fraction was measured using 
O-nitrophenyl-B-D-galactopyronoside as substrate. Using the enzyme 
immunoassay5as l i t t l e  as 1 ng methotrexate per ml, could be detected.
The assay is highly specific for methotrexate in the presence of fo l in ic  
(citrovorum fa c to r) ,  fo l ic  acid, tetrahydrofo lic  acid, and other possible 
methotrexate metabolites. The in tra -  and inter-assay coeffic ients  of 
variance were less than 5% and 10% respectively. Results from this  
procedure were compared with those obtained with radioimmunoassay and 
la te r  with EMIT procedures, the results were in good agreement.
In Chapter three, a new coupling reagent(the bifunctional 
imidoester (DMA))was used to conjugate 3 -D-galactosidase to small 
hapten. The formed conjugates were used as label in an enzyme 
immunoassay technique. In the present study the mixed anhydride method 
(Erlanger et al 1959) was used to prepare the methotrexate-3 -D -galact-  
osidase conjugate. It  is necessary to avoid modifying the immunochemically 
characteris tic  parts of the methotrexate mol ecu!e° These involve the 
2,4-diamino groups as ■ antigenic determinants in the anti serum binding 
s ite  (Aherne et al 1977). During the coupling reaction a peptide bond 
was formed between the carboxyl group of the hapten and the amino group 
of the enzyme. The mixed anhydride method is widely used to couple haptens to 
proteins for preparing immunogens and to enzymes for preparing enzyme 
labels for enzyme immunoassays (Van Weemen et al 1972, 1975; Bosch et al 
1975; Comoglio et al 1976).
Chemistry
N- V >  CONH
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L-Glutamic acid, N -[4-[(2 ,4 -d iam ino-6-pterid inyl)m ethyl] -  
methyl amino]benzoyl] .
L - ( + ) -N-CP-CT(2 ,4-Di ami no-6 -p te r i dinyl)methyl]methylami no]- 
benzoylDglutamic acid; 4-Amino-N10-methylpteroylglutamic acid; 
Amethopterin; 4-Ami no-10-methylfolic acid
Description: Orange-brown, c rys ta ll ine  powder.
S o lu b ility :  P ractica lly  insoluble in water, in alcohol, in chloroform, 
and in ether; free ly  soluble in d ilu te  solutions of a lk a li  hydroxides 
and carbonates; s l ig h t ly  soluble in d ilu te  hydrochloric acid (1 in 2 ) .
The antimetabolic methotrexate is a c l in ic a l ly  useful member of a 
large series of fo l ic  acid antagonists. This group of anti cancer agents 
are f a i r l y  well understood with regard to th e ir  mechanisms of action 
and c e llu ta r  kinetics (Bertino e t a l  1973).
Methotrexate has also been used with benefit in the therapy of psoriasis 9 
a non neoplastic disease of the skin characterized by abnormally rapid 
p ro life ra t io n  of epidermal cells  (Van Scott et al 1964; McDonald and 
Bertino 1968). Additionally,methotrexate is a potent in h ib ito r  of some 
types of immune reactions and has been employed as immunosuppressive agent, 
e.g. in organ transplantation (Hitchings and Elion 1963; Schwartz 1965;
Johns and Bertino 1973, and Bertino 1975).
Mechanism of Action
For fo l ic  acid to become an active coenzyme, i t  must f i r s t  be reduced 
to fo l in ic  acid (tetrahydrofo lic  acid). The reduction takes place in 
two steps; f i r s t ,  to dihydrofolic acid and then, to tetrahydro compound.
Each step is catalyzed by Dihydrofolic acid reductase. The tetrahydro  
compound is the acceptor of formate from formylglutamate and purines.
The a n t i fo l ic  a c t iv i ty  of the fo l ic  acid antagonists is most probably due 
to in h ib it ion  of fo l ic  acid a c t iv i ty  in one of two ways. One is the 
prevention of the reduction of fo l ic  acid to fo l in ic  acid. This step 
would thwart the metabolic role of the acid as a coenzyme. The second 
is the inh ib it ion  of one-carbon transfers, which are a function of the 
reduced fo l ic  acid or fo l in ic  acid(Fig 4 .1 ) .  An example of th is is the blockin 
of the transfer of a methyl group for the conversion of deoxyuridylic acid
to thymidylic acid. In this manner the synthesis of DNA is blocked.
A c l in ic a l ly  useful derivative of tetrahydrofolate. (THF) that can 
circumvent the in h ib it ion  of dihydrofolic acid reductase is leucovorin 
( fo l in ic  acid, N5-formyl -THF; Citrovorum fa c to r ) ,  available as leucovorin 
Calcium U.S.P. Properly tim ed(l-2  hours) administration of this normal 
metabolite following large doses of methotrexate has been employed in 
order to protect normal tissues from the lethal effects of the drug.
The procedure has been called leucovorin or fo l in ic  "rescue".
Glycine
Purine nucleotide
4
biosynthesis
5CH0FH4 — FH4
(leucovorin) %
MTX
Figure4-1 Inh ib ition  of dihydrofolate reductase by methotrexate (MTX). 
Abbreviations used are: FH4 , tetrahydrofolate; FH2 » dihydrofolate; 
dUMP, deoxyuridylate; dTMP, thymidylate. The three enzymes involved in 
methylation of deoxyuridylate are: (a) dihydrofolate reductase, (b) serine 
transhydroxymethylase, and (c) thymidylate synthetase.
Toxic E ffects
A fter a single large dose of methotrexate ( i . e .  1 to 5 mg/kg) 
leukopenia, thrombocytopenia, and reticulocytopenia may be produced 
(Condit et a [ ,  1962). All replicating cells  in the bone marrow are 
affected, but not mature blood ce ll elements. Toxicity  may also be 
enhanced in patients with impaired renal function, and a creatinine  
clearance test is advisable in a l l  patients before treatment with large 
doses of methotrexate (C onditet al 1969). Since methotrexate i t s e l f  can 
lead to renal to x ic i ty ,  repeat kidney function tests should be carried  
out during therapy with methotrexate. I f  methotrexate is to be used in  
patients with impaired kidney function, f a c i l i t i e s  should be available  
to monitor blood levels of the drug, and leucoverin "rescue" should 
be u t i l iz e d  appropriately i f  drug clearance is delayed s ig n if ic a n tly  
(Mitchell and Bertino, unpublished observations). Mucositis may be 
observed a f te r  drug administration: nausea.and anorexia, and less commonly 
vomiting5may also be noted. With high doses of methotrexate more severe 
gastrointestinal signs and symptoms, progressing to gastrointestinal 
ulceration and bleeding, may be produced. Fever has also been reported 
(Gottlieb et a l ; 1970). Skin rash and hair loss, especially in older 
individuals has been observed.
Two types of l iv e r  damage appear to be associated with methotrexate 
adm inistration:lea reversible transient to x ic ity  with large acute doses 
of the drug (Hertz et a l , 1961):and 2. less commonly, hepatic f ib ro s is  
associated with long term use of the drug (Roenigk et a l , 1971).
Pulmonary in f i l t r a te s  have been reported to occur with chronic 
methotrexate administration.
Methotrexate is known to be a potent abortifac ien t, especially i f  
administered during the f i r s t  trimester of pregnancy.
Methods o f  Measurement 
Spectrophotometry and Spectrofluorimetry
Most techniques for measuring the concentration of methotrexate in 
blood employ spectrophotometry or spectrofluorimetry (Kinkade e t al 1974,
1976; Chakrabarti e t al 1969; Freeman 1957; and Halprin et al 1971).
With few exceptions, none is s u ff ic ie n t ly  spec ific , sensitive, and 
precise to be useful a t plasma levels needed for an accurate pharmaco­
k inetic  analysis. An additional problem, is the interference from 
natura lly  occurring compounds such as fo l ic  acid, tetrahydrofo lic  acid, 
and fo l in ic  acid in the plasma.
Enzymic Assays
The basis fo r  the enzymic assays of methotrexate is the stoichiometric 
in h ib it io n  of the enzyme dihydrofolate reductase (EC 1 .5 .1 .3 )  by methotrexate 
(Werkheiser et al 1961). Whether the a c t iv i ty  is measured by monitoring 
the oxidation of NADPH (Bertino et a l , 1964; Werkheiser e t a l , 1962;
Overdijk et al 1975, Falk et al 1976., and Finley et al 1977) or by 
radioenzymic analysis (Rothenberg, 1965, 1966) the enzymic assay depends 
on the binding of the in h ib ito r  to the enzyme; and on the reaction of 
the residual enzyme with the assay substrate (fo lic  acid or dihydrofolic  
ac id). Consequently, conditions that perturb e ither the inhibitor-enzyme
reaction or the enzyme-substrate reaction may e ffec t the results of the 
assay procedure. In existing enzymic methods, the s ta b i l i ty  and 
a v a i la b i l i ty  of reagents has been a serious problem. The enzyme assay 
procedures appears to be more cumbersome than is desirable fo r  routine 
c lin ic a l use (Chabner et al 1975), and may not distinguish methotrexate 
from folin 'ic  acid or CF and possible metabolites.
Microbiological Assays
Microbiological methods for fo l ic  acid antagonists have been described 
by Burchenal et al_ 1951, Fountain et al_ 1953 and modified by Shapiro 
et aj_ 1975, and Noble et al_ 1975. The s e n s it iv ity  of these assays is 
about 10 ng/ml, but the s p e c if ic ity  is poor, because both fo l ic  acid 
and certain antib io tics  in te r fe re . They also require a long incubation 
time (about 36 hours) and suffer from a large v a r ia b i l i ty  that l im its  
i ts  usefulness.
Direct Ligand Binding and Competitive Protein Binding Assays
A d irec t ligand-binding radioassay for methotrexate (Arons et a]_ 1975) 
has been developed using dihydrofolate reductase, contained in the lysate  
of L I210 leukemia c e l ls ,  as the binding determinant.
A competitive protein binding assay has been developed for methotrexate 
(Myers et al 1975) based on the t ig h t  binding of this drug to lactobacillus  
Casei dihydrofolate reductase. These methods, while sensitive , require  
time-consuming manipulation and expensive equipment.
Radioimmunoassay Methods
Recently radioimmunoassays have been developed for methotrexate 
measurement (Bohoun et al 1974; Levine et al 1974; Raso et al 1975; 
Hendel e t al 1976; Loeffler e t al 1976; Aherne et al 1977, and Paxton 
et al 1977). These appear to have good inherent s e n s it iv ity ,  and are 
f a i r l y  spec if ic , furthermore solvent extraction and derivatisation  on 
the whole are generally unnecessary.
Materials
Methotrexate, ami nopterin, 4-amino-N10-methyl pteroic acid, N10-methyl 
fo l ic  acid, 2 , 4-diamino-6-methylpteridine were kindly supplied by 
Lederle Laboratories, Pearl River, N.Y. 7-Hydroxy methotrexate was a 
generous g i f t  from Dr. A. Jacobs, NIH, Bethesda, M.D. Folic acid and 
i ts  analogues, Ethyl (dimethyl amino propyl) - y  carbodiimide(EDC),
Norit A charcoal and Tris(hydroxymethyl ami noethane(tris)) were purchased 
from Sigma Chemicals Ltd. B-D-Galactosidase (EC (3 .2 .1 .23 ) from 
Escherichia Coli was purchased from Boehringer Mannheim, Mannheim,
West Germany as a suspension in 2.2 mmol/litre ammonium sulphate. 
[ 3H]-Methotrexate (TRK 224) was obtained from the Radiochemical Centre, 
Amersham. Sephadex G-25 and dextran T-70 were obtained from Pharmacia Fine 
Chemicals, Uppsala, Sweden; bovine serum albumin (300 g / l i t r e  solution) 
from Armour Pharmaceutical Co., London, and BCG.vaccine:.from.Glaxo. Laboratories 
Greenford, Middlesex.
The methotrexate antiserum (S261, bleed 16/9/1975), supplied by Dr. G. W. Aherr 
et al_ 1977 of this Department, was raised in a sheep against a methotrexate- 
oval bumin conjugate prepared following the method of Jaton and Ungar-Waron 
(1967) using 1-e th y l- 3 - (3-dimethyl ami no propyl) carbodiimide (EDC) as a 
coupling reagent.
Preparation o f MethotreXate-B-D-6alactosidase Conjugate
Methotrexate was coupled to B-D-galactosidase by the mixed anhydride 
method of Erlanger et al (1959). A representative procedure is as 
follows: methotrexate ( 6 . 8  mg; 15 ymoles)and tri-n-butylamine ( 2 . 8  mg 15 ymoles) 
were dissolved sequentially in dimethyl formamide ( 0 . 1  ml) and cooled to 
10° C. Isobutyl chloroformate (2 mg; 15 ymoles)was added and the mixture 
s tirred  for 30 minutes at 10° C before mixing with a solution of 
B-D-galactosidase (1.5 mg; 3 nmoles)in d is t i l le d  water (2 ml) adjusted to 
pH 9.4 with 100 mmol/litre NaOH. The reaction was allowed to proceed for  
4 hours at 10° C maintaining the solution at pH 9 by the addition of NaOH 
(0.1 m) as required. The solution was then l e f t  overnight at 4° C. To 
separate compounds of low re la t iv e  molecular weight from the 3 -P-galactosidase 
the solution was subjected to gel f i l t r a t io n  on a Sephadex G-25 column and 
eluted with Tris buffer 50 m m ol/litre , adjusted with acetic acid to pH 7.5 
and containing magnesium chloride ( 1 0  mmol) sodium chloride ( 1 0 0  mmol), 
and 2-mercaptoethanol (10 mmol). Fractions containing enzyme a c t iv i ty  were 
pooled, and bovine serum albumin and sodium azide were added to produce 
a 0.1% w/v and a 0.02% w/v solution respectively. The solution was then 
stored at 4° C until required.
Determination of the Immunoreactivity of the B-D-Galactosidase Conjugate
The proportion of B-D-galactosidase bound to immunologically reactive  
methotrexate was determined by incubating an a liquot of the treated enzyme 
(approximately 3 units) with excess methotrexate anti serum. The enzyme 
bound by methotrexate antibodies was precipitated by the addition of 
donkey anti-sheep second antibody. The precip ita te  was washed twice with
1.5 ml of d iluent buffer, pH 7.4 containing sodium phosphate (50 m m ol/litre )  
sodium chloride ( 1 0 0  m m ol/litre) and bovine serum albumin (0 . 1% w /v).
The enzyme a c t iv i ty  in the precip itate  was measured. Serum and urine 
samples from patients receiving methotrexate were supplied by 
Dr. W. F. White, St. Luke's Hospital, Guildford, and Dr. H. E. M. Kay, 
The Royal Marsden Hospital, Sutton, Surrey.
Assay Procedure
The assay protocol is shown in Table 4 ,1 . All dilutions of anti serum, 
labe l, standards and samples were made with diluent buffer.
Approximately 3 units (roughly 40 ng) of the B-D-galactosidase-methotrexate 
conjugate were used per assay tube. The donkey anti-sheep IgG was used 
to separate the antibody -bound from free fractionse
In order to determine.the f i r s t  antibody t i t r e  and to optimise the amount of 
second antibody a serum d ilu tion  curve was constructed. Methotrexate a n t i ­
serum was i n i t i a l l y  diluted 1:25 and then double-diluted with d iluent buffer  
over the range to be studied. 100  yl diluted anti serum was added to the 
appropriate tube and the assay carried out as described below.
For the standard curves, a stock solution of the standard was prepared 
in buffer and diluted to the appropriate concentration with bu ffe r , 10 yl 
of the stock solution ( 1 0 0  yg/ml) was made up to 10 ml with buffer ( 1 0 0  ng/ml) 
and then double diluted to give the range of standards used in the assay.
For serum samples, each sample was diluted with buffer according to the 
dose of methotrexate given and the time of the sample a f te r  the dose.
See Table 4*2.
TABLE 4.1 Assay Protocol
REAGENTS TOTAL NON-SPECIFIC
BINDING
yl yl
ANTISERUM
DILUTION
CURVE
yl
STANDARD CURVE 
ZERO STD SAMPLE
yl yl yl
Diluent
buffer
Std
Sample
Label
Methotrexate 
anti serum
100
500
100
400
100
100
400 300
100
100
100
100
100
300
100
100
100
INCUBATE FOR 3 HOURS AT ROOM TEMPERATURE
Second - 100 100 100 100 100
anti serum
INCUBATE OVERNIGHT AT 4° C
Add I ml bu ffe r , centrifuge a t 2000 rpm at 4 C for 20 min, aspirate  
and add 1.5 ml bu ffer , centrifuge, aspirate. Add substrate solution 
(1 .0  m l), mix and hold at 30° C for 1 hour, add 1.5 ml of 200 m mol/litre  
sodium carbonate solution and read the absorbance at 420 nm.
TABLE 4,2
Dilution Range for Dilution Range for
Time . 200 mg methotrexate 325-375 mg methotrexate
I .Y .  I .V .
10 min 1500 -  4000 3330 - 1 0 , 0 0 0
30 min 500 -  3000 1000  - 5000
60 min 5 0 0 -1 5 0 0 1000  - 4000
2 hrs 300 -  1000 1000  - 2000
3 hrs 200 - 500 500 - 200 0
4 hrs 100 -  500 500 - 1500
6 hrs 60 - 200 200  - 1000
12-14 hrs 10 - 40 20 - 100
24 hrs 2 - 20 4 - 40
Serum samples were assayed at three or four d ilu tions.
The reagents were added in the order indicated in the protocol, into  
numbered p lastic  tubes (LP3, Luckham) using Oxford microsamplers. A fter  
addition of the anti serum, the contents of the tubes were mixed fo r  
5 sec on a vortex mixer (Fison) and allowed to incubate at room 
temperature for 3 hrs. Second anti serum (100 yl) was added into the 
assay tubes and mixed b r ie f ly  on a vortex mixer, the tubes were l e f t  
overnight at 4° C. After the incubation 1 ml of buffer was added into  
the tubes followed by centrifugation(2000 rpm at 4° C) fo r  20 min on a 
Mistral 4L centrifuge (MSE). The supernatant was aspirated, leaving about 
50 yl above the p rec ip ita te , washed with 1.5 ml buffer and centrifuged as 
before followed by aspiration, of supernatant.
The substrate solution (1.0 ml) was added (phosphate buffer 100 m m ol/litre ,  
pH7.0, containing 2.3 mmol/litre  O-nitrophenyl-8 -D-galactopyronoside,
1 m mol/litre magnesium chloride and 10 mmol/litre 2 -mercaptoethanol) .
A fter mixing the contents, the tubes were l e f t  fo r  1 hour a t 30° C, then
1.5 ml of 200 mmol/litre sodium carbonate solution was added and the 
optical density was read at 420 nm.
Calculations
The mean absorbance readings for each set of duplicates, a f te r  subtraction  
of the mean non-specific bound (NSB) readings, was expressed as a percentage
of the zero bound mean readings.
In the anti serum d ilu tion  curves, the t i t r e  o f the anti serum was calculated
from a plot of the % to ta l values against the anti serum d ilu t io n .
Properties o f the Methotrexate-Enzyme Conjugate
Immunological Properties
The proportion of 8 -D-galactosidase bound to immuno-reactive methotrexate 
was assessed by incubating an aliquot of the treated enzyme (three units 
approximately) with excess methotrexate antiserum of an i n i t i a l  d i lu t io n  
of 25-fo ld . I t  can be seen from Figure 4.2 that 90% of the enzymic 
a c t iv ity  was bound to methotrexate antiserum. Using this quantity of 
lable the t i t r e  was found to be at 1 : 2 0 0 0  in i t i a l  d ilu tion  and this  
dilu tion  was used to construct the standard curves and assay the samples 
from patients. Typically  optical densities for the standard curve cover 
the range 0 to 0 .7 .
Enzymic Properties
A high y ie ld  of enzyme a c t iv i ty  was retained a f te r  the coupling 
procedure (about 90%)0
Stabi1i ty
The enzyme-methotrexate conjugate, showed less than 10% loss -jn the
enzyme a c t iv i ty  when stored in a lyophilized state at -20° C or in a liqu id
form at 4° C for six months, but the conjugate did-, lose a proportion of 
i ts  immuno-reacti v.ity (see Figures 4 .3 , 4 .4 ) 0
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enzyme label in solution three days 
a f te r  preparation stored at 4° C
enzyme label in 1yphi1ized form stored for  
six months a f te r  preparation at -20° C
enzyme label in solution a f te r  six months 
of preparation stored at 4° C
NSB = Non specific binding
7T
NSB
NSB
NSB
Methotrexate concentration (ng/ml)
Figure 4 .3  Effect of Storage on Immunoreactivity of the Enzyme Label
lOOr enzyme label in solution three days 
a fte r  preparation was stored at 4° C
enzyme label in lyphilized form stored 
for six months a fte r  preparation at -20°C
enzyme label in solution stored for six  
months at 4° C a fte r  preparation
Bo
Methotrexate concentration (ng/ml)
Figure 4. 4 Effect of Storage on the Immunoreactivity of the Label
The lyoph iliza tion  was achieved by freezing 0.5 ml aliquots of the 
conjugate in t r is  buffer (containing 2% w/v bovine serum albumin in 
addition to the other constituents) in liquid  nitrogen fo r  5 minutes 
and then transferring i t  to a lyo p h il ize r .
Factors A ffe c tin g  the Methotrexate Enzyme Immunoassay
Some of the factors affecting the enzyme immunoassay fo r  methotrexate 
were examined by constructing d ilu tio n  and standard curves under d if fe re n t  
conditions. Unless otherwise stated the antiserum (S261, 16/9/76) were 
used at 1:2000 - . i n i t i a l  d i lu t io n , and the second antibody (D1 8 /4 /76)  
at 1 :2 0 - d i lu t io n .
Interference of Serum
The addition of 50 yl of normal human serum to the standard curve did not 
a lte r  i ts  shape or the percentage binding over the series of standards used. 
Figure 4.5 shows that standard curve with 50 yl normal human serum and "the 
one in buffer are superimposable.
Immunolological Incubation 
a. Equilibrium Conditions
The assay was optimised for both equilibrium and disequilibrium conditions 
and i t  was found that for an equilibrium assay, the anti gen-anti body binding 
reaction was completed a f te r  2| hours. An experiment was set up using the 
same reagents ( la b e l,  standards, f i r s t  and second anti sera). For each period 
of incubation a series of standards was set up in duplicate. Separation was 
achieved using second antibody, the precip ita te  was washed twice and the 
supernatant was aspirated. The tubes were read a f te r  incubation of the 
precip ita te  with the enzyme substrate. The results were calculated as the 
percentage of the reading for the zero tubes and are shown in Figure 4 . 6 .
standard curve in buffer
standard curve plus 
50 yl human plasma
Methotrexate concentration (ng/ml)
Figure 4.5 Effect of Human Serum (50 y l ) on the Methotrexate Assay
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Figure 4.6 Effect of time of incubation on the s e n s it iv ity  of methotrexate assay
d . comparison or bquinpnum ana sequential conditions
Two methotrexate standard curves were set up in duplicate using the 
same reagents. One standard curve was set up under normal equilibrium  
conditions with an incubation period of 2.5 hours. The other series 
were under'sequential conditions s im ilar to those introduced by Hales 
and Randle (1963) fo r the assay of insulin ( i . e .  the antiserum and 
standards were incubated for 60 min before the addition of the la b e l) .  
Figure 4*7 shows the standard curves produced by the two methods; i t  
indicates that a sequential assay results in a slightly greater f a l l  in 
percentage binding over the range of standards used. However, in view 
of the fac t that there is l i t t l e  to be gained by increasing the s e n s it iv ity  
of the methotrexate enzyme immunoassay, the sequential condition has not 
been introduced in the assay protocol.
c. E ffect of Temperature on the Immunological Incubation
Two methotrexate standard curves were set up in duplicate using the 
same reagents. One standard curve was set up at room temperature (about 
20° C) with an incubation time of 2*5 hours. The other curve was set 
up at 37° C with the same incubation time. Figure 4 . 8  shows the two 
standard curves produced and indicates that at the higher temperature less 
displacement occurred in percentage binding over the range of standards 
used. . This may be due to s lig h t damage to e ither the enzyme label or 
the anti serum caused by the higher temperature.
■ Equilibrium assay 
^ Sequential assay
B/
/
Methotrexate concentration (ng/ml)
Figure 4.7 Effect of the Late Addition of the Label (Sequential Assay) on the 
Sens it iv ity  of the Methotrexate Assay
100
37° C
Room temoerature
NSB 3.87% T
Methotrexate concentration (ng/ml)
Figure 4.8 Effect of Temperature of the Incubation on the Sens it iv ity  
of Methotrexate Assay
E ffe c t o f lemperature on the Final Colour Development
Three series of tubes containing methotrexate standards were set up 
in duplicate using the same reagents; each series consisted of at least  
four standard curves. The f i r s t  set of standard curves was set up under 
the conditions already described: the temperature chosen for the enzymic 
reaction was 30° C. Figure 4.9 shows the l in e a r i ty  of the colour 
produced over 60 min,the time normally used in the assay fo r  B-galactosidase 
a c t iv i ty .  The second set of standard curves was set up as before,except 
that the temperature used for the enzymic incubation was 40° C.
Figure 4.10 shows the absorbance of the standards, zero-binding, to ta l  
tubes is s t i l l  linear for one hour. The th ird  set of standard curves was 
set up as before,except that the temperature used for the enzymic incubation 
was 24° C which is very near to the room temperature. Figure 4.11 shows 
the l in e a r i ty  of the colour produced over 140 min. The results are plotted  
in Table 4 .3 .
Measurement of the Free Fraction
I t  is po ten tia lly  simpler to automate an assay based on estimating the 
enzymic content of the supernatant. To investigate the f e a s ib i l i t y  of 
this approach a methotrexate standard curve was set up in duplicate  
measuring the free frac tion . After separation was achieved using the 
second antibody 500 yl aliquots of each supernatant was transferred to 
other tubes, and substrate solution was added for enzyme incubation.
The results were calculated as the percentage of zero and are shown in 
Figure 4.12. In p rinc ip le , one can choose to assay the enzyme a c t iv i ty  
in e ither the solid or the supernatant phases.
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TABLE 4.3 .The Effect of Temperature on the 'Reaction Rate of 
B-D-galactosidase A c t iv ity  in the Bound. Fraction
Temperature 
of Enzymic 
Reaction
24° C
30° C
40° C
Time for
Enzymic Reaction 
in minutes Total
Mean 
zero ng
Absorbance 
0.2 ng 0.5 ng 1 n<
35 .385 .19 .15 . 1 2 .07
70 .650 .32 .26 . 2 2 .15
105 .93 .44 .38 .27 .21
140 1.15 .56 .48 .36 .29
20 .32 .13 . 1 0 . .06 .04
40 .58 .25 . 2 1 0 .14 . 1 0
60 .82 .35 .29 .23 .16
80 1.08 .46 .41 .31 .23
15 .37 .17 .14 .11 .07
30 . 6 8 .31 .21 .17 .14
45 1 . 0 .45 .37 .25 .21
60 1.3 .56 .42 .35 .28
F = enzyme a c t iv i ty  on the free fraction
Fo = enzyme a c t iv i ty  on the zero tube in 
the free fraction1-8 -
Fo
1-4
20Methotrexate concentration (ng/ml)
Figure 4.12 Methotrexate Standard Curve on the Free Fraction (0.5 ml) 
of the Supernatant
The selection of the supernatant for this purpose, however, has several 
disadvantages: the necessity of using a second tes t tube, the p o ss ib il i ty  
of interference with the enzyme reaction by constituents of the assay 
f lu id ,  and the requirement of an appropriate purif ication  of the enzyme 
conjugate to remove a l l  free enzyme.
Comparison of the Double Antibody and DASP Separation Techniques
Two methotrexate standard curves were set up in duplicate using the 
same reagents. The f i r s t  standard curve was set up using the normal 
procedure in which second antibody is used for the separation phase.
The second standard curve was set up using the DASP (Double Antibody 
Solid Phase) separation technique, the results were calculated as the 
percentage of zero and are shown in Figure 4.13. The results indicate  
that DASP separation technique results in a s l ig h t ly  greater f a l l  in 
percentage binding over the range of standards used. However, the DASP 
method had a poor precision compared to the Double Antibody prec ip ita tion  
method. The double antibody precipitation method was therefore employed 
in a l l  further studies.
Characteristics of Methotrexate Enzyme Immunoassay Using the 
Original Label (5000-1)
S ens it iv ity
Figure 4.14 shows the methotrexate standard curve. From the graph the
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Figure 4.13 Comparison between DASP Separation and Double Antibody Separation
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Figure 4.14 Standard curve for Methotrexate Enzyme Immunoassay
the detection l im i t  was calculated to be 1 ng/ml of methotrexate according 
to the widely accepted de fin it io n  of s e n s it iv ity  ( i . e .  the concentration 
of methotrexate measurered a t twice the standard deviation of the zero 
binding).
Assay Variation
An estimate of the intra-assay variation was determined by measuring 
the same sample ten times in one assay. Plasma samples from patients  
treated with methotrexate having a wide range of drug concentrations 
(50, 110, 8750, 36700 ng/ml) were used. The coeff ic ien t of variance was 
less than 8% in a l l  cases.
The inter-assay variation was estimated by assaying seven samples from 
patients receiving the drug. The coe ff ic ien t of variance did not exceed 
15% fo r  any of the samples tested. The results are shown in Table 4 .4 .
Analytical Recovery
Known amounts of methotrexate were added to a normal serum pool. A stock 
methotrexate solution (100 yg/ml) was prepared in diluent bu ffer . A 100 yl 
aliquot of th is  solution was added to 900 yl a liquot of the pooled sera 
to give a sample concentration of 10 yg/mlc Samples containing 1000, 500, 
1 0 0 , 10 ng/ml of methotrexate in pooled sera were prepared in a s im ilar way. 
For the assay, the samples were diluted with d iluent buffer to be within  
the range of the standard curve. The standards were prepared from the same 
stock methotrexate solution diluted to give 100  ng/ml and then double 
diluted with d iluent buffer.
TABLE 4.4 The In tra -  and Inter-Assay V aria tion  o f the
Methotrexate Enzyme Immunoassay
Intra-Assay Number of Mean
Sample No. Measurements Standard Deviation c .v .
ng/ml
1 10 50.7 + 4.0 7.9
2 10 109 + 6 . 6 6 . 0
3 10 8775 + 486 5.6
4 10 36700 + 2410 6.5
Inter-Assay 
Sample No.
1 5 2 . 0 + 0.3 15.0
2 5 50.0 T 4.3 8 . 6
3 5 1 1 0 . 0 + 8.7 7.9
4 5 626.0 + 22 3.5
5 5 1458.0 + 53 3.7
6 5 12400.0 + 1400 11.3
7 5 37100.0 + 2200 5.9
Table 4.5 shows the amounts o f methotrexate recovered from these samples.
The recoveries are within the range normally found in radioimmunoassays.
High plasma volumes are not l ik e ly  to be used in routine measurements 
since therapeutically  e ffec tive  plasma levels of methotrexate are normally 
considered to be around 450 ng/ml (Hryniuk and Bertino 1969).
Cross-Reactivity
The cross-reactiv ity  of the methotrexate antiserum (S26 /  16/9/76) with 
possible metabolites of methotrexate, fo l ic  acid and other s tru c tu ra lly  
related compounds were examined. Standard curves for each of these 
compounds were set up. The percentage cross re a c t iv it ie s  were calculated  
from the curves by applying the formula:
Amount of methotrexate inh ib iting  binding at zero by 50%
--------------------   x 100  = %cross-reactivit
Amount of hapten inh ib iting  binding at zero by 50%
Table 4.6 shows the interference from the s tructu ra lly  related compounds 
with the methotrexate enzyme immunoassay and its  comparison with 
cross-reactiv ity  of radioimmunoassay.
Comparison with the Radioimmunoassay Method
Thirty  serum samples from patients receiving methotrexate therapy were
obtained from St. Luke's Hospital, Guildford. The samples were assayed,
using the same anti serum by enzyme immunoassay and by radioimmunoassay
method (Aherne et a l , 1977) and the concentrations of methotrexate were
calculated. The values obtained by enzyme immunoassay were plotted against
the results of radioimmunoassay (Figure 4.15) .  A highly s ig n if ican t corre la tio
( r  = 0.999) between the two assays was seen and the student's paired "t" test  
revealed no s ign ificant difference between them.
TABLE 4.5 Percentage Recoveries o f Methotrexate from Normal Serum Pools
ng/ml ng/ml Plasma volume
added to pooled. recovered used
plasma yl
10,000 9630 0.1
9500 0.05
1000 1000 1.0
960 0.5
500 490 2.0
480 1.0
100 93 10.0
103 5.0
10 8.2
9.1
100
50
Mean Recovery
%
96
95
100
96
98
96
93
103
82
91
MEAN RECOVERY: 95%
TABLE 4.6 Cross Reaction of Various Methotrexate S tructura lly  
Related Compounds in Enzyme and Radioimmunoassay 
(Aherne et al 1977)
Hapten .
Methotrexate
4-ami no-N1°-methyl-pteroi c 
acid
Aminopterir.
7-Hydroxy methotrexate
2 , 6 -Di ami no-6 -methyl 
pteridine
N10-M ethy l-fo lic  acid
Folic acid, Dihydrofolic  
acid, Tetrahydrofolic acid, 
fo l in ic  acid, P-amino-benzoic 
acid, Glutamic acid
Percentage
Enzyme
Immunoassay
100
40
20
0.25
0.06
0.01
<0.001
Cross-reaction
Radio
Immunoassay
100
31
19
0.23
0.12
0.03
<0.0065
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Figure 4.15 Correlation between Enzyme Immunoassay and Radioimmunoassay 
methods for Methotrexate determination
The mixed anhydride procedure was used to couple the enzyme to 
methotrexate with a high y ie ld  of enzyme a c t iv i ty  a f te r  the reaction.
Using the present assay 1 ng of methotrexate per ml could be detected, 
which provides more than enough s e n s it iv ity  to measure c l in ic a l ly  
s ign if ican t concentrations of methotrexate in the plasma.
The assay has precision, with an intra-assay coeffic ien t of variance 
of less than 8% and an inter-assay coeff ic ien t of variance of less than 15%.
The performance of this assay was compared with that of the radioimmunoassay 
and the results correlated w ell. (Marks et al 1978).
The present assay requires 24 hours to perform,which is a potential 
disadvantage as rapid results may be required. The standard curve appears 
to be shallow;and as a resu lt the working part of i t  is narrow so i t  may 
require a wider series of dilutions for samples to bring the concentration 
to this range. In order to improve this method i t  is necessary to overcome 
these deficiencies and to make i t  easier to perform so that i t  is an ... 
a ttra c t ive  tool to apply fo r  c lin ic a l routine measurements. The approach 
selected to reduce the time of the assay was to change the separation 
technique. The separation techniques which could be followed are 1. pre­
incubation of f i r s t  and second antibody and using the formed complex for  
the separation phase o r 2 .coupling covalently (ornon covalently) to a solid  
phase (ce llu lose, sepharase, or tube w a ll ) .
The former approach-was chosen for investigation.
Optim ising the Coupling Procedure fo r  Preparing Methotrexate-
6-P-galactosidase Conjugate„
An attempt to improve the conjugation procedure was tr ie d  by using a 
buffering system (sodium bicarbonate TOO mmol / l i t r e  pH 9 .5) during 
the coupling instead of d is t i l le d  water and 0 .1  mol / l i t r e  sodium 
hydroxidecThis resulted in a higher retention of enzyme a c t iv i ty  a f te r  the 
reaction.
To optimise the incorporation of methotrexate into 6-D-galactosidase 
during the coupling, d if fe re n t  molar ratios of MTX to g-D-galacto- 
sidase were t r ie d .  The e ffec t  of d if fe re n t molar ratios can be
seen on the serum d ilu tion  curve and the standard curve of methotrexate 
enzyme immunoassay.
a. Serum Dilution Curves
Using the mixed anhydride procedure, molar ratios of methotrexate to
6 -D-galactosidase of 5000-1, 2500-1 and 1000-1, were examined for th e ir  
influence on the effectiveness of the coupling reaction. Figure 4.16 
shows that at high molar ratios there is a high degree of incorporation 
of the enzyme onto methotrexate but a re la t iv e ly  lo w 't i t re  resu lts . The c 
molar ra tio  of 50Q0-1 has been used fo r .the  previous procedure. A molar ra tio
2500-Lwasselected fo r use in the improved short procedure (which w i l l  be
discussed la te r )
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4.16 Methotrexate serum d ilu tion  curves using three 
d iffe re n t labels
b. Standard Curves
Three sets of methotrexate standard curves were set up using the three 
d if fe re n t  labels of methotrexate-enzyme conjugate. Approximately the 
same amounts of enzyme were used (roughly about 3 un its ). The anti serum 
t i t r e s  using the three labels were 2000, 3000, 4000 in i t ia l  d ilutions -  
for the labels having re la t iv e ly  high, medium and low degrees of 
incorporation of enzyme onto methotrexate. Figure 4.17 shows that  
decreasing the degree of incorporation produces an increase in s e n s it iv ity  
and in the steepness of the standard curve.
od
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Figure 4.17 Three Methotrexate Standard Curves Using D ifferent Enzyme Labels
Improved Methotrexate Enzyme Immunoassay
Assay Procedure
The assay protocol is i l lu s tra te d  in Table 4 .7 . All d ilu tions  of 
antiserum, lab e l,  standards and samples were made with diluent buffer.  
Approximately 3 enzyme units of the conjugate were used per assay tube.
The phase separation was achieved by using a pre-incubated complex of 
f i r s t  and second antibody. This complex was prepared by incubating 
f i r s t  and second antiserum for at least 24 hours at 4° C in diluent  
buffer only. The f i r s t  anti serum was used at a f in a l d i lu tion  of 
1 0 , 0 0 0 - fo ld  ( in i t i a l  d ilu tion  1 0 0 0 - fo ld ) ,  while the second antiserum 
was used at a f in a l d ilu tion  of 60-fold ( in i t i a l  d ilu tion  of 6 - fo ld ) .  
Standards and samples were prepared and diluted as in the previous 
procedure for methotrexate enzyme-immunoassay. The reagents were added 
in the order indicated in the protocol into numbered p lastic  tubes 
(LP3 , Luckham) using Oxford microsamples. F irs t  the pre-incubated 
complex was pipetted into the tubes Ithen the standards or samples 
and the labels were'added.The solution was then vortex mixed. The contents 
of the tubes were allowed to incubate at 30° C fo r  1 hour. Diluent
buffer (1 .5 ml) was added into the tubes which were then spun at 2000 rpm
for 20 min at 4° C on a Mistral 4L Centrifuge (MSE). The supernatant 
was aspirated leaving about 50 yl above the precip ita te . The p rec ip ita te  
was washed with 2 ml of diluent buffer, spun and aspirated. Substrate 
solution (1 ml) was added to the precip ita te  which was then l e f t  a t 40° C
for 1 hour. The reaction was terminated by adding 1.5 ml carbonate
solution and the absorbance measured at 420 nm.
TABLE 4.7 Improved Assay Protocol
REAGENTS TOTAL NON-SPECIFIC 
BINDING
yl yl
ANTISERUM
DILUTION
CURVE
yl
STANDARD CURVE 
ZERO STD SAMPLE
yl yl yl
Pre-incubated 
Complex of 
F irs t  and 
Second Antibody 
in Diluent 
Buffer
STD
SAMPLE
LABEL
DILUENT
BUFFER
SECOND
ANTIBODY
100 100
700
100
700
100
100
700 700
100
100 100 
100
700
100
100
Incubate fo r 1 hour at 30° C. Add (1.5 ml) diluent buffer and spin at  
2000 rpm and at 4° C for 20 min. Aspirate the supernatant and wash again 
with (2 ml) diluent bu ffer, spin and aspirate. Add 1 ml of substrate 
solution to the p rec ip ita te , mix, and leave i t  at 40° C for 1 hour. To 
stop the reaction, add carbonate solution and measure the absorbance at  
420 nm.
C alculations
The results were expressed in the same way as that in the orig inal 
procedure, i . e .  as a percentage of zero bound mean readings.
Factors Affecting the Improved Enzyme Immunoassay Procedure fo r  Methotrexate
Effect of D ifferent Dilutions of Anti serum on the Standard Curve
Five sets of methotrexate standard curves were set up using the improved 
procedure. The following dilutions of the anti serum were used 
1/500, 1/1000, 1/1500, 1/2000, 1/2500 (calculated as in i t i a l  d i lu t io n s ) .  
Figure 4.18 shows that the s en s it iv ity  of the standard curve as well as 
the steepness were increased b / higher d ilu tion  of the anti serum, but 
the zero binding decreased (calculated as a percentage of to ta l )  which 
entailed a longer time for assay of enzyme a c t iv i ty .  Because the levels of 
methotrexate required in patients are normally considered to be around 
450 ng/ml (Hyrniuk et al 1969), the d ilu tion  of anti serum chosen was 
1 / 1 0 0 0  which gives a f a i r ly  sensitive standard curve, and good y ie ld  of 
colour in reasonable time of incubation which is 1 hour in th is  case.
Effect of temperature on the Immunological Incubation
Three sets of methotrexate standard curves were set up following the 
improved procedure protocol and using the same reagents. The f i r s t  
standard curve was set up using 4° C fo r the immunological incubation
I n i t i a l  In i t i a l
1st Antibody 2nd Antibody 
d ilu t ion
1 0 0
Zero
bindingd i1ution
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Figure 4.18 Standard Curves for Methotrexate using various Dilutions 
of F irs t  Antibody (improved method).
between the antigen and antibody, while the second one was set up using 
25° C and the th ird  one using 34° C. Figure 4.19 shows there is a 
s light difference both in se n s it iv ity  and in the displacement of the 
labelled methotrexate by the unlabelled one. The zero binding (calculated  
as a percentage of to ta l )  showed a considerable varia tion . However, in 
view of the fac t that there is l i t t l e  to be gained by increasing the 
s en s it iv ity  of the standard curve by using the condition of 4° C, and since, 
at 4°C, longer w ill  be required to develop a good y ie ld  of colour during 
the enzymic reaction, 30° C was chosen because i t  permits a shorter 
incubation time.
Characteristics of the Improved Methotrexate Enzyme Immunoassay 
Sensitiv ity
Figure 4.20 shows the methotrexate standard curve. From the graph the 
detection l im i t  ( i .e . sensitivity)was calculated to be 1 ng/ml of 
methotrexate on the basis of twice the standard deviation of the zero 
binding.
Assay Variation
The intra-assay variation was determined by measuring the same sample 
f i f te e n  times in one assay. Plasma samples from patients treated with 
methotrexate having a wide range of the drug concentration (55;506; 11 ,440 ng/m’ 
were used. The coeffic ients of variance were less than 5% in a l l  cases.
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Figure 4.20 Methotrexate standard curve (Improved Method)
The inter-assay variation was determined by assaying samples from 
patients receiving the drug. The coeff ic ien t of variance did not exceed 
10% in any case. The results are shown in Table 4 .8 .
i i  i . Analytical Recovery
Using the improved assay procedure, known amounts of methotrexate were 
added to the normal serum pool. Table 4.9 shows the amounts of methotrexate 
recovered from samples to be between 98% .and 105.4%.
iv . a. Comparison with the Radioimmunoassay Method
F if ty  serum and urine samples from patients receiving methotrexate 
therapy were obtained from St. Luke's Hospital, Guildford. The samples 
were assayed using the improved enzyme immunoassay procedure and radio­
immunoassay method of Aherne et al (1977);and methotrexate concentrations 
were calculated. The values obtained by the two methods were plotted as 
a scattergram (Figure 4 .21 ). A highly s ign ificant correlation ( r  = 0.999) 
between the two methods was seen, and the 'student' paired "t" tes t showed 
no s ign if icant difference between them.
b. Comparison of the EMIT Procedure with the Improved Enzyme 
Immunoassay Procedure for Methotrexate
In a la te r  stage of establishing this procedure for methotrexate an
EMIT procedure was reported (Gushaw et al 1978). A correlation investigation
TABLE 4.8 The Intra- and Inter-assay Variation of the Improved
Methotrexate Enzyme Immunoassay
Intra-Assay Number of Mean
Sample No. Measurements Standard Deviation c.v.
ng/ml
1 15 55 + 2.5 4.7
2 15 506 + 1 5  3.0
3 15 11,440 + 457 4.0
Inter-Assay 
Sample No.
1 5 5 5 + 4 . 4  8.0
2 5 510 + 39 7.7
3 5 11,500 +1080 9.4
TABLE 4.9 Percentage Recoveries of Methotrexate from Normal Serum 
Pools Using the Improved Procedure.
ng/ml ng/ml plasma volume
added to pooled recovered used in the assay Mean recovery 
plasma pi %
10,000 10,443 0.02 104.4
10,310 0.05 103.1
500 490 0.25 98
506 0.30 101
50 52.5 4 105
52.7 3.3 105.4
Mean Recovery 102.6%
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Figure 4.21 Correlation between Improved Enzyme Immunoassay and
Radioimmunoassay methods for Methotrexate Determination
Detween tne two procedures was carried out using f i f t y  serum and urine 
samples from patients receiving methotrexate therapy. The samples were 
assayed by both procedures and the results were calculated and plotted  
as a scattergram (Figure 4 .2 2 ) .  I t  indicates that there is a high 
correlation co e ffic ien t ( r  = 0.98) between the two methods; but 
in teresting ly  the slope of the regression line  is 1.84.
A s im ilar resu lt was obtained when the EMIT was compared with the radio­
immunoassay procedure (Aherne et al 1977).
No s ign if ican t difference showed between results of radioimmunoassay and 
results of the improved enzyme immunoassay when both use the same 
anti-serum. EMIT procedure, using a d if fe re n t anti-serum, gives a high 
correlation coeffic ien t with both the radioimmunoassay and the improved 
enzyme immunoassay. But EMIT values are consistently lower -  down almost 
to h a lf  the values given by each of the other procedures.
S ta b i l i ty  of Reagents
The pre-incubated complex of f i r s t  and second antibody was stable fo r a t  
least one month a t 4° C. The other reagents also have a long shelf l i f e .
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Figure 4.22 Correlation between improved Enzyme Immunoassay and 
EMIT methods for Methotrexate Determination
G E N E R A L  D I S C U S S I O N  
a n d  C O N C L U S I O N S
In the mixed anhydride reaction a hapten containing a carboxyl group 
is transformed into a mixed anhydride using secondary butyl chioroformate 
in an organic solvent, when the enzyme is added in aqueous solution, the 
hapten forms a peptide bond with an amino group of the enzyme (Erlanger 
et al 1959). This method has been used to couple haptens to horse radish 
peroxidase (Van Weemen et al 1972, 1975, Bosch e t al 1975) 3 -D-galactosidase 
(Comoglio et al 1976) lysozyme (Schnieder et al 1973 and Rubenstein et al 
1972) and malate dehydrogenase (Rowley et al 1975).
During coupling of haptens to the enzyme, some loss in enzyme a c t iv i ty  
often occurs i f  the pH of the reaction mixture is kept a lka line  to prevent 
enzyme precip ita tion during the reaction (Van Weemen et al 1972, 1974, 1975). 
In the present study coupling of methotrexate to 3 -D-galactosidase resulted  
in l i t t l e  loss in enzyme a c t iv i ty .  At least 80% of the 3 -D-galactosidase 
contains immunoreactive methotrexate a f te r  coupling. The number of metho­
trexate residues per 3 -D-galactosidase molecule has not been estimated, 
because of the no n-ava ilab il ity  of radioactively labelled free acid methotrexate.
I t  is notable that up to 10 cortisol residues can be bound per molecule of 
3-D-galctosidase using the mixed anhydride method (Comoglio et al 1976).
The mixed anhydride method of preparing methotrexate-3-D-galactosidase 
conjugate was chosen in the present work to avoid modifying the immuno- 
chemically characteristic  parts of the methotrexate molecule which involve 
the 2,4-diamino groups (Aherne et al 1977). The results show that this  
method of coupling can be used to synthesise methotrexate-enzyme conjugates 
in high y ie ld  with minimal damage to e ither enzyme or hapten.
The enzymic a c t iv i ty  of the conjugate was stable on storing for at 
least six months; a greater loss of immunoreactivity was observed but 
this was not s u ff ic ie n t ly  large to make the label unusable.
The s e n s it iv ity  of the assay po ten tia lly  enabled determinations to be made 
on microsamples of blood, such as those obtained from a f in ger-p rick .
This is an important factor pa rt ic u la r ly  when the patient is an in fan t.  
However, therapeutically  e ffec tive  levels of methotrexate are normally 
considered to be around 450 ng/ml which is 1 y m o l/l itre  (Hryniuk et al 1969) 
this s e n s it iv ity  is not required for most purposes.
The method could prove to be an invaluable research tool because i ts  high 
s e n s it iv ity  permits more accurate pharmacokinetic studies to be made. I t  
does, however, cause problems, in so fa r  as multiple d ilutions are often 
required to bring the methotrexate concentration within the range of the 
standard curve.
Measurement of the cross-reactiv ity  of various methotrexate analogues 
and metabolites by radioimmunoassay (Aherne et al 1977) and enzyme 
immunoassay method gave s im ilar resu lts , indicating that fo l ic  acid, 
tetrahydrofo lic  acid, fo l in ic  acid (citrovorum factor) and 7-hydroxy metho­
trexate metabolite (Jacobs et al 1976) a t levels l ik e ly  to be encountered 
in plasma and urine, cause l i t t l e  interference in the methotrexate assay.
This fac t permits measurement of the drug in the presence of these commonly 
occurring folates even when they occur at a r t i f i c i a l l y  elevated leve ls .
The probable entero-hepatic bacterial metabolite 4-amino-N10-methylpteroic  
acid does cross-react to about 40%. This metabolite may be found in the 
urine of patients 24 hours or more following the intravenous administration  
of methotrexate as well as during long term treatment with the drug (Valerino  
et al 1972, Johns e t 'a l  1971, and Huffman e t  al 1973).
Because o f i t s  in te rfe rence  in  the methotrexate immunoassay, urine
samples taken 24 hours or more a f te r  a single dose of methotrexate or
at any time during maintenance therapy, may y ie ld  a r t i f i c i a l l y  high 
results fo r  methotrexate content unless a separation procedure is  
inserted prio r to analysis.
The analytical recovery of methotrexate in the presence of various 
amounts of plasma l ik e ly  to be used in practice indicates that methotrexate
measurements are unaffected by natural constituents of plasma.
The assay has a precision which is within acceptable immunoassay standards, 
with an intra-assay coeffic ien t of variance of less then 5% and an in te r ­
assay coeffic ien t of variance of less than 10%.
The validation of the accuracy of this method has been achieved through 
comparison with radioimmunoassay method (Aherne et al 1977) and la t t e r ly  
to an EMIT procedure (Gushaw et al 1978).
Separation of the bound from free label was achieved by the addition of 
second antibody in the original assay. The time required to obtain the 
results was 24 hours which is a potential disadvantage as rapid results  
may be required.
In the improved procedure of methotrexate enzyme immunoassay the separation 
of the bound from the free label was achieved by a pre-incubated complex 
of f i r s t  and second antibody.
The improved procedure has several advantages over the orig inal assay; 
i t  has a steeper curve with better precision and reproducib ility  and most 
important i t  is much more rapid to perform (about 3 hours); i ts  only 
disadvantage is that i t  uses more anti sera than the orig inal method and 
i t  could be shortened i f  fluorogenic substrate were used.
This method is amenable to large batch handling and at least semi-automation. 
Thus the method would appear to be suitable for the routine measurement 
of methotrexate in plasma and samples from patients undergoing methotrexate 
treatment with or without fo l in ic  acid rescue.
CHAPTER 5
TRIIODOTHYRONINE ENZYME IMMUNOASSAY
3 -D-Galactosidase (EC 3 .2 .1 .23 ) from Escherichia Coli was conjugated 
to triiodothyronine (Tg)  by means of a bifunctional cross-linking  
reagent, dimethyl adipimidate (DMA). Eighty per cent of the enzyme 
a c t iv i ty  was retained following the conjugation reaction, of which 
approximately ninety per cent was conjugated to immunologically active  
Tg.  This conjugate was used in an enzyme-immunoassay (EIA) for Tg.
Second antibody attached to cellulose was used as the separation phase.
In the f in a l immunoassay the enzyme a c t iv ity  of the bound fraction  was 
determined with O-nitrophenyl-3 -D-galactopyranoside as substrate. The 
s e n s it iv ity ,  precision, and sim plic ity  of the enzyme immunoassay compared 
favourably with that of a published radioimmunoassay method. Results for  
triiodothyronine plasma samples correlated well with those determined 
by the radioimmunoassay method.
General consideration and chemistry
The active principles of the thyroid gland are the iodine containing 
amino acid derivatives of thyronine-thyroxine and triiodothyronine  
(Table 5 .1 ) .  Triiodothyronine (Tg )  was f i r s t  recognised as a secretory 
product of the thyroid gland by Gross & P itt-R ivers  (1952). Following 
i ts  isolation and synthesis, T3 was soon proved the 
most potent of the ca1 origenic thyroactive hormones» I t  has some 3-4 
times the potency of thyroxine (T^) in terms of i ts  a b i l i t y  to restore 
to normal the metabolic a c t iv i ty  of patients with hypothyroidism (Gross 
et al 1952 b; and Lerman 1953). In the thyroid gland, Tg is synthesized 
by coupling of monoiodotyrosine and diiodotyrosine, which are incorporated 
in the thyroglobulin of the fo l l ic u la r  lumen by means of peptide bonds 
(Figure 5 .1 ) .  Coupling of two diiodtyrosine residues results in T^ 
formation. The exact chemical mechanism of these coupling reactions 
is not known: though in v i t ro  evidence suggests that they are enhanced by 
the thyroid peroxidase enzyme system (Lamas et al 1972). When iodide 
a v a i la b i l i ty  is  adequate, thyroglobulin contains considerably more T^ than 
T g,  the ra t io  of T^ to Tg being approximately 10 - 20 : 1 (Nagataki 
e t al 1972, and Chopra et al 1973). Thyroid tissue also contains a 
thyroxine deiodinase, a product of whose action is Tg (Dawber e t  al 1971; 
and Haibach et al 1971). The contribution, i f  any, of this pathway to  
thyroidal Tg secretion is unknown. Only since 1970 has i t  been realised  
that a substantial portion of the c irculating Tg is produced from T^ 
outside the thyroid gland, that is , from the extrathyroidal monodeiodina- 
tion of T^ (Braverman et al 1970, 1973, Pittman e t al 1971, and Surks 
et al 1973). Understanding' of the role o f Tg in the maintenance of the
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euthyroid state and in the production ot various states ot thyroid 
hormone excess or insufficiency,has greatly  increased in recent years.
This has occurred prim arily  as a resu lt of the development of simple 
and re lia b le  methods fo r  measurement of serum Tg concentrations. The 
rapid advances in the methodology of Tg assay have led to wide a v a i la b i l i t y  
of serum Tg assays: and Tg measurements have been shown to have important 
diagnostic value in certain c lin ic a l situations.
Tg Transport and Production
As is the case for T^, Tg in serum exists in both bound and free forms. 
Previous studies had suggested that Tg was bound only to thyroxine binding 
globulin (TBG) and albumin. But Davis et aj_ (1972) and Larsen (1972) have 
demonstrated binding of Tg to thyroxine binding prealbumin (TBPA) as w ell.  
The a f f in i t y  of Tg fo r these binding proteins is c learly  less than that  
of T^, in v itro  studies indicating that Tg has approximately 1/30th of the 
a f f in i t y  of T^ for TBG (Hao et al 1971). However, the d istr ibution  of 
endogenous Tg among the various binding proteins in viva is not known 
with certa in ty . Because the a f f in i t y  of Tg fo r  the various binding 
proteins is less than that of T^, a r e la t iv e ly  higher proportion of the 
tota l serum Tg exists in the free or unbound form. In serum from normal 
subjects, the proportion of Tg that is unbound ranges from 0.18 -  0.46% 
of the tota l serum Tg concentration (Braverman et al 1970, Nauman et al 
1967, Oddie e t  aj_ 1971, Hollander et al_ 1972, Dussault et al 1973; and 
Chopra e t aj_ 1973 a ) .  Since to ta l serum Tg concentrations average 100 -  
150 ng /  100 ml, the serum free Tg concentration is  approximately 
0.1 - 0.4 ng /  100 ml (Braverman et al_ 1970, Oddie et aj_ 1971, Hollander 
et al_ 1973 b ) . In contrast, approximately 0.03% of the to ta l serum T^ 
is unbound, resulting in a free T^ concentration of about 2 ng /  100 ml 
(Woeber, 1971).
The differences in the degree of binding of the two hormones provide 
the key explanation fo r  th e ir  differences in fractional turnover ra te ,  
volume of d is tr ib u tio n , serum concentration, and biological a c t iv i ty .
The fractional turnover rate of Tg is approximately 50 -  70% day 
whereas that of T^ is 10% day. I ts  volume of d istr ibution  is about
35 -  45 l i t r e ,  whereas that of T^ is 10 -  12 l i t r e  (Pittman e t  al 1971, 
Braverman et aj_ 1970, Oddie e t  al_ 1971, and Nicoloff et al_ 1972). In
contrast, the serum concentration of T^ is 60 -  80 fold greater than that
of Tg.  From such data, estimates of hormone production rates can be 
made. I t  appears that the to ta l d a ily  production rate o f T^ is about
70 - 90 yg, whereas that of Tg is about 15 -  30 yg (Braverman et al
1973, Oddie et aj_ 1971, Nicolof e t_  al_ 1972, Fisher et_ al_ 1971, and 
Singer e t al_ 1972). What is less clear is the proportion of da ily  Tg 
production that results from extrathyroidal deiodination of T^. That 
th is process occurs has been demonstrated by multiple techniques 
(Braverman et a2 1970, 1973, Pittman e t al_ 1971, Surks e t  al_ 1973,
Lieblich e t al_ 1972). That i t  accounts for a major portion of the Tg 
produced, and also a considerable fraction of the T  ^ metabolised, is  
clear from the evidence that hypothyroid patients receiving 0 . 2  mg doses of 
T^ have both serum T^ and Tg concentrations that are normal or s l ig h t ly  
elevated and that are present in almost the same ra t io  as in normal 
subjects (L ieb lich  et aj_ 1972). Using a varie ty  of techniques, d if fe re n t  
workers have estimated that extrathyroidal T^ to Tg conversion accounts 
fo r  40 -  80% of to ta l da ily  Tg production (Pittman et a_l_ 1971, Surks 
ejfc al_ 1973, Braverman et al_ 1973, and Singer et aj_ 1972).
States which require measurement of serum triiodothyronine (Tg)  
concentration
Scattered data are available  concerning a lterations in serum Tg concentration
in various pnysioiogicai states. Nevertheless, three situations have 
already been uncovered in which measurements of serum Tg concentration 
w il l  be required i f  analysis of blood hormone concentrations are to be 
employed as an index of the metabolic state. Several patients have 
been found in whom a c l in ic a l  state of thyrotoxicosis was associated with 
normal values of the serum T^, but with increased values of serum Tg con­
centration as seen in the usual case of hyperthyroidism (Sterling et al 
1969, and Hollander, 1968). This remarkably interesting finding should 
not be considered as license fo r  the diagnosis of thyrotoxicosis in the 
many patients suspected of having this disorder in whom the serum 
concentration is normal, however. Although i ts  precise frequency is  
unknown, Tg thyrotoxicosis is doubtless quite rare. The demonstration of 
a normal Tg suppression te s t  w i l l  serve to exclude Tg thyrotoxicosis in 
patients in whom i t  is not present.
Patients who have received radioiodins therapy for hyperthyroidism may 
appear c l in ic a l ly  euthyroid despite the fact that th e ir  serum PB1 
(Protein Bound Iodine) or T^ concentrations are in the hypothyroid 
range. A group of such patients has been found to have values of the 
serum Tg concentration within the normal range, and i t  is this hormone, 
presumably, that is sustaining th e ir  normal metabolic state (S terling  
et al 1969).
F in a lly , patients with autonomously functioning, mostly s o li ta ry , nodules 
of nontoxic nodular goitre may have low normal concentrations of T^ in 
serum but d is t in c t ly  elevated Tg levels (Radichevich and Werner 1968).
Such patients are e ith e r  euthyroid or borderline hyperthyroid to 
examination.
The exact manner in which the thyroid hormone acts to produce i ts  
characteris tic  e ffects is not known. P r inc ipa lly  because of the wide 
variety  of these e ffec ts , many believe that the hormone exerts a single 
primary action, probably on energy metabolism, to which a l l  other actions 
are secondary, depending upon specific local target-organ mechanisms and 
responsiveness. However, thyroid hormone may have a function in tissue  
d if fe re n t ia t io n  and development,independent of i ts  e ffe c t  on energy 
transformations and oxygen consumption. The hormone may be concerned 
exclusively with energy metabolism and, a t the same time, may influence 
the a v a i la b i l i ty  of energy for many specialized processes.
The concept has been advanced that the thyroid hormone regulates a l l  
metabolic functions by controlling the level of cytochrome C in the 
tissues; this is increased in hyperthyroidism and decreased in hypothy­
roidism. In teres t has been centred upon observations that, in v i t r o ,  
thyroid hormone can (a) induce mitochondrial swelling, reversible by 
ATP, and (b) uncouple phosphorylation from oxidation reactions in the 
oxidation o f  beta-hydroxbutyrate. I f  the la t te r  occurs, in vivo, 
a portion of the energy produced during c e llu la r  oxidation processes 
might be lost in heat instead of being u t i l ize d  for synthesis o f high-energy 
phosphate compounds. This could account fo r  the ca1 origenic action of 
thyroid hormone. However, these effects have been produced only with 
unphysiologically high concentrations of thyroxine,and are produced also 
by other substances, some calorigenic, others not, which exert none of 
the other biological actions of thyroid hormone. Consequently, the 
physiological significance of these observations is not c lear. Moreover, 
the mitochondrial swelling produced by thyroxine, which has been related  
to the uncoupling phenomenon, is countered by dinitrophenol, which i t s e l f  
uncouples oxidative phosphorylation.
therapeutic Uses o f Thyroid Hormone
The two specific indications for the therapeutic use of thyroid hormone 
are myxedema and simple goitre. Inasmuch as they result from thyroid 
hypofunction, these uses represent true replacement therapy.
Methods o f  Tg measurement
The f i r s t  reasonably practical methods for the measurement of Tg in serum 
were those in which Tg and T^ were extracted from serum, the Tg and T^ 
separated from one another by chromatography and the Tg measured by 
competitive protein binding analysis, using TBG as the Tg binding agent 
(Nauman e t  al 1967, S terling e t al 1969, and Wahner e t al 1971). Later 
studies in several laboratories indicated that this methodology resulted  
in overestimation of the Tg concentration in serum, as i t  was shown that 
the chromatographic systems employed did not completely separate Tg and 
T^ and that monodeiodination of T  ^ to Tg occurred during the in v it ro  
separation procedures (Fisher e t al 1971 b, and Larsen et al 1971).
Further refinement of these procedures subsequently led to the development 
of methods that appeared to obviate these problems, and serum Tg concentration 
results varying from 50 - 75% of those o r ig in a lly  reported were found 
(Larsen e t al 1971, and Dussault e t al 1971). Other techniques applied 
to Tg measurement have included gas-liquid chromatography and double 
isotope derivative methodology (Mitsuma e t al 1971 and Hagen e t  al 1973).
While these methods may provide re liab le  and precise measurements of serum 
Tg concentrations, they are rather cumbersome, time-consuming and insensitive  
and, since 1970, have been almost universally superseded by radioimmunoassay 
methods.
The development of radioimmunoassay procedures for the measurement of Tg 
has now been reported by many laboratories (L ieblich e t  al 1972, Mitsume
et a l , 1971 , 1972, Brown e t  al 1970, Gharib et al 1970, 1971, Chopra e t  al 
1972 a , 1972 b, Larsen e t  a l 1972 b, Surks et al 1972, Patel e t  al 1973, 
Hufner e t  al 1973, Hesch e t al 1973, Premachandra 1976, Rugg e t  al 
1977, Alexander e t  al 1974, Fang e t  al 1974, Haynes e t al 1977,
Meinhold e t al 1974, R atc lif fe  e t  al 1974, Persson e t  a l 1976,
Q u ih i l la l t  e t  al 1976, Challand e t  al 1975, Ljunggren e t  al 1976, and 
Seth et al 1976.) The presence in serum of thyroid hormone binding 
proteins, especially TBG, has posed a problem in the assay of Tg in serum. 
The presence of these Tg binding proteins has been shown to result in 
a r t i fa c tu a l ly  increased serum Tg leve ls , undoubtedly because some of the 
radioactively  labelled Tg used in the assay becomes bound to these proteins. 
This binding of labelled Tg has been circumvented in several ways. Perhaps 
the simplest has been with the use of various competitive inh ib iters  of the 
Tg binding protein interaction such as 8 -anilinonaphthalene sulphonic acid, 
diphenylhydantoin, sodium s a lic y la te , te tra  chlorthyronine, and thiomerosal. 
Secondly Tg has been separated from serum by adsorption to and subsequent 
elution from sephadex or by extraction of serum with ethanol (Surks e t  al 
1972, Patel e t  al 1973). Th ird ly , other investigations have used thermal 
inactivation (S terling  e t al 1974) before the radioimmunassay.
Tg radioimmunoassays evolved using these procedures have been found to have 
good r e l i a b i l i t y ,  precision, s p e c if ic ity ,  and s u ff ic ie n t s e n s it iv ity  to 
detect serum Tg concentrations. The importance of these measurements 
in the c l in ic a l  assessment of thyroid function is now well documented 
(Larsen 1972 c, Robbins 1973, Utiger 1974).
The technique of enzyme immunoassay has proved useful for measuring 
hormones in biological flu ids (Wisdom 1976, Schuurs et al 1977, and 
Voller e t al 1976) and is potentia lly  an a ttra c t ive  technique to apply 
to the determination of Tg.  The assay to be described incorporates
use or a g-u-galactosiaase -  ig conjugate as tracer , with the separation 
of "free and bound" tracer being affected by means of DASP (Double 
Antibody Solid Phase).
MATERIALS AND METHODS
Triiodothyronine ( T g ) ,  thryroxine, 3, 5 -  diiodtyrosine, 8 -  an il ino  -  
1-naphthalene sulphonic acid (AMS), 1 -  ethyl -  3 (3 -  dimethyl ami no­
propyl) carbodiimide, 0 -  nitrophenyl -  3 -  galactopyranoside (ONPG),
2 -  mercaptoethanol, and N -  ethylmorpholine were obtained from Sigma
125
Chemical Company, London. Tg -  I label (specific  a c t iv i ty  474 
yci/yg) was supplied by Abbott Laboratories, Queensborough, Kent. The 
3 - D  -  galactosidase (EC 3 .2 .1 .23) from Escherichia Coli was purchased 
from Boehringer Mannheim, Mannheim, West Germany, as a suspension in 
2.2 mmol /  l i t r e  ammonium sulphate. Dimethyl adipimidate dihydrochloride 
(DMA) (Pierce Chemical Co., Rockford, 111.) was stored in 10 -  mg aliquots  
under reduced pressure a t  -20°C. Micro fine cellulose was supplied by 
the Whatman Company, Maidstone, Kent. Bovine serum albumin was obtained 
as a 30% W/V solution from Armour Pharmaceutical Company, London. 
Precipitating and non-precipitating donkey - antisheep IgG were supplied 
by Guildhay Anti sera. Sephadex G-25 gel was from Pharmacia fine  
chemicals, Uppsala, Sweden, a l l  other reagents were purchased from 
BDH Chemical Limited, Parkstone, England.
The triiodothyronine(Tg) anti serum (bleed BIO 12 .8 .76 ), supplied by 
Guildhay Anti sera, Guildford, Surrey, England, was raised in a sheep 
against a Tg - bovine serum albumin conjugate prepared by use o f the 
carbodiimide method (Goodfriend et al_ 1964). This antiserum was found 
to contain 4.3 moles of Tg per mole of BSA.
The non-precipitating donkey anti-sheep second antibody was coupled to a
ceiiuiose support using tne metnoa reported oy burevicn e t  a [  ( ly b l j  to 
prepare a DASP (Double Antibody Solid Phase).
PROCEDURE
The p u r i ty 'o f  3 -  D - galactosidase preparation was ascertained 
by electrophoresing 50 ug of the material on polyacrylamide gel 50g/ 
l i t r e  in Tris /g lyc ine bu ffe r , pH 8 .3 . The gels were stained for  
protein with Coomassie Blue and for 3 -  D -  galactosidase a c t iv i ty  by 
using 6 -  bromo -  2 -  naphthyl -  3 -  galactopyronose (Cohen e t  al_ 1952).
To examine further the purity of the conmercial enzyme, an enzyme sample 
(2 mg) was applied to a sepharase 6B column (90 x 0.9 cm) and eluted 
with sodium phosphate buffer (10 mmol /  l i t r e ,  pH 7-0) containing sodium 
chloride ( 1 0 0  mmol /  l i t r e )  and magnesium chloride ( 10  mmol /  l i t r e ) .
The absorbance of the eluate was monitored a t 280 nm and 3 - D -  
galactosidase a c t iv i ty  was assayed using 0 -  nitrophenyl -  3 -  D -  
galactapyronoside and measuring the absorbance of 420 nm. A ll commercial 
preparations, which were used without further pu rif ica t io n , contained 
65,000 units of a c t iv i ty  per milligram (where 1 unit is the amount of 
enzyme that hydrolyses 1 nmole 2 -  nitrophenyl - 3 - D  - galactopyronoside 
in 1 min a t  28°C in the diluent buffer described above. (Craven e t  al 
1965).
Preparation of 3 -  D - Galactosidase -  Tg Conjugate
3 - D  -  Galactosidase was coupled to Tg using the cross-linking  
bifunctional imidoester dimethyl adipimidate. A typical preparation 
is described below:
Tg (6 .5  mg, 10 y mole) was dissolved in dry methanol (1 ml) containing 
5% W/V N-ethylmorpholine, dimethyl adipimidate (DMA) (3 .9  mg.,
16 y mole) was added and the solution maintained a t  room temperature 
for ten minutes. A 50 y£ aliquot was then transferred to a solution 
of g -  D -  galactosidase (100 yg, 0.2 n mole) in Sodium Carbonate 
buffer (1 ml, 100 m m o l / l i t r e ,  pH 9.9 containing magnesium chloride  
( 1 0  m m o l/ l i t re )  2 -mercaptoethanol, 10  m m o l/ l i t re )  and kept at room 
temperature fo r  90 minutes. The reaction was terminated by addition  
of Tris  buffer (1 ml, 50 m m o l / l i t r e ,  pH 7.5 adjusted with acetic acid, 
contained magnesium chloride, 10  m m o l / l i t r e ,  sodium chloride,
100 m m o l/ l i t re  and mercaptoethonol 10  m m o l / l i t r e ) .
P urif ica tion  of 3 -  D - Galactosidase - Tg Conjugate
To separate re la t iv e ly  low molecular weight compounds from the enzyme, 
gel f i l t r a t io n  on a Sephadex G-25 column was carried out and the column 
eluted with Tris buffer described above. The fractions containing 
enzyme a c t iv i ty  were collected, pooled, and diluted to a f in a l volume 
of 10 ml with Tris  buffer, sodium ozide, and bovine serum albumin were 
added to give 0.1% W/V of f in a l  solution. The solution was stored a t  
4°C until required.
Determination of the Immunoreactivity of the 3 -  D ■ Galactosidase 
-  Tg Conjugate
The proportion of 3 -  D - galactosidase bound to immunoreactive Tg was 
determined by incubating a portion of the enzyme conjugate (equivalent 
to 3 enzyme units) with excess Tg anti serum (0.1 ml, 200 -  fo ld  d ilu tio n  
of antiserum). The d ilu tion  was done with barbitone buffer (50 m mol/ 
l i t r e ,  pH 8 . 6 ) contained 0.1% W/V BSA.
1.1i ^ y m c  u u i i j u y a u c  u u u n u  u y  i g  a n u i u u u i e b  wcib i p i  L d t e a  e i c n e r  D y
donkey anti sheep second antibody or the DASP (Double Antibody Solid 
Phase) preparation. Enzyme conjugate bound by Tg antibody was measured 
in the prec ip ita te  a f te r  washing i t  once with barbitone buffer as 
described above.
Enzyme Immunoassay procedure
The protocol fo r  the Tg enzyme immunoassay is shown in Table 5 .2 .  A ll 
dilutions of ( la b e l,  standards, antiserum and DASP) were made in 
barbitone buffer. The Tg standards were made up in charcoal stripped 
pooled human plasma.
Tg Free plasma was prepared as follows: 20 g of Norit A (Sigma.) was
added to 100 ml of plasma. The solution containing the charcoal serum 
mixture was placed on a cold tray and mixed by means of an overhead 
s t i r r e r  for 24 h. The beaker was removed and the charcoal allowed to 
se ttle  for an hour or so. The supernatant was f i l te re d  under pressure 
using bacteriological f i l t e r  pads and a seitz f i l t e r  (Amicon Limited).
The resultant c lear plasma was aliquoted in 5 ml lots into small glass 
bottles and stored a t  -20° C. I t  was used as the medium fo r  preparation 
of working standards, the zero standard and non-specific binding tubes.
Tg standards were prepared from a stock solution by dissolving Tg free  
acid (sigma) in 0 . IN NaoH (added dropwise) and making up to 100 ml with 
saline/albumin (10.9% sodium chloride + 0 . 1 %  bovine serum albumin). 1 ml 
of the solution was made up to 100 ml with saline/albumin, (concentration 
1040 ng Tg/ml). 1 ml of this solution was made up to 10 ml with sa line /  
albumin, (concentration 104 ng Tg/ m l). This solution was aliquoted 
in 100 y£ lots and stored a t -20°C. For use an a liquot of the Tg 
standard was added to 0.9 ml of Tg Free plasma. This solution contains
TABLE 5.2 : Protocol fo r  Tg enzyme immunoassay
Volumes are expressed in yl
Non specific  Anti serum standard curve
Reagents Total binding 10n _ . . . ,
3 3 curve zero standard sample
Sample 100
Standard 100
Barbitone 
buffer + ANS
400 300 300 200 200
Enzyme
label
100 100 100 100 100 100
Tg-Anti
serum
100 100 100 100
Leave to incubate at 4 C for 
overnight
DASP 500 500 500 500 500
Leave for three hours at 4 C, spin, aspirate and wash once with barbitone 
buffer. Substrate solution (1 ml) was added, mixed and incubated 
at room temperature for 90 minutes. The reaction was terminated with
1.4 ml of 0.2 mol / l i t r e  sodium carbonate solution. The tubes were spun 
and the optical density of the solution measured at 420 nm (Typ ica lly  
optical densities for the standard curve covered the range 0.1 to 0 .5 ) .
This 1 ml of top standard was mixed w e ll ,  0.5 ml aliquot was removed 
with an Oxford sampler and transferred to 0.5 ml of Tg Free plasma.
This gave a standard containing 8 n mol of Tg per l i t r e .  Double 
dilu tions  were continued in th is  manner to obtain additional standards 
of 4, 2, T, and 0.5 n m o l / l i t r e .  The standards were treated in 
exactly the same way as the serum samples in the assay.
The blocking reagent ANS 0.1 m mole/tube was added to minimise binding
of Tg by thyroid binding globulin (R a tc l i f fe  e t al_ 1974).
Standard curves were set up using an in i t i a l  d ilution of 1/8000 of
Tg -  anti serum.
Calculations
Standard curves were plotted as the ra tio  of the fraction  of the 
enzyme-label ' T3 bound a t  a given Tg concentration to the fraction  
bound when no T  ^ was present, i . e .  (B/T) /  (B /T) = B/B,where B =o O O
enzyme a c t iv i ty  bound at given concentration, Bq = enzyme a c t iv i ty  
bound a t  zero concentration, and T = tota l enzyme a c t iv i ty .
RESULTS
Purity  of 3 -  D -  Galactosidase
On staining with Coomassie Blue a f te r  polyacrylamide gel electrophoresis 
of the commercially available $ -  D - galactosidase, one major and s ix  
r e la t iv e ly  fa in t  protein bands were v is ib le .  Most of the b - D - 
galactosidase a c t iv i ty  was located in the same position as the major 
protein band (F ig .5 .2 ) .  Four minor B-D-galactosidase bands were also
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detected, which were aligned with four of the minor protein bands.
The elution profiles  of protein and 3 - D  -  galactosidase a c t iv i ty  
from the Sepharose 6B column coincided very closely; no separate 
protein peaks were present ( F i g .5.3 ) .  These results indicate that  
the commercially.available 3 - D  - galactosidase preparation contained 
a t most only very l i t t l e  impurities. This preparation was therefore 
used without further purif ication .
Factors affecting Tg -  Enzyme Immunoassay
( i )  The e f fe c t  of d if fe re n t  molar ratios of Tg and DMA to 
enzyme on the production of label
Various molar ratios of Tg and DMA to the enzyme, were examined for  
the ir  influence on the effectiveness of the coupling reaction using a 
similar procedure to that described in the methods section of th is  
chapter. Table 5 .3  shows that at high ratios there was a high degree 
of incorporation of the enzyme to immunoreactive Tg* although some loss 
of enzyme a c t iv i ty  did occur. A molar ra t io  of 2500 -  4000 - 1, 
between Tg -  DMA - 3 - D  - galactosidase was therefore selected as the 
best condition for preparing 3 - D  -  galactosidase - Tg conjugate 
(F ig . 5 .4 ).  Incorporation of 125I -  Tg label into the conjugation 
reaction indicated that eight moles of Tg were incorporated per mole 
of galactosidase when a ra t io  of 1000  - 1000  -  1 was used.
( i i ) E ffect of human plasma on Tg Enzyme Immunoassay
( a ) Effect on the standard curve
Two Tg standard curves were set up using the same reagent, the f i r s t  
one was carried out in b u ffe r  only. The second one was carried out 
using 50 of hormone free plasma and the blocking agent ANS (0.1 n mol
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TABLE 5.3 Preparation o f T3 B-D-galactosidase conjugate
Ratio of % Retention of % Binding by I n i t i a l  d i lu t io n
DMA : Tg Enzyme enzyme a c t iv i ty  T^-antiserum* of -antiserum
5000 : 5000 : 1 76
1000 : 1000 : 1
500 : 500 : 1
100 : 100 : 1
Untreated enzyme
91
75
.88
100
97
82
82
70
61
47
21
12
18
9
: 10 
: 80 
: 10 
: 80 
: 10 
: 80 
: 10 
: 80 
: 10 
: 80
*  Non-specific binding has not been subtracted
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Fig. 5.5 shows that the presence of the plasma does have an e ffec t  
on the standard curve. Thus i t  is necessary to set up T3 standard 
curves using hormone free plasma in the routine measurements of in 
the serum of patients.
(b) E ffect of plasma on the s ta b i l i ty  and determination 
of galactosidase a c t iv i ty
This was examined using plasma from 29 hospital patients. Plasma 
( 0 . 2  ml) was mixed with barbitone buffer ( 0 . 6  ml) and galactosidase 
(200 ng) in barbitone buffer (0 .2  ml) and l e f t  at 4°C for 24 hours.
An a liquot (0 .2 ml) was assayed for galactosidase a c t iv i ty  (Table 5 .4 ) .  
The results showed that none of the samples tested changed the s ta b i l i t y  
of the enzyme. The galactosidase assay had a coe ffic ien t of variation  
of less than 2% when carried out in the presence of 40 y£ plasma. None 
of the determinations varied from the mean by more than 5%.
( i i i )  Optimising of amounts of DASP in the assay
Two serum d ilu t io n  curves for T  ^ anti serum were set up using the same 
reagents. The f i r s t  one used 500 yg of DASP per each assay tube, the 
second one used 200 yg of DASP in each assay tube (F ig . 5 .6 ) .  There 
was l i t t l e  difference in the t i t r e o f  the anti serum, and so on economic 
grounds 200 yg DASP per tube was used for routine measurements.
( iv )  E ffec t of d if fe re n t  dilutions of antiserum on the standard 
curve
Two T  ^ standard curves were set up using the same reagents and the 
normal procedure of T  ^ enzyme immunoessay. The f i r s t  standard curve 
used the anti serum at 1/8000 d i lu t io n , and the second one used the T  ^
anti serum a t  1/15000 d ilu tion  (F ig . 5 .7 ) .  The results indicated
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+ ANS 0.1 mmol/litre (te s t  concentration)
■ In absence of plasma
200 pg DASP used
•  Zero binding 57% maximum binding
■ Zero binding 54% maximum binding
T3 Antiserum (BIO, 8 /7 /76 , 1/10,000) 
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IGURE 5.5 EFFECT OF HUMAN PLASMA ON T3 -STANDARD CURVE
TABLE 5.4 E ffect of plasma on the s ta b i l i t y  and determination 
of galactosidase a c t iv i ty
Enzyme A c tiv ity *
(A optical density/hour)
Enzyme in buffer alone fo r
24 hours = 0.770 0.790
Samples - mean of 29 d if fe re n t
plasma samples = 0.785 ± 0.015
Lowest value measured = 0.760 0.770
Highest value measured = 0.830 0.830
Unconjugated galactosidase was used in this
experiment
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FIGURE 5.7 T3 - STANDARD CURVE USING DIFFERENT DILUTIONS OF ANTISERUM
over the various T3 standards used. The zero binding of the standard 
curve using 8000 -  fo ld  d ilu tion  was (50.8% T) higher than that using 
15000 -  fo ld d ilu tion  (33.7% T) which entailed a longer time for colour 
development of the enzymic reaction with l i t t l e  gain in assay 
s e n s it iv ity .
Characteristics of T3 Enzyme Immunoassay
( i )  Sensi t i v i t y
S en s it iv ity  in radioimmunoassay has been defined by Ekins et al_ (1968) 
and accepted by the American Chemical Society and B rit ish  Standard 
In s t itu t io n  (Ekins et al_ 1971). These workers defined s e n s it iv ity  
(or detection l im i t  of an assay) in terms of the slope of the dose 
response curve, i . e .  the change in the response metameter (antigen 
concentration) fo r a given change in the "dose". The detection l im i t  
of an assay, which can also be defined as "sensitiv ity"  is  the minimum 
amount of antigen that can be measured with acceptable precision. With 
this d e f in it io n , s e n s it iv ity  is  usually estimated as the amount of 
standard required to produce a 10% decrease in the zero binding.
According to one widely used d efin it io n  of s e n s it iv ity  (the concentration 
measured a t  twice the standard deviation) the s e n s it iv ity  is equal to 
0.7 n m o l / l i t r e  455 pg T3/ml) (see Fig. 5.33 whereas using the approach 
of Ekins ejt aj_ the 10% f a l l  in binding from zero is  produced by 
0.5 n mol T ^ / l i t r e  (325 pg T /m l) .
Comparison of a standard curve obtained with a T3 -  radio-label with a 
standard curve obtained by using T3~enzyme conjugate (Fig.5.8)shows that  
both assays have more or less the same s e n s it iv ity .  The normal T3 plasma
level is approximately 1 to 3 '.5 n m o l/ l i t re .
1 0 0
9 0
8 0
Isotope label
70 & Enzyme label 
200 yg DASP was used
ntiserum ( in i t ia l  dilution  
= 1/ 10 ,000)
5 0
4 0
3 0
20
8420 0-5 1
T3 concentration (nmol/litre)
FIGURE 5.8 COMPARISON OF T3 STANDARD CURVES USING THE ENZYME AND 
THE ISOTOPE LABELS
An estimate of the inter-assay variation was determined by setting up 
ten standard curves spread over a one month period. The coeff ic ien t  
of variance was less than 12%.
( i i i )  Cross-Reactivi ty
The cross-reactiv ity  of the T3 -  anti serum (BIO 12/8/76) with thyroxine 
and with 3,5 -  diiodotyrosine was less than 0.2%. The percentage cross­
re a c t iv ity  is expressed as the amount of T  ^ that inh ib its  binding at  
zero concentration by 50% /  amount of cross reactant that in h ib its  
binding a t  zero concentration by 50%.
( iv )  Comparison of T  ^ -  Enzyme Immunoassay with the Radioirmmoassay 
procedure (R a tc l i f fe  e t al 1974).
The T^ plasma levels of 59 patients whose thyroid function was under 
investigation was measured by.both the enzyme immunoassay and the radio­
immunoassay procedures. A scattergram comparing T  ^ levels by the two 
procedures is shown in Fig. 5 .9 . The two methods have a correlation  
c oeff ic ien t of 0.90 and a regression line o f Y = 0.98x + 0 .2 4 , where 
(X) equals results determined by radioimmunoassay.
(v) S ta b i l i ty  of the Enzyme Label
The label was stored in Tris buffer containing 0.1% W/V BSAand 0.1%
W/V Sodium Azide a t 4°C. Both the enzymic a c t iv i ty  and the immuno- 
re a c t iv i ty  v/as measured a t  monthly in terva ls . The enzyme retained 67% 
of i ts  enzyme a c t iv i ty  and 92% of i ts  immunoreactivity a f te r  six months
of storage under the condition described above.
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FIGURE 5.9 CORRELATION BETWEEN ENZYME IMMUNOASSAY AND RADIOIMMUNOASSAY 
METHODS FOR PLASMA TRIIODOTHYRONINE DETERMINATION
DISCUSSION
A new coupling reagent (dimethyl adipimidate) was used to prepare 
Tg -  $ -  D -  galactosidase conjugate. Eighty percent of the enzyme 
a c t iv i ty  was retained following the conjugation reaction, of which 
approximately ninety percent was conjugated to immunologically active  
Tg. DMA, a bifunctional imidoester has been used to form crosslinkages 
in several proteins (e .g . bovine pancreatic ribonuclease A, Hartman &
Wold 1967). We have used th is  imidoester (DMA) to link several small 
haptens to $ -  D -  galactosidase (see Chapter 3 ) .
Imidoesters react in a lkaline solutions with amines to form imidoamides 
( i . e .  Amino-group specific reagents). Using the enzyme immunoassay
0.7 nmol T g / l i t r e  could be detected. The normal range of Tg is 1 to
3.5 n m o l/ l i t re .  Further increase in assay s e n s it iv ity  may be possible 
i f  3 -  D -  galactosidase a c t iv i ty  is  measured by the very sensitive  
f luorim etric  assay using 4-methyl-umbelliferyl-B-D-galactoside (Kato 
et al_ 1975) as substrate.
The assay has a precision which is generally regarded as acceptable 
for  immunoassay, with an inter-assay coeff ic ien t of variation of less 
than 12%.
Separation of the bound from free label was achieved by using the DASP 
(Double Antibody Solid Phase) separation technique (0 * Sul 1 i van e t  al 1978).
The enzyme label was s t i l l  usable a fte r  storage for six months a t  
4° C.
The a c t iv i ty  or s ta b i l i ty  of 8 -  D -  galactosidase was not affected  
by the presence of plasma from a number of hospital patients.
m e  u i u u N i n y  a y e n t  u b e u  i ur 1 0 a  h i  u i i b  c i i i a y  wab n w o , a i i u  u h  b a y e n  t
was e ffec tive  to block TBG e ffe c t  by increasing the binding of the 
hormone Tg to the antibody. Measurements of the cross-reactiv ity  of 
thyroxine and 3, 5 -  diiodotyrosine by this procedure and by 
radioimmunoassay (R a tc l i f fe  et al 1974) gave s im ilar resu lts , and i t  
indicates tha t these compounds a t the levels l ik e ly  to be encountered 
in plasma w i l l  cause very l i t t l e  interference with the Tg -  assay.
The time required to perform the assay was 24 hours. The validation  
of the accuracy of this method was achieved through comparison with 
the radioimmunoassay method (R a tc li f fe  e t  al 1974).
Thus the enzyme immunoassay fo r  Tg described above would appear to be 
suitable for the routine measurement of Tg in plasma samples. This 
technique has proved to be useful fo r  measuring low levels of drugs 
and hormones in biological flu ids and proved to be as sensitive as 
radioimmunoassay methods.
CHAPTER 6
DEVELOPMENT OF A SIMULTANEOUS ENZYME IMMUNOASSAY 
FOR THE MEASUREMENT OF TRIIODOTHYRONINE AND THYROXINE
B-D-Galactosidase (EC 3 .2 .1 .23 ) from Escherichia coli was conjugated 
to triiodothyronine (Tg) by means of a bifunctional cross-1 inking 
reagent, dimethyl adipimidate (DMA). Alkaline phosphatase (EC 3 .1 .3 .1 )  
from Escherichia coli was also conjugated to thyroxine (T^) by means 
of dimethyladipimidate. In each reaction approximately eighty per­
cent of the enzyme a c t iv ity  was retained following the conjugation 
reaction, of which approximately ninety percent was conjugated to 
immunologically active Tg or T^. These conjugates were used to 
establish the basis of a simultaneous enzyme immunoassay for Tg and 
T  ^ in the same sample. In the f in a l immunoassay the enzyme a c t iv i t ie s  
of the bound fraction were determined with O-nitrophenyl-b-D- 
galactopyranoside and phenolphthalein monophosphate as substrates.
Donkey anti-sheep IgG second antibody was used to precipitate  the 
sheep anti-Tg and anti-T^ f i r s t  antibodies.
Radioimmunoassay techniques fo r  the determination of thyroxine (T^) 
levels in human sera under normal and pathological conditions have 
recently been described by several investigators (e .g. Chopra, 1972; 
Larsen et a l , 1973; Dunn and Foster, 1973). The estimation of serum 
thyroxine is probably the most widely used single test of thyroid  
function. Over the las t few years the measurement of serum tr i io d o ­
thyronine (Tg) has been introduced and is rapidly becoming accepted 
as a measurement yield ing important information. In p a r t ic u la r ,  i t  
is thought to be useful in detecting early hyperthyroidism (Burke and 
Eastman, 1974), in establishing the diagnosis of Tg-thyrotoxicosis  
(Starling et a l . ,  1970; Hollander et a l . ,  1972; Shalet et a l . ,  1975), 
and in assessing thyroid status in patients treated fo r  thyrotoxicosis  
both as an indicator of euthyroid state in the presence of low T  ^
level (Hoffenberg, 1973) and in providing early biochemical evidence 
of relapse (Marsden et a l . ,  1975). A few investigators have combined 
both T^ and Tg radioimmunoassays (Mitsuma et a l . ,  1972; Werner e t a l . ,  
1974; Ljunggren et a l . ,  1976; Haynes and Goldie, ,1977). Many 
laboratories now find themselves measuring serum Tg in an increasing 
proportion of samples sent for thyroid function tes ts , both fo r  the 
specific  reasons mentioned above and to c la r i fy  the position in any 
patient whose T^ resu lt is equivocal. In an attempt to reduce the 
work involved thereby reducing the turn-round time for the samples 
involved and to economise on sample s ize , the basis of an enzyme 
immunoassay in which both T^ and Tg are measured simultaneously in the 
same aliquot of serum has been embarked upon. The simultaneous assay 
of several components in a sample by enzyme immunoassay is in princip le
r e la t iv e ly  straightforward. The c r i te r ia  adopted in selecting the
enzyme fo r labe lling  Tg and T^ were the fo i l  owing
1. Both enzymes should be readily  availab le , inexpensive and have high 
turnover numbers.
2. Each must be .stable under simultaneous assay condition, i . e .  not 
susceptible to interference from the other enzyme or i ts  substrate.
3. Each enzyme must have s im ilar optimum pH and belong to the same 
group of enzymes (e.g. hydrolases, transferases, e tc . ) .
4. The f in a l assay method for each enzyme should be simple, sensitive,
rapid and cheap.
5. Neither enzyme should occur in the biological flu ids to be assayed 
and in terfe r ing  factors should be absent.
6 . Each enzyme should contain po ten tia lly  reactive groups which allow
linking to haptens while retaining a substantial part of the enzyme
a c t iv i ty .
7. The spectrum of the products of the enzyme a c t iv i ty  should not 
overlap with each other.
Based on the above c r i te r ia  B-D-galactosidase (EC 3 .2 .1 .23 ) from
E.coli and a lkaline phosphatase (EC 3 .1 .3 .1 )  from E.coli were selected
to label Tg and T^ respectively.
Triiodothyronine ( T g ) ,  thyroxine, O-nitrophenyl-B-galactopyranoside 
(ONPG), phenolphthalein monophosphate, 2-mercaptoethanol, N-ethyl- 
morpholine, and alkaline phosphatase (EC.3 .1 .3 .1 )  from Escherichia col 
(as a suspension in ammonium sulphate) were purchased from Sigma 
Chemical Company, London. 3-D-Galactosidase (EC.3 .3 .1 .23 ) from 
Escherichia coli was purchased from Boehringer Mannheim, Mannheim, 
West Germany as a suspension in 2.2 mmol/litre ammonium sulphate. 
Dimethyladipimidate dihydrochloride (DMA) (Pierce Chemical Co., 
Rockford, 111.) was stored in 10 mg aliquots under reduced pressure 
at -20°C. Bovine serum albumin was obtained as a 30% w/v solution 
from Armour Pharmaceutical Company, London. Sephadex G-25 gel was 
from Pharmacia Fine Chemicals, Uppsala, Sweden. All other reagents 
were purchased from BDH Chemical Limited, Parkstone, England.
The triiodothyronine (Tg)  antiserum (bleed 12 /8 /76 ), supplied by 
Guildhay Anti sera, Guildford, Surrey, England, was raised in a sheep 
against a Tg-bovine serum albumin conjugate prepared by use of the 
carbodiimide method (Goodfriend et a l . ,  1964). The thyroxine (T^) 
antiserum, a g i f t  from Scottish Antibody Production Unit, Glasgow, 
was raised in a sheep against a T^-human serum albumin conjugate 
prepared by use of the carbodiimide method. The cross-reactiv ity  of 
the anti-T^ serum batch no. (0052A) was 2.4% with triiodothyronine  
( T g ) .  The donkey anti-sheep IgG precip ita ting second antibody was 
obtained from Guildhay Antisera. Tris buffer (100 m mol/litre pH 8.5  
adjusted with hydrochloric acid)contained 10 m m ol/litre  Magnesium
Procedure
Simultaneous spectrophotometric measurements of a lkaline phosphatase 
and g-D-galactosidase a c t iv it ie s
The substrate used to estimate a lkaline phosphatase a c t iv ity  was 
selected on the basis that the product should have a quite d if fe re n t  
absorption spectrum from O-nitrophenol the product used to measure 
3-galactosidase a c t iv i ty .  Phenolphthalein monophosphate appeared to be 
p a rt icu la r ly  appropriate. To ensure that no overlapping of these
spectra occur the assay on O-nitrophenol in the presence of various 
concentrations of phenophthalein was carried out. The effects of 
various concentrations of O-nitrophenol on phenolphthalein estimation 
was also examined. To this end 1 mmol/litre of O-nitrophenol in 
d is t i l le d  water brought to pH 11 by 0.1N sodium hydroxide and 1 mmol/ 
l i t r e  of phenolphthalein in d is t i l le d  water, brought to pH 11 by 0 .1N 
sodium hydroxide were prepared. Three d if fe ren t concentrations of 
these solutions were prepared by double d ilu tion  of the stock solutions 
Various concentrations of O-nitrophenol were mixed with concentrations 
of phenolphthalein, then absorption spectra of each mixture were 
determined using a Uni cam SP 1800 u l t ra v io le t  spectrophotometer. The 
spectra of these mixtures were compared with the spectra of the pure 
solutions.
S ta b i l i ty  study of a lkaline phosphatase and 3-P-galactosidase using 
phenolphthalein monophosphate and 0 -nitrophenyl g-D-galactopyranoside 
as substrates in single and dual modes under the f in a l assay conditions
Various amounts of a lkaline phosphatase (5, 2 .0 , 1 .2 , 0.5 pg) in 100 pi 
aliquots of Tris buffer were incubated with 1 ml phenolphthalein mono­
phosphate substrate solution (2.5mmol/litre in Tris buffer) and 1.1 ml 
Tris buffer for 1 h at 25°C. The same amounts of a lkaline phosphatase
in 100 yl aliquots Tris buffer were incubated with 1 ml phenol­
phthalein monophosphate solution plus known amounts of B-D-galacto- 
sidase in 100 pi aliquot of buffer and 1 ml of 0-nitrophenyl b-D- 
galactopyranoside (2.5 mmol/litre in Tris bu ffe r) . All incubations 
were carried out in duplicate for 1 h at 25°C. The reaction was 
terminated by addition of 0.5 ml 0.1N NaOH. The optical densities 
were then read at 540 nm. A s im ilar experiment was performed with 
3-D-galactosidase in d if fe re n t  amounts (200, 100, 30, 15 ng in 100 pi 
aliquots) both alone and in the presence of a lkaline phosphatase and 
i ts  substrate for 1 h at 25°C. The optical densities were then read 
at 420 nm.
Preparation of a lkaline phosphatase-T/j conjugate
Alkaline phosphatase was coupled to T  ^ using the cross-linking b i-  
functional imidoester dimethyl adipimidate. The procedure is described 
below:-
T  ^ (10 mg, 12.5 pmoles)was dissolved in dry methanol (2 ml) containing 
25% w/v N-ethylmorpholine, dimethyl adipimidate (DMA 6 mg, 25 pmoles) 
was added and the solution maintained at room temperature for th i r ty  
minutes. The solution was then transferred to a solution of a lka line  
phosphatase (2 mg, 25 nmoles) in sodium carbonate buffer (2 ml,
100 m m ol/litre , pH 9.9) containing magnesium chloride (10 m m ol/litre )  
and kept at room temperature for 90 minutes. The f in a l solution was 
applied to a Sephadex G-25 column to separate re la t iv e ly  low molecular 
weight compounds from the enzyme. The column was eluted with Tris  
buffer (50 m m ol/litre , pH 7.5 adjusted with acetic acid)contained 
magnesium chloride, ‘10 m mol/litre. The fractions containing enzyme 
a c t iv i ty  were collected and pooled. Sodium azide and bovine serum
albumin were then added to give a 0.1% w/v f in a l solution. The 
solution was stored at 4°C un til required.
Determination of the immunoreactivity of the a lkaline phosphatase- 
T/| conjugate *
The proportion of a lka line  phosphatase bound to immunoreactive T  ^
was determined by incubating a portion of the treated enzyme with 
excess T  ^ antiserum (0.1 ml, 50-fold d ilu tion  of antiserum). The enzyme 
was diluted with Tris buffer (100 m m ol/litre , pH 8.5) containing 
10 mmol/litre magnesium chloride and 0.1% w/v BSA,
Enzyme conjugate bound by T  ^ antibodies was precipitated by donkey 
anti-sheep second antibody. Enzyme conjugate bound by T^ antibody 
was measured in the precip itate  a fte r  washing i t  once with Tris  
buffer. The Tg-3-D-galactosidase conjugate was prepared as described 
in Chapter Five.
T/|-enzyme immunoassay procedure
The protocol for the T  ^ enzyme immunoassay is shown in Table 6 .1 .
All d ilutions ( la b e l,  standards, antiserum) were made in Tris buffer.
T  ^ standards were prepared from stock solution by dissolving L- 
thyroxine (sodium s a lt  pentahydrate) in a few drops 0.1N NaOH (added 
dropwise) and making up to 50 ml with ethanol. An intermediate 
stock solution having a concentration of 1 0 , 0 0 0  nm ol/litre  was made 
with Tris buffer. The following working standards were made by 
multiple dilutions of this intermediate stock solution: 1000, 500,
250, 125, 62.5 and 31 nm ole/litre . The bulk of the intermediate 
stock solution was then divided with 200  ul a liquots, which were
TABLE 6. 1  Protocol fo r  enzyme immunoassay
(The volumes expressed in  y l )
Reagents Total ^ " -s p e c i f ic  binding
Anti serum 
dilu tion  
curve
Zero
Standard
Standard
curve
Samp!
Sample - - - - 100
Standard - - - 100 -
Tris buffer 500 400 400 300 300
Enzyme label 100  100 100 100 100 100
T^-antiserum - 100 100 100 100
Leave to incubate at room temperature fo r  3 hours
Donkey anti-sheep 
second antibody 100 100 100 100 100
Leave overnight at 4°C, wash with 1.5ml buffer, spin for 20 min at 
2000 rpm (Mistral 4L), aspirate the supernatant, wash with 2 ml of buffer  
and spin. Aspirate, add 1 ml substrate solution (phenolphthalein mono­
phosphate 2 mmol/litre in Tris buffer) and incubate at 25°C for 2 hours. 
Terminate the reaction by 0.5 ml 0.1N NaOH. Spin the tube and measure 
the optical density of the solution at 540 nm.
stored at -20°C until required.
Simultaneous and Tg enzyme immunoassay procedure
The protocol for the simultaneous T  ^ and Tg enzyme immunoassay is 
shown in Table & .2V All dilutions ( la b e l,  standards, antisera) were 
made in Tris buffer. The second antibody donkey anti-sheep conc­
entrations were optimised in the assay.
TABLE 6.2 Protocol fo r  simultaneous enzyme immunoassay fo r  and Tg
(The volumes expressed in  y l )
Reagents Total Non-specificbinding
Anti serum 
dilu tion  
curve
Zero
Standard
Standard
curve
Samp"
Sample - - - - 100
T  ^ standard - - - - 100
Tg standard - - - - 100 -
T  ^ anti serum - - 100 100 100 100
Tg antiserum - - 100 100 100 100
Tris buffer - 500 300 300 100 200
Tg enzyme label 100 100 100 100 100 100
T  ^ enzyme label 100 100 100 100 100 100
Leave to incubate at room temperature fo r 3 hours
Donkey anti-sheep 
second antibody - 200 200 200 200 200
Leave overnight incubation at 4°C, wash with 1.5 ml bu ffer , spin fo r  
20 min at 2000 rpm (Mistral 4L), aspirate the supernatant, wash with 
second buffer, spin again and aspirate. Add 0.5 ml 0-nitrophenyl-&-D- 
galactopyranoside substrate and 0.5 ml phenophthalein monophosphate 
substrate and incubate at 25°C for 2 hours. Terminate the reaction by
0.5 ml 0.1N NaOH. Spin the tubes and measure the optical density of the 
solution a t 540 nm and 420 nm.
The spectra o f O-nitrophenol and phenolphthalein
The spectra of solutions of pure O-nitrophenol and phenolphthalein in 
d is t i l le d  water brought to pH 11 by 0 . IN sodium hydroxide were compared 
with spectra of equivolume mixtures of the two (F ig .6 .1 ) .  No over­
lapping of the two spectra was observed and no interference was found between 
the spectra of the two compounds at any concentration tested. Similar  
results were obtained when a lkaline phosphatase and g-D-galactosidase 
enzymes were assayed simultaneously using phenolphthalein monophosphate 
and O-nitrophenyl-g-D-galactopyranoside as substrates.
S ta b il i ty  study of a lka line  phosphatase and g-D-galactosidase using 
phenolphthalein monophosphate and 0 -nitrophenyl-g-D-galactopyranoside 
as substrates in single and dual modes under the f in a l assay conditions
Table 6 . 3  shows no interaction between the enzymes when they were assayed 
together using the two substrates and comparing these results with single 
assays.
The e ffec t of d if fe re n t  molar ratios of T^  and DMA to alkaline  
phosphatase on the production of label
Two molar ratios of T  ^ and DMA to the enzyme alkaline phosphatase were 
examined for th e ir  influence on the effectiveness of the coupling 
reaction using a s im ilar procedure to that described in the Methods 
section of this chapter. F ig .6 .2 shows that at high ra tio  there was 
a high degree of incorporation of a lkaline phosphatase to immunoreactive 
T  ^ (ninety percent of the enzyme was conjugated), while at the lower 
molar ra t io  low degree of incorporation of the enzyme to immunoreactive 
T  ^ (46% of the enzyme was conjugated). The retention of enzyme a c t iv i ty
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conjugate using T^-alkaline phosphatase conjugate as label.
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phosphatase
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T^-antiserum dilutions ( i n i t i a l )
in both cases was not less than eighty percent a f te r  the coupling 
reaction.
Simultaneous and Tg antisera d ilu tion  curves
Simultaneous serum d ilu tion  curves of Tg and anti sera were set up 
following the assay protocol indicated in Table 6 .2 . The a lkaline  
phosphatase-T^ conjugate having the molar ra tio  of 100-200-1 between 
T^-DMA-alkaline phosphatase was used. The $-D-galactosidase-Tg 
conjugate having the molar ra tio  2500-4000-1 between Tg-DMA-e-D- 
galactosidase was used. The results shown in F ig .6.3 indicate that 
i t  is technically  possible simultaneously to determine Tg and T '^.
The reaction condition for the preparation of the e-D-galactosidase-T. 
conjugate was d if fe re n t  from that described in the Methods section of 
Chapter Five. In the present preparation a four-fo ld  increase in the 
concentrations of Tg,  DMA and enzyme was used. This resulted in precipi^ 
tation of some of the Tg when i t  was transferred to the enzyme solution, 
and probably explains the lower degree of incorporation of Tg into the 
enzyme which occurred in this experiment.
Standard curve for thyroxine enzyme immunoassay
The a lkaline phosphatase-T^ conjugate having the molar ra t io  of 1- 
1000-500 between the enzyme-DMA-T^ was used to set up standard curves.
The standard curve for thyroxine shown in F ig .6.4 indicates tha t a dose 
of 62 nm ole/litre  of thyroxine causes a 22% displacement from the zero 
binding state ( i . e .  no thyroxine is present).
o
d i lu t io n  curves
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Is i t  desirable to measure the le ve ls  o f both Tg and in  c l in ic a l
practice? From the laboratory point of view the experience of many workers
(Haynes and Goldie, 1977; Ljunggren et a ! . ,  1976) suggests that the tes t
with simultaneous determination of both hormones in unextracted serum is
almost as simple and rapid as the determination of only one hormone in
unextracted serum. From the c l in ic a l point of view i t  is more
satisfactory to have the results of both hormones. Tg values are more
useful than those of T  ^ in patients with hyperthyroidism or receiving
thyroid medication (Larsen, 1972) and knowledge of T  ^ values is of
greater importance than Tg in patients with hypothyroidism (U tiger,
1974). The widespread use of simultaneous radioimmunoassays for Tg
and T^, however, would add s ig n if ican tly  to the costs of thyroid
function testing , as Tg reagents are re la t iv e ly  expensive, p a rt icu la r ly
125high specific  a c t iv i ty  I Tg.  A simultaneous enzyme immunoassay for  
Tg and T^ could be much cheaper than an equivalent radioimmunoassay.
An alkaline phosphatase-T^ conjugate can be readily  prepared using the 
dimethyladipimidate as cross-linking agent. In su ff ic ien t time was 
available to optimise the conjugation conditions. A more sensitive  
label could probably be produced by chosing a molar ra t io  between 
100-200-1 and 500-1000-1 T^-DMA-alkaline phosphatase.
The Tg standard curve can be performed using the £-D-galactosidase-Tg 
conjugate which can be prepared following the protocol indicated in. 
the Methods section of Chapter Five.
The simultaneous measurements of alkaline phosphatase and e-D- 
galactosidase using phenolphthalein monophosphate and 0-nitrophenyl- 
6-D-galactopyranoside as substrates proved to be straightforward.
There was no overlap of the two spectra of the products of the enzyme 
reactions and no interference or inh ib ition  of one enzyme by the other
enzyme or i ts  substrate was noted. The s p e c if ic ity  of anti-Tg and 
anti-T^ antibodies appeared to be unchanged under the simultaneous assay 
conditions used to assay Tg and T^. Thus, the principle that enzyme 
immunoassay can be applied to the simultaneous assay of several 
components in a sample has been demonstrated. By extending this  
p rinc ip le , i t  should be possible to assay more than two compounds 
simultaneously. Because of the lack of time, no further work has 
been carried out to complete the simultaneous enzyme immunoassay fo r  Tg 
and T^. The following experiments were planned:-
1. Improvement of assay s e n s it iv ity  of T  ^ by modifying the enzyme 
label probably by employing a molar ra tio  of 200-400-1, or 300- 
600-1 for T^-DMA-alkaline phosphatase and following the same 
procedure indicated in the Methods section of this chapter.
2. Investigating the e ffec t of plasma on the simultaneous standard 
curves of Tg and T^.
3. Removing TBG from serum samples using ANS or heating plasma 
samples.
4. Assaying plasma samples from euthyroid, hypothyroid, hyperthyroid 
patients and comparing the results with single enzyme and radio­
immunoassay fo r  Tg and T^.
CHAPTER 7
FINAL DISCUSSION AND CONCLUSIONS
Radioimmunoassays are being used increasing ly  in  c l in ic a l  p ractice .
However, radio labelling is not ideal, because radioactive decay does not 
change s ig n if ica n tly  when antibody and antigen combine ( i . e c only hetero­
geneous assays are possible), radiolabelled materials may have a rather  
short h a lf  time and health hazards are po ten tia lly  involved in th e ir  
production and use. Therefore, many other possible labels have been 
studied in recent years, including enzymes, fluorescent or chemiluminescent 
molecules, viruses and free radicals. Enzyme labelling  has been the subject 
of most work, and evidence is increasingly accumulating that enzyme immuno­
assay (EIA) provides a feasible a lternative  to RIA.
Reasons for the emphasis given to enzyme labelling include: fa m i l ia r i ty
with the basic principles involved because of i ts  previous applications in 
cytochemistry and histochemistry; the a v a i la b i l i ty  and re la t iv e  cheapness 
of many enzymes and of manual and automated systems for th e ir  assay; the 
long s h e l f - l i f e  of the labelled product; lack of hazards during la b e l l in g ;  
the s e n s it iv ity  (aris ing from the 'photo m u lt ip l ie r 1 properties of enzymes); 
s p e c if ic ity  and a p p lic a b il i ty  s im ilar to that of RIA; technical manipulations 
are simple and the assays may be very rapid, as separation steps are not 
generally required (Homogeneous EIA); the variety  of labels available  may 
allow multiple simultaneous assays to be performed.
It/has been an a r t ic le  of fa i th  among most immunoassayists that radio­
immunoassays are the most sensitive and reproducible immunoassays (Landon,
1977). This view is held in spite of the available evidence which suggests 
that for assays of large molecular weight substances enzyme immunoassays 
have the same se n s it iv ity  and precision as isotopic assays. A possible 
disadvantage of EIA for assays of small substances is that the attachment 
of a label of high molecular weight, such as the enzyme, can influence the 
re a c t iv i ty  of the molecule more than the small isotope does. For this  
reason a number of workers believe that for assaying small molecules RIA 
is preferable (Wisdom 1976, Schuurs and Van Weemen 1977, Voller 1978).
EIA is s t i l l  in an early phase of development and w il l  not immediately 
replace RIA in those areas where RIA has achieved major success. However, 
there w i l l  be pressure to replace RIA by EIA in a number of situations  
for the following reasons: i t  is expected that s t r ic te r  rules and regulation'
for the preparation, transport, use and disposal of radioactive isotopes 
w ill  be established in many countries. This w il l  lead to s tipu la tion  for  
upgrading of laboratory f a c i l i t i e s ,  safety training of personnel etc. This 
w ill  inevitab ly  resu lt in higher costs and restr ic tions  on the ues of 
RIA's. Furthermore, hospitals with limited laboratory f a c i l i t i e s  w i l l  
increasingly want to perform th e ir  own assays, p a r t ic u la r ly  in cases where 
a quick answer is desired. This is p o ten tia lly  easier to achieve with EIA 
than with RIA. In frequent usage, RIA may be uneconomical because of the 
lim ited shelf l i f e  of the label and problems of quick supply of labelled  
reagents to laboratories remote from the manufacturers of such materials  
may not be simple to overcome. In those countries where RIA has never 
been introduced on a large scale, i t  is l ik e ly  that EIA w i l l  be a serious 
candidate for many tests and assays.
EIA is showing a wide range of applications in Endocrinology, immunopathology. 
haematology, microbiology and parasitology. I t  is l ik e ly  that EIA w i l l  soon 
be used in many microbiological laboratories for routine purposes.
I t  is also l ik e ly  that new tests in virology w i l l  be of the EIA type.
A very important development l ie s  in the diagnosis and epidemiology of 
tropical diseases (Vo ller  e t al 1976, 1978). I t  is here that the 
sim plic ity  of EIA w il l  probably be decisive in i ts  adoption.
Sophisticated automated equipment is readily  available for radioassays: 
and although this has made i t  popular with analysts because of the 
convenience in performance of the te s ts * i t  has also made radioimmunoassay 
as i t  is normally practised an expensive technique to establish in a 
laboratory. Enzyme immunoassay is more versa tile  in the measuring devices 
that can be employed. Simple bench colorimeters or fu l ly  automated 
instruments can be used.
For large laboratories, routine application of modern analytical techniques 
is inseparably linked to mechanization and automation. In such laboratories  
development of homogeneous EIA's has a particu lar appeal since homogeneous 
EIA's are easy to mechanize and automate because of th e ir  simple performance 
and short incubation times. Inexpensive methods for automation and semi­
automation of heterogeneous EIA's are needed.
Several aspects of EIA require further development; these include 
optimization of conjugate preparation; characterization of conjugate 
preparations; examination of new enzyme labels and the other labels which 
influence enzyme a c t iv i ty  (enzyme inhib itors and co-factors); evolving 
of sensitive methods of enzyme assay such as co-factor cycling; separation 
procedures that are rapid and reproducible; better cross-linking reagents; 
quality  control c r i te r ia  for reagents and reagent combinations; investigation  
of the potentials of alternative enzyme a c t iv ity  end point determinations, 
e.g. fluorim etry , chemiluminescence; maturing of sensitive homogeneous 
assays able to measure macromolecules.
In the present study a new cross-linking reagent specific for amino 
groups (bifunctional imidoester e .g. dimethyladipimidate) has been 
successfully applied to couple d if fe re n t antigens (e .g . desmethylnortriptyline  
n o rtr ip ty l in e , and T^) to 3 -D-galactosidase and alka line  phosphatase.
High y ie ld  of enzyme a c t iv i ty  (75-90%) was retained a f te r  conjugation.
At least 70% of the enzyme was conjugated to the antigen (hapten) used, 
except fo r n o rtr ip ty l in e . The success of this label indicates that the 
use of the presently available hetero bifunctional cross-linking reagents, 
and hopefully the development of new reagents of this type w i l l  greatly  
simplify the routine production of enzyme labelled antigens and antibodies.
The enzyme immunoassays developed here have s e n s it iv it ie s  comparable to 
the s en s it iv it ie s  of the corresponding radioimmunoassays. For drug assays 
the s en s it iv it ie s  were more than enough to measure c l in ic a l therapeutic  
plasma levels . In the T3 assay the s e n s it iv ity  was enough to measure the 
normal plasma levels . Sens it iv ity  can be much improved by employing a 
fluorogenic substrates and using a very small quantity of enzyme labe l.  
Preliminary experiments in our laboratories (M. O'Sullivan personal 
communication) indicate the v a l id i ty  of this approach. The analytical 
recoveries of no rtr ip ty l in e  and methotrexate,in the presence of various 
amounts of plasma l ik e ly  to be used in practice , indicates that these 
drugs are unaffected by natural constituents of plasma.
The assays have precisions which are within acceptable immunoassay standards 
and are more or less comparable to the precisions of the corresponding 
radioimmunoassays.
The s ta b i l i ty  of enzyme labels was studied for six months storage,and the 
results indicate that the labels were s t i l l  usable.
The assays showed sp e c if ic ity  the same as the corresponding radioimmunoassays 
using the same antisera. No evidence was produced which might indicate  
that the use of a bulky enzyme label modifies the a b i l i t y  of the anti serum 
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